Development of magnetic resonance imaging techniques for mouse models of Alzheimer's Disease by O'Callaghan, JM
1 
 
Development of magnetic 
resonance imaging techniques 
for mouse models of 
Alzheimer’s Disease 
 
 
 
James  Martin O’Callaghan 
 
 
Ph.D. Thesis 
Submitted for the degree of Doctor of Philosophy, 
University College London, 
October 2015 
  
2 
 
Declaration 
 
I, James Martin O’Callaghan confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis.  This work is based on research that I carried out at the Centre for 
Advanced Biomedical Imaging, University College London, UK, between September 2011 
and September 2015. 
 
 
 
 
 
 
 
James O’Callaghan 
 
 
 
 
 
 
 
Publications arising from this thesis 
 
 
Is Your System Calibrated? MRI Gradient System Calibration for Pre-Clinical, High-
Resolution Imaging.  
PLoS ONE 2014; 9(5):e96568.  
J O’Callaghan, J Wells, S Richardson, H Holmes, Y Yu, S Walker-Samuel, B Siow, MF Lythgoe.  
 
In-Vivo Imaging of Tau pathology using Multi-Parametric Quantitative MRI 
NeuroImage, 2015, 111(0): 369-378 
J Wells*, J O'Callaghan* , H Holmes, N Powell, R Johnston , B Siow, F Torrealdea , O Ismail, S 
Walker-Samuel, X Golay, M Rega , S Richardson, M Modat, M Cardoso, S Ourselin, A 
Schwarz, Z Ahmed, T Murray, M O'Neill, E Collins, N Colgan, M F Lythgoe  
*Joint first authors 
3 
 
Acknowledgements 
 
I would like to extend my deepest gratitude to all those who have guided and supported 
me over the last four years.  Firstly, I am thankful to Professor Mark Lythgoe for taking me 
on as a Ph. D. student.  He has provided endless words of encouragement, inspiration and 
also cappuccinos when I needed them most and has inspired me with his drive and 
dedication to science.  In the Centre for Advanced Biomedical Imaging he has created a 
truly unique environment of learning and collaboration.   
For the practical and theoretical understanding of MRI physics I have gained, I am indebted 
to Dr. Jack Wells.  Not only did he spend a disproportionate amount of his days and 
evenings teaching me the workings of the 9.4T scanner and the pulse programming 
environment, he always did it with a smile on his face.  His guidance and words of wisdom 
have been hugely helpful in many aspects of my work.  Jack has played a key role in my 
progress both academically and at table tennis, and I am hopeful that our paths will cross in 
both endeavours in the future. 
I am grateful to Dr. Bernard Siow for his insight, advice and knowledge on all things physics.  
The close proximity of his desk to mine meant that it was a little too easy interrupt what he 
was doing and fire questions his way, yet he was always willing to share his infectious 
excitement for science and encourage me to pursue new directions in my work. 
I would like to thank my collaborators at Eli Lilly & Co. Ltd. for providing mouse models and 
performing histology. I am also grateful to all members of CABI and in particular I’d like to 
thank Holly Holmes for performing perfuse fixations (of which there were many); Nick 
Powell for helping with image registration; Dr. Karin Shmueli for her expertise in magnetic 
susceptibility; and Dr. Rajiv Ramasawmy for organising regular football games. 
I’d also like to extend a huge thank you to all my family members.  My parents Mary and 
Patrick O’Callaghan have always offered unwavering support and have given my wife and I 
so much help in settling in the UK after moving from the USA.  I am also very grateful to my 
American parents-in-law Deb and Ken Grass for their encouragement – and also for being 
so understanding of our transatlantic move.  When he was born last year, my son Thomas 
O’Callaghan transformed my life immeasurably for the better and he has been a source of 
joy even during the difficult final stages of writing this thesis.  Finally, and most importantly 
by far, I would like to acknowledge the exceptional role of my wife, without whom this 
4 
 
work would never have come to pass.  Her love, inspiration, support, and self sacrifice have 
made it possible to get to this point and I therefore dedicate this thesis to her, Tiffany 
O’Callaghan, the love of my life. 
   
 
 
  
5 
 
Abstract 
Due to increasing life expectancy in western societies, a rise in the prevalence of 
Alzheimer’s Disease (AD) is expected to have adverse social and economic consequences.  
The success of emerging treatments for AD relies heavily on the ability to test their efficacy.  
Sensitive biomarkers are required that provide information specific to the therapeutic 
targets.  Through manipulation of the genome, transgenic mice have been bred to exhibit 
particular pathological features of AD in isolation.   Magnetic Resonance Imaging (MRI) of 
these mouse models can be used to observe phenotypic abnormalities in-vivo in a 
controlled environment.  As summarised in the introductory chapter, the aim of this work 
was to develop MRI techniques for inclusion in multi-parametric protocols to characterise 
AD models in-vivo. 
Structural MRI has become an increasingly popular tool in the measurement of atrophy of 
brain tissue over time and requires both accuracy and stability of the imaging system.  In 
chapter 3, a protocol for the calibration of system gradients for high resolution, pre-clinical 
MRI is described.  A structural phantom has been designed and 3D printed for use in a 9.4T 
small bore MRI and micro CT system.  Post processing software is used to monitor gradient 
stability and provide corrections for scaling errors and non-linearity.   
Diffusion Tensor Imaging (DTI) and Quantitative Susceptibility Mapping (QSM) are MRI 
techniques that have shown sensitivity to changes in white matter regions of the brain.  
QSM may also provide a non invasive method for measurement of increased iron 
concentration in grey matter tissue observed in AD.  Chapters 4 and 5 evaluate the utility of 
these measurements as imaging biomarkers in a mouse model that exhibits tau pathology 
associated with AD.  Discrepancies between transgenic and wild-type groups were 
identified for both MRI techniques indicating the potential benefit of their inclusion in a 
multi-parametric in-vivo protocol. 
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1 Alzheimer’s Disease 
1.1 A brief history 
In 1901 Alois Alzheimer(Figure 1a) admitted a patient suffering memory loss, confusion and 
other symptoms of a neurological disorder to Frankfurt Hospital(1,2).  When Auguste D. 
died four years later, Alzheimer conducted a post mortem investigation of her brain. As 
well as finding plaques that had been described previously(3), Alzheimer became the first 
to discover tangle pathology using silver stains(Figure 1b).  In 1906 he presented his 
findings at the 37th meeting of the Society of Southwest German Psychiatrists, defining the 
characteristic clinical and neuropathological features of a disease that would come to bear 
his name.  It was not until 1979 that the first Alzheimer’s Disease (AD) association was 
formed in the USA to attract funding for the necessary pursuit of an understanding of the 
biology of the disease.  In the intervening years, a clinicopathological distinction was 
developed between senile dementia patients (onset > 65 years of age), many of whom 
exhibited AD pathology, and pre-senile dementias (onset < 65 years of age), which include 
conditions such as Picks disease and Creuzfeldt-Jakob disease.  The discovery of familial 
forms of the disease by Schottky in 1932(4) seeded a genetic avenue of scientific research 
in AD. This work has fused with studies of the molecular composition of proteinaceous 
aggregates in the brain over the last three decades to provide some insight into the 
etiology of the disease. 
 
Figure 1. Alzheimer’s disease historical images 
Photograph of Alois Alzheimer(a), and his sketch of stained tangle pathology(b) from his 
1911 publication(5,6). 
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Neuritic plaques that accompany the tangle pathology discovered by Alzheimer had been 
reported previously in 1898 by Redlich(2).  Preliminary electron microscopy (EM) 
investigations of post mortem tissue in the 1960s(7,8) revealed abnormal plaque filaments  
located in the extracellular space, whilst tangles appeared in helical filaments within cell 
bodies and in neurites as well as at the periphery of plaques(1).  It was another 20 years 
before the identification of Amyloid-Beta(Aβ), formed from the cleavage of Amyloid 
Precursor Protein (APP), as a major component of plaques though biochemical 
analysis(2,9).  The primary function of APP remains unclear but it is thought to have an 
impact on neuronal development and function through its involvement in a range of 
biological activities(10).  The role of tau protein, detected within tangle pathology, is to act 
as a microtubule binding and stabilising agent.  Hyperphosphorylation processes are 
thought to be responsible of the manifestation of tau in its tangled filamentous form in AD, 
sometimes described as neurofibrillary tangles (NFTs) (2).  
NFTs in dementia cases are not homogeneously spread throughout the brain but display a 
characteristic pattern(11).  A progressive spread of tau pathology was identified in 1991 
that has become known as ‘Braak Staging’(11).  Six stages were defined corresponding to 
the level of infiltration across distinct brain regions.  In the mildest cases, NFTs are 
restricted to the transentorhinal region (stages 1 and 2).  In the limbic stages (3 and 4), 
pathology builds up and also spreads to the hippocampus.  The low density of tau tangles 
present in the isocortex during the limbic stages increases in the final stages with a heavy 
burden throughout the aforementioned regions of the brain.  Comparisons with cognitive 
tests have indicated that the transentorhinal stages are clinically silent(12).  Mild stages of 
AD memory impairment are associated with NFT spread to the limbic regions, with severe 
memory loss occurring in the final Braak stages.  Furthermore, studies of neuronal cell 
death and tissue atrophy also follow Braak staging patterns(13-16).  In contrast, the 
regional distribution of plaques remains fairly consistent as accumulation occurs over time 
and post mortem analyses show variability in the density of plaques between patients that 
exhibit mild clinical symptoms of AD.  Therefore, although amyloid pathology appears to 
occur early in disease, its utility as a method by which to stage the time course of AD with 
close affinity to clinical symptoms is limited. 
The vast majority of AD cases are of the sporadic form with autosomal dominant(familial) 
cases accounting for less than 1%(1).  This subset of cases often present with symptoms 
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before the age of 65, known as early onset, and is a more rapidly progressing form of the 
disease.  The first links between genetics and pathology were made between plaque 
deposition and mutations and duplications of the APP gene(2).  Discoveries of mutations in 
Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) genes on chromosome 14 in familial AD 
followed.  The proteins encoded by these genes are involved in the processing of APP and 
Aβ(17) with PSEN1 mutations being the most common cause of autosomal dominant AD.  
The over expression of Aβ generated in these cases is described as a disease trigger in what 
is known as ‘amyloid cascade’ hypothesis(1).  This suggests that the appearance of tangles, 
neurodegeneration, and dementia are downstream events of the disease.  Mutations of 
the Microtubule Associated Protein Tau(MAPT) gene are not implicated in AD but have 
been associated with fronto-temporal dementia linked to chromosome 17(1).  The APOEε4 
allele on chromosome 19 has been identified as a genetic risk factor for late onset AD and 
is associated with mild cognitive impairment(MCI)(17).  MCI is a clinical term used to 
describe patients at an intermediate stage between normal cognition and dementia. 
Functional independence is retained in MCI sufferers but the likelihood of developing AD, 
relative to non-sufferers at a similar age, is increased(18).  Studies have associated APOEε4 
with both MCI and its progression to AD(17). 
Alzheimer’s Disease is now the most common type of dementia  contributing 60-70% of the 
36 million cases worldwide(19).  Lifestyle choices such as diet, exercise and intellectual 
stimulation, are thought to offer protective benefits to developing AD. However, the 
inescapable process of aging is by far the greatest risk factor, with incidence of AD doubling 
every five years after the age of 60(18).  The toll that decline into AD takes on both 
sufferers and their carers is immense with loss of memory and cognitive abilities affecting 
every facet of daily life.  The increasing life expectancy of the population suggests the 
prevalence of AD will increase to 115 million by 2050(20).  A recent study has suggested 
that these projections may be an overestimation since they do not take into account other 
changing factors such as improvements to living conditions, education, and general health 
of the population(21). Nevertheless, there is already an urgent need to develop therapeutic 
treatments to alleviate the burgeoning social and economic burden of AD.  
The connection made between the genetic mutations in familial forms and Aβ in plaque 
pathology provide an obvious target for pharmaceutical development.  Strategies 
implemented in mouse models of familial AD have attempted to block Aβ production by 
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immunisation or by modulating the cleavage process in APP processing using secretase 
inhibitors.  The complete inhibition of these proteases may have potential harmful side 
effects due to the multiple functions they serve and in the case of the γ secretase, this is 
toxic(2,22).  Partial suppression of secretase activity  has been shown to reduce Aβ levels in 
the brain  and cognitive decline in animals and in the case of β secretase, some inhibitors 
are currently at an advanced stage in clinical trials(23).  Aβ immunotherapies have been 
shown to reduce plaque load in the brain in clinical studies of AD but the cognitive benefits 
are less certain(24).  These treatments are also associated with a number of amyloid-
related side effects including increased severity of cerebral amyloid angiopathy, thought to 
be exacerbated by the removal of plaques(24).   
Besides amyloid, other aspects of the AD pathogenesis have been targeted using anti 
inflammatory drugs, metal chelators, antioxidants, tau phosphorylation inhibitors, and 
compounds to lower cholesterol(2).  The recent use of tau immunotherapies in mouse 
models has demonstrated efficacy in reducing tangle pathology and cognitive decline and 
may offer another promising target for AD pharmaceutical development(25,26).  The 
translation of promising preclinical results to viable therapies has been impeded in some 
cases by findings of adverse side effects.  It is also suspected that improvement in the 
design of clinical trials is necessary to better detect the  positive effects of drugs, especially 
with regards to the stage of disease progression at which the treatments are 
administered(27).  To this end, researchers in the field see the development of in-vivo 
biomarkers sensitive to disease pathology essential to guiding and facilitating drug 
development(27). 
1.2 Biomarkers 
The Mini Mental State Examination(MMSE), is a clinical tool widely used to screen for 
dementia and is thought to successfully discriminate sufferers from healthy patient 
groups(28).  However, it lacks specificity to AD and is insensitive to MCI (29).  These tests 
may result in a diagnosis of ‘probable AD’, with post-mortem analysis necessary to confirm 
dementia type.  In 2007, the International Working Group for New Research Criteria for the 
Diagnosis of AD proposed a frame work that combined episodic memory tests and the use 
of biomarkers for the in-vivo diagnosis of AD as differentiated from other dementias(30).  
The use of biomarkers to take biochemical, pathological or anatomical measurements may 
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improve early detection and allow staging of disease providing longitudinal measurements 
by which therapeutic effects can be evaluated.  Techniques developed offer sensitivity to 
different factors in the multifaceted pathogenesis of AD and can be broadly divided in to 
biofluid sampling and medical imaging categories. 
The measurement of protein concentrations in sampled Cerebrospinal Fluid (CSF) is the 
most developed biofluid analyte technique(18).  Depressed levels of Aβ have been detected 
in MCI and AD patients, although the relationship with plaque deposition is unclear(17).  
Conversely, CSF concentrations of total tau and phosphorylated tau are elevated in AD and 
have been shown to rise with disease severity(18,31).  Variability between studies indicate 
there may be other factors influencing levels of tau in CSF(32) and the specificity to AD is 
lacking, with similar increases observed in other tauopathies(33,34). The cycle of Aβ 
production by platelets and deposition in the brain maintains a constant level of Aβ in the 
blood in healthy individuals(17).  Detection of disruptions to this status quo in disease has 
been attempted by analysing plasma samples.  While blood Aβ levels increase in familial AD 
have been reported, findings in studies of sporadic forms are inconclusive(17).   
Imaging biomarkers offer a method by which to probe tissue vitality and pathology and 
unlike biofluid markers provide spatial localisation of abnormalities.  The measurement of 
atrophy using MRI and plaque burden using amyloid positron emission tomography (PET) 
are two of the most frequently used techniques for the clinical study of AD(18).  The 
resolution and soft tissue contrast generated using MRI can be used to measure subtle 
volumetric changes in brain structures.  Atrophy occurs in normal aging and is accelerated 
in a number of conditions.   In AD, volume decreases in brain structures measured using 
MRI appear closely linked to both severity and rate of impairment in cognitive 
function(35,36).  Hippocampal reductions and brain-wide distribution of volume changes 
have been shown to correlate with the Braak stages of NFT pathology in AD(37).   
Plaque burden may be measured using amyloid PET which uses Pittsburgh Compound B as 
a tracer (sometimes called PiB PET).  It binds to plaques and the increased signal observed 
in AD has been shown to correspond with Aβ  burden at post mortem and is inversely 
correlated with CSF Aβ(17).  A recent hypothetical model suggests the sensitivity of these 
techniques is such that cases may be detected prior to the appearance of clinical 
symptoms(38).   However, some studies have identified pathology indicative of AD  at 
autopsy in almost one third of healthy subjects which is similar to the proportion of 
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abnormal scans in cognitively normal individuals reported in amyloid PET studies(18).   
Therefore, although sensitive to in-vivo levels of Aβ, amyloid PET may not be the most 
accurate predictor of the development of clinical symptoms.  More recently, fluorine based 
tracers that bind to amyloid have been developed that can successfully differentiate AD 
cases from healthy controls.  These compounds may prove more popular than PiB due to 
their greater availability(18).  Additional AD PET targets include reduced cerebral glucose 
metabolism detected by FDG-PET, and microglial activation detected using molecular 
imaging probes.  SPECT probes have been developed primarily to target dopamine 
transporters or receptors and may find application in the development of neuroprotective 
treatments in AD by providing  a measure of neuronal population (17). 
When envisaging the future of routine clinical care in AD, and the role that imaging might 
play, the completely non-invasive nature of MRI is a favourable attribute.  This confers a 
considerable comfort benefit to patients receiving regular monitoring of their condition 
and may be especially important in AD where subjects are likely to be elderly.   MRI 
includes the spatial information lacking in biofluid analytes and offers increased spatial 
resolution compared to nuclear imaging methods.  Besides structural methods, MRI 
measurements of diffusion, perfusion and spectroscopy are emerging as techniques that 
may provide sensitivity to the deleterious effects of the condition.  The disruption to the 
highly ordered microstructure of white matter tracts is thought to occur early in AD and in 
MCI, which causes measureable alterations in Diffusion Tensor Imaging (DTI) indices(39).  
Arterial Spin Labelling(ASL) is an MRI method used to measure blood perfusion in the brain 
and has shown deficits in AD that correspond to impaired cerebral metabolism in FDG-PET 
scans(18).  It can both differentiate between MCI and AD cases as well as predict transition 
from the MCI to AD(17,40).  Magnetic Resonance Spectroscopy(MRS) of hydrogen can be 
used to detect cellular metabolite levels.  AD patients exhibit reduced N-
acetylaspartate(NAA), thought to reflect decreases in neuronal population, in early 
neurodegeneration.  Neuronal activity can be probed, albeit indirectly, using fMRI and 
studies have been carried out for both task based and resting state paradigms.  There is a 
decreased BOLD signal in the hippocampus of AD patients during cognitive tasks(41) and  in 
the resting state, disruptions to the default mode network can be detected that 
differentiate normal cases from AD and MCI(40).  The endogenous nature of MRI contrast 
means that an assortment of measures of tissue composition, integrity and function may 
be gathered in a single, non-invasive, imaging session.  A number of studies have used 
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Multi-parametric MRI protocols to acquire data in MCI and AD patient cohorts(39,42-46). 
Many of these studies have collected structural MRI and DTI and report that an increased 
diagnostic accuracy is achieved through a combination of parameters(42,43,46).   
The biomarkers described in this section are not in current clinical use due to a lack of 
standardisation and questionable effects on disease outcomes given the absence of an 
effective treatment.  The use of animal models of AD can be used to expedite the 
optimisation of imaging markers for clinical use.  Pathology develops in a much shorter 
timeframe than in humans, typically over a few months, enabling a high throughput of 
biomarker testing.  Genetic mutations in transgenic mice can produce different ‘AD like’ 
pathophysiological features in isolation.  Therefore, biomarkers can be tested in a 
controlled environment and sensitivity to biological changes can be validated using 
histology.   
1.3 Mouse models of disease 
Early in the twenty-first century, in a testament to the value of big science, the sequencing 
of the human genome was completed.  This opened the floodgates for a plethora of 
scientific investigations into gene function and profiling.  Relationships between 
phenotypes and the DNA instructions detailing their architecture could now be defined.  
The benefits of genetic testing are being reaped clinically providing robust diagnostic 
testing for a growing number of conditions.  The mouse was the first animal to have its 
genome sequenced which was found to be very similar to that of humans.  Powerful 
genetic techniques have been developed that can introduce abnormalities into the mouse 
genome to generate AD models.  There are now a number of mice lines available that 
exhibit ‘human like’ plaque and tau pathology.  Low variability in phenotypes can be 
achieved using inbred strains, and the low costs and rapid maturation of these animals 
allows a high experimental throughput(47).    
Mouse models may vary in both the specific genes that are targeted as well as the way in 
which they are manipulated.  Genes can be inactivated known as knocking out, introduced 
known as knocking in, and mutated using chemical processes.  The earliest models of AD 
are based around the known genetic mutations in familial forms and are therefore 
associated with abnormal Aβ processing.  These mice develop plaques, cognitive deficits, 
and in some cases atrophy of brain tissue to varying degrees(48).  The different mutations 
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and promoters - DNA sequences that define where transcription begins, can be used to 
vary the regional distribution of pathology and age at which phenotypic changes occur. 
Transgenic mouse lines have been bred to over express normal hAPP (human APP) which 
causes reduced density in presynaptic terminals but not the accompanying plaque 
pathology observed in models expressing the mutated form(49).  Mutations in the 
presenilin gene produce an increase in Aβ levels(50) without cognitive deficits and plaque 
formation(48) that are only observed when crossed with mice expressing hAPP mutations 
to form a PSAPP model(51).  Interestingly, plaques occur at an earlier age compared to 
hAPP models(52), and appear after measurable cognitive deficits are detected in this 
double transgenic line(53). 
The full pathological profile of AD incorporates both plaque and tangle pathology.  NFTs 
accumulate in a progressive manner with age in mice with the P301L htau (human tau) 
mutation along with motor and behavioural deficits that are similar to the human 
condition(54).  The tau pathology in these mice is more severe when crossed with a hAPP 
model implying that amyloid deposition may intensify NFT formation(55).  Tau models 
expressing wild-type human tau display neuronal dysfunction without the aggregation and 
NFT formation in mutant forms(48).  In a study where mice with no endogenous tau alleles 
were crossed with a hAPP line,  an improvement in memory and learning was observed but 
there was no decrease in amyloid pathology(56).  Combined with the result from the 
P301L/hAPP double transgenic experiment, these findings suggest that tau aggregation 
may be a downstream event from plaque formation in line with the amyloid cascade 
hypothesis.  However, these studies do highlight a detrimental effect of both mutated and 
wild-type human tau on neuronal vitality that is not observed in models expressing 
mutated hAPP only.  Models that can replicate tau deregulation and aggregation in human 
AD therefore have an important place in the ongoing investigation of the disease.   
The increasing number of models available means that it is crucial to make an appropriate 
choice as part of the experimental design process.  In the case of drug development, the 
well documented time course of appearance of plaques and cognitive impairments in 
different models(48,57) should aid selection when targeting a specific stage of AD related 
pathology.  The administration of a pharmaceutical at discrepant timepoints in mouse 
models relative to AD patients may lead to failure to translate successful tests in mice to 
the clinic.  In-vivo biomarkers that provide spatial distribution and density of NFT pathology 
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could be used stratify the Braak stage of the disease and provide homologues between pre-
clinical and clinical studies.  Other important considerations include the fact that transgenic 
mice do not model sporadic AD in which there are differences in clinical and pathological 
symptoms compared to the relatively small population of familial forms.  Drug delivery is 
complicated by the large disparity in pharmacokinetics and the difficulty in equating doses 
in humans to those in mice(48).  These factors may have played a role in the failure of 
amyloid targeting drugs in human trials that had previously shown success in transgenic 
mice. 
The benefits of mouse models in the study of AD so far are undeniable: correlative 
relationships in degenerative processes observed in humans have been replicated and 
validated in mice; potential therapies developed; and the powerful isolation of amyloid and 
tau pathologies have demonstrated that they both have important roles in AD.  The failure 
of candidate amyloid modulating drugs to arrest cognitive decline in clinical trials to date 
has caused a shift in interest to alternative therapeutic pathways(2).  The more recent 
availability of mouse models that develop tau pathology that mimics the human condition 
may provide a new target for diagnostic imaging and therapeutic development. 
1.4 Pre-clinical imaging biomarkers 
Histological staining of ex-vivo tissue in cross sectional studies has provided quantification 
of the plaque and tangle pathology in mouse models of AD.  The age and severity at which 
deposits appear varies between lines, as does the extent of cognitive impairment observed.  
Imaging biomarkers offer the potential to track pathological changes over time in 
longitudinal studies and in many cases have analogous human protocols.  The repeated 
examination of the same subjects generates both group and individual comparison data 
that is both cheaper and reduces animal use.  This can expedite the testing and validation 
of new imaging techniques for clinical applications in AD.  External effects such as lifestyle 
choices are controlled for in animal studies and composite influences from multiple 
pathological processes can be dissected to provide new insights into mechanisms of 
disease. 
Pib-PET studies in mice with APP mutations have previously reported poor retention of the 
tracer(58,59) but more recently PSAPP mice have displayed a correlation between uptake 
and Aβ pathology(60).  Using a fluorine based tracer(florbetapir), thought to bind better to 
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fibrillar amyloid, excellent uptake can be achieved in PSAPP mice(61) and brain regions 
with plaque pathology are differentiated in PET images(62).  Decreases in FDG-PET signal 
have also been observed in PSAPP mice indicating the reduced metabolic activity 
associated with AD(52).  Methods specific to NFT pathology are under development(63) but 
PET has been shown to detect increases in tracers sensitive to reactive microglia in mice 
with a tau mutation(64).  The limited resolution of PET relative to the size of the mouse 
brain is a major drawback of the technique which can make accurate delineation of signal 
from specific structures challenging(65). 
The sophisticated methods of structural MRI analysis developed for measurements of 
volumetric changes in the human brain have been adapted for mice.  Studies in both 
Amyloid and Tau models have detected volumetric reductions in specific brain structures 
relative to wild-type controls(66-70) as well as measuring longitudinal changes(71).  
Plaques can be visualised in hAPP and PSAPP mice using high resolution T2 and T2* 
weighted imaging which may be due to the presence of iron(72-78).  Deficits in cerebral 
blood flow and white matter abnormalities have also been observed in amyloid models 
using ASL and DTI respectively(79-82).  The decrease in NAA levels associated with AD also 
occur in MRS of hAPP and PSAPP models(83). This effect has been shown to be attenuated 
after administration of anti-inflammatory drugs(84).  In a study that used manganese 
enhanced MRI to probe axonal transport transgenic mice that develop amyloid and tau 
pathology, deficits were observed prior to the age at which plaques and tangles appear(85).  
Tau pathology in AD progresses through the brain in a region-by-region manner described 
by Braak staging(11).  Imaging methods sensitive to the regional spread of NFTs over time 
would constitute a powerful marker of disease severity for longitudinal clinical assessment 
and pharmaceutical testing.  Due to the lack of an identified tau mutation in autosomal 
dominant forms of AD, mouse models are selected for the likeness of the pathological 
characteristics they develop to that of the human form.  One such model is the rTg4510 
model of tauopathy which expresses human tau with the P301L mutation.  The soluble tau 
expressed, co migrates with a hyperphosphorylated tau species observed in NFTs in the 
human disease(86).  In the rTg4510, aggregated Tau and NFTs accumulate in an increasing 
age dependent manner in parallel with memory impairment, neuronal cell loss and 
atrophy(87).  The calmodulin kinase II promoter system is used to direct expression to 
frontal brain structures causing high concentrations of tau pathology in the cortex and 
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hippocampus with gliosis(87).  The prevalence of NFTs appears to be independent of 
neuronal cell death in agreement with findings in clinical studies of AD(86,87).  As with 
Braak staging, a progressive regional spread of pathology is observed with age in the 
rTg4510(although this regional pattern is different to that observed in sporadic AD 
sufferers).  NFTs first appear in the cortex at 2.5 month before spreading to the limbic 
structures at 5 months(87).  At 8.5 months, high NFT density is observed throughout the 
forebrain structures and is accompanied by neuronal cell loss with gross atrophy apparent 
in visual comparisons of histology at 10 months(86).   
Prior to this work, a volumetric MRI study of the rTg4510 at five months showed early 
sensitivity to reductions in the hippocampus and cortex relative to wild-type controls.  This 
study also included proton MRS data that showed increases in myo-inositol to creatine 
ratios, indicative of glial activity in the hippocampus(70).  Investigations using manganese 
enhanced MRI revealed a reduction in neural activity in regions associated with memory 
formation at six months of age(88).  These early studies provide an indication of the 
sensitivity of MRI to pathology and degeneration in the rTg4510.  Investigation into 
techniques that probe other distinct aspects of AD pathophysiology such as perfusion, 
microstructure, and protein aggregation may provide a more complete characterisation of 
the rTg4150 phenotype.  
1.5 Summary and thesis aims 
In this introductory chapter, a brief overview of some of the major events in the discovery 
of AD is provided.  There is a need for this debilitating disease to be better understood.  
One method by which to achieve this may be to use mice as reductionist tools to observe 
and analyse individual known biological factors that may be tracked using biomarkers.  In 
this way, MRI may provide a tool to evaluate therapeutics and also elucidate new 
mechanisms in the pathogenesis.  The real power of this non-invasive modality may lie in 
the combination of data from the application of multiple techniques that are directly 
translatable to the clinic, providing a holistic approach to describe the neurodegenerative 
process.  In comparison to studies of mouse models of plaque pathology, there is paucity of 
pre-clinical studies into the role of tau in AD. 
To aid the development of pharmaceuticals that target tau pathology in AD, a collaboration 
was born between CABI and Eli-Lilly & Co. Ltd. with the aim of developing an in-vivo multi-
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parametric MRI protocol sensitive to pathology in the rTg4510.  In addition to structural 
MRI, the goal was to develop new techniques that provide sensitivity to other degenerative 
aspects of the disease to complement the information from this established biomarker.  
Total scan time is restricted by limits of anaesthesia duration in the mouse.  Development 
of time efficient acquisitions are necessary to collect multiple MRI metrics sequentially in a 
single session.  
Magnetic field gradients used for spatial localisation of signal are central to most MRI 
techniques.  Imperfections can cause distortions in structural MRI data used for volumetric 
analysis, and errors in diffusion estimates from DTI protocols.  The first aim of this work 
was to develop a novel calibration protocol that could be used to perform quality 
assurance by monitoring the accuracy of the system gradients of the MRI scanner.  This is 
described in chapter 3 and provided a foundation for the acquisition of consistent multi-
parametric data.  Secondly, the primary aims of this thesis focussed on the development of 
MRI protocols that would provide sensitivity to white matter degeneration in AD mouse 
models.  Diffusion Tensor Imaging and Quantitative Susceptibility Mapping protocols 
suitable for multi-parametric acquisition are designed, systematically optimised, and 
implemented in the rTg4510 mouse in Chapters 4 and 5 respectively.  In the next chapter, 
the theoretical MRI concepts applied in this thesis are outlined. 
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2  Magnetic resonance imaging theory and 
methodology 
2.1 Chapter summary 
In the first chapter, an overview of the current understanding of Alzheimer’s Disease was 
provided.  A case was made for the great potential of emerging MRI techniques to provide 
biomarkers of the various pathological traits of the disease and to aid in the development 
of new therapies.  In this chapter, the fundamental principles of MRI and the theory behind 
the relevant MRI techniques that have been applied in this thesis are described.  Firstly, the 
physics of NMR signal generation is outlined as well as basic pulse sequences and MR 
relaxation time constants that are referred to throughout this work.  Chapter three 
describes a technique developed to calibrate gradients so key concepts involved in the 
spatial encoding of the MRI signal are covered.  In the latter sections of this chapter, 
methods of Diffusion Tensor Imaging and Quantitative Susceptibility Mapping are detailed 
to provide the reader with some understanding of steps involved in the protocols applied in 
chapters 4 and 5.  
2.2 NMR signal generation 
The signal in Nuclear Magnetic Resonance(NMR) can be described theoretically using a 
mixture of classical physics and quantum mechanics with each providing an explanation of 
different aspects of the phenomenon.  Whereas quantum mechanics is useful for 
describing the interaction of magnetic fields with individual atomic nuclei, a classical 
treatment is more helpful in understanding the cumulative behaviour of a population.  
Electromagnetic radiation travels in waves consisting of packets of energy known as 
quanta.  The relationship between these wave and quantal properties of radiation are 
described by the equation  
     
Equation 1  
where   is the energy of a quantum, h is Planck’s constant and   is the frequency of the 
electromagnetic wave.  The interaction between magnetic radiation and molecules can 
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involve absorption or emission of a quantum of energy.  This will result in a molecular 
energy level transition that is of equal energy to the quanta.  This interaction between 
matter and radiation is central to the quantum mechanical theory of MRI. 
The 1H nucleus imaged in MRI is a member of a class of nuclei that possess the property of 
spin.  The nucleus of such atoms is often referred to simply as a ‘spin’ in NMR and gyrates 
around its own axis generating an angular momentum(Figure 2) like a spinning top.  The 
hydrogen nucleus consists of a single proton giving it positive electric charge.  In the 
manner of a circulating electrical current in a loop of wire, the spinning motion of this 
positively charged nucleus generates a magnetic field.  When placed in an external 
magnetic field, a turning moment acts on this ‘nuclear dipole’.  This is known as the 
magnetic moment,    and is associated with the angular momentum, of the spin.  This 
angular momentum, p, can only take discrete values specified by quantum number I  and is 
calculated as(89) 
                   
Equation 2  
where          
 
Figure 2. Spin angular momentum 
Schematic of various orientations of the angular momentum vector of a nucleus labeled 
with z components pz and quantum number m.  Figure adapted from (89). 
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I can take integral or half integral values based on the number of protons and neutrons in 
the nucleus in question.  In the case of the 1H nucleus, I = 1/2.  In MRI we are interested in 
the component of angular momentum in the direction of the main magnetic field (B0).  The 
angular momentum is a vector quantity and therefore has both magnitude and direction.  
Another quantum number, m, can be used to define the component in the direction of the 
magnetic field (z) as(89)     
         
 
 
 
Equation 3  
reflecting two possible spin states.  The interaction between the magnetic moment and the 
B0 field causes the nucleus to acquire an energy, E, given by(89) 
         
Equation 4  
where γ is the gyromagnetic ratio (approximately 2.68x108 rad/s/T for the hydrogen proton 
in water). A difference in energy between the two possible values of ±1/2 that m can take 
can be calculated as 
        
Equation 5  
The NMR signal is generated through the transition of spins between the two energy states 
described by Equation 4.  This is achieved through the absorption of energy from an 
oscillating magnetic field, B1, generated using Radio Frequency (RF) pulses.  To induce 
transitions, the frequency of oscillation,  0 , must be such that  
       
Equation 6  
where 
        
Equation 7  
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Equations 5,6, and 7 can be combined to give 
       
Equation 8  
This relationship defines the frequency, known as the Larmor frequency, that nuclei of a 
particular gyromagnetic ratio, will precess at in a magnetic field.  It is also the frequency 
that is required for the oscillating magnetic field, B1, to induce spins to undergo transitions 
between energy levels. 
One of the factors governing the amount of signal available in MRI is the difference in the 
number of nuclei in the higher N+ and lower N- energy states at equilibrium.  This is 
described by the Boltzmann distribution which gives the relative populations of spin states 
in a sample(89) 
  
  
   
 
    
   
 
Equation 9  
where k is the Boltzmann constant  and T is the temperature in Kelvin.  The spins in the 
positive energy state are in parallel alignment with the main magnetic field and have less 
energy than those in the negative energy state that are in anti parallel alignment.  The 
lower energy state is more populated at equilibrium and there is a net absorption of energy 
when an oscillating B1 field is applied at the Larmor frequency.  If energy state populations 
were equal, there would be equal transitions in both directions and no signal would be 
generated.  The population difference that gives rise to the NMR signal is very small and is 
responsible for the limited sensitivity of NMR.  As indicated by Equation 9, a greater 
discrepancy in spin states can be generated at greater B0 values, and SNR is increased with 
magnetic field strength. 
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Figure 3. Spin energy states 
Spins with their magnetic moment aligned parallel and anti parallel to the magnetic field.  
Energy equal to ΔE must be absorbed to transition from the lower energy state (m=+1/2) to 
the higher energy stat(m=-1/2).  Figure adapted from (89). 
 
This quantum mechanical description indicates that the source of the measured signal is 
born from the difference in the populations between the two spin energy states.  From 
here on, a more classical physics approach will be taken in describing the properties of the 
cumulative magnetic contributions from the signal generating proton population i.e. only 
those that transition to the higher energy state during a particular RF excitation.  When 
placed in a magnetic field, the angular momentum of a spin causes it to process about the 
field at the Larmor frequency.  At equilibrium, the precessing protons are all out of phase 
with each other and the angles made between their magnetic moments and B0 are 
distributed randomly.  By taking the vector sum of the magnetic vectors we can describe 
the proton ensemble by a net magnetization vector, M, which is at equilibrium is aligned 
along the direction of the main field, z(Figure 4a).  The cancelling of components 
perpendicular to the z axis means that, “at rest”, there is no magnetisation in the xy plane 
(known as the transverse plane), Mxy, necessary for signal detection.   
The equilibrium magnetisation, M0, can be rotated towards the xy plane using an RF pulse 
applied perpendicular to the B0 direction at the Larmor frequency.  The net magnetisation 
vector will precess around the direction of the B1 field generated by the RF pulse.  This 
causes it to tip away from the z axis direction towards the xy plane.  The angle subtended 
between the magnetisation and the z axis directly after the pulse is switched off is known 
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as the flip angle(Figure 4b).  In the case of ‘hard pulses’ which are simply switched on and 
the off, the flip angle(α) is defined by(89) 
          
Equation 10  
where B1 is the strength of the magnetic field applied and tp is the pulse duration.  
Considering the case where a pulse is applied with a flip angle of 900, all magnetisation is 
now aligned with the transverse plane and the z component is zero(Figure 4c).   As soon as 
the pulse is switched off, the protons once again precess around the static B0 field and 
there is now an Mxy component known as transverse magnetisation because the spins 
precess in phase.  The Mxy component rotates round the z axis and can be detected using a 
receiver coil.  An electromotive force is induced in the receiver coil that oscillates at the 
Larmor frequency that is further processed by the receiver hardware to produce the NMR 
signal.   
 
Figure 4. Rotation of the net magnetic vector 
Net magnetic vector in the rotating frame at equilibrium(a), after application of a B1 field 
along x to tip the magnetization by flip angle, α,(b), and when tipped 90
0
  into the 
transverse plane aligned with the y axis(c). 
 
The signal received is known as the free induction decay (FID) since over time the Mxy 
component is reduced to zero again and the Mz component recovers to its initial value 
equal to M0. The mechanisms governing the evolution of each component after excitation 
are different.  The Mz component recovers through spin-lattice relaxation described by the 
T1 time constant, sometimes called T1 relaxation.  During this process, energy absorbed 
through RF excitation is transferred to the lattice.  The Mxy signal decays without energy 
transfer and is caused by dephasing and loss of coherence of the magnetic vector 
33 
 
contributions of individual protons.  This decay is driven by spin-spin relaxation, described 
by the T2 time constant, in addition to the T2’ time constant which describes dephasing 
caused by inhomogeneities in the main magnetic field.  These two parameters are often 
combined to give the time constant T2* as 
 
   
  
 
  
 
 
   
 
Equation 11  
The recovery over time, t, of the magnetisation following the excitation pulse along the z 
axis to its initial value, M0, is given by 
            
       
Equation 12  
And the decay of the transverse signal can be calculated as 
          
     
 
 
Equation 13  
 
The T2* decay of the magnitude of the FID signal induced in the receiver coil over time is 
depicted in Figure 5.  The net magnetic vector of the transverse magnetisation rotates 
around the z axis with an angular frequency that can be described in terms of phase angle 
as 
       
Equation 14  
i.e. frequency is the rate of phase change with respect to time, t.  Differences in frequency 
between spins will generate a difference in phase over time.  In the case of the FID, the 
effect of a 900 phase difference on the signal can be observed in Figure 5 .  Frequency 
differences can be induced by gradients in the B0 magnetic field across the spin population 
which will give rise to phase differences that can be exploited for spatial encoding or 
contrast purposes. 
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Figure 5. Free Induction Decay 
Two FIDs that are approximately 90
0
 out of phase with each other, at time zero the FID in 
(a) has minimum signal whilst the FID in (b) has maximum signal.  Figure adapted from (89). 
2.3 Echo formation 
An alternative method to sampling the FID is to further manipulate the NMR signal to form 
what is known as an ‘echo’, which is more commonly acquired in MRI.  The two most basic 
sequences used to generate signal in this format are called gradient echo and spin echo 
sequences (Figure 6).  Whereas gradient echoes are formed using magnetic field gradients, 
spin echoes require an additional RF pulse.   
To form a spin echo, spins are left to dephase in the transverse plane after excitation using 
a 900 RF pulse.  At a time equal to half of the time to echo(TE), a 1800 refocusing RF pulse is 
used generate a B1 field in the y direction(orthogonal to the 90
0 pulse) in the rotating 
frame, to flip the spins in the xy plane such that it reverses the sign of the phase difference 
they have accumulated relative to the Larmor frequency.  The spins precessing at a higher 
frequency now have a phase lag and will catch up with those precessing at a lower 
frequency in the second half of the TE to form a spin echo(Figure 6a).  The effects of field 
inhomogeneities will be reversed by the refocusing pulse and therefore spin echoes are 
unaffected by T2’ relaxation.  The dephasing caused by spin-spin relaxation does occur and 
spin echoes are therefore described by the T2 time constant.   In the case of a spin echo, 
the transverse magnetisation decay over time can be calculated by substituting the T2* 
term for T2 in Equation 13.  Images can be generated through the repeated acquisition of 
echoes combined with spatial encoding using magnetic field gradients which is discussed in 
section 2.5.  This time between excitations is known as the time to repeat (TR) and controls 
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the amount of signal recovery in the longitudinal plane (Mz). The signal from a spin 
isochromat(group of spins precessing at the same frequency) using a spin echo sequence is 
given by 
        
               
Equation 15  
where S0 is the signal measured with infinitely long TR and infinitely short TE. 
 
Figure 6. Echo formation 
Echo formation using a spin echo sequence(a) and a gradient echo sequence(b). 
 
In the case of gradient echo acquisitions, a magnetic field gradient is applied after RF 
excitation that causes rapid dephasing of the transverse magnetisation (Figure 6b).  This 
gradient field is then reversed so spins experience an equal and opposite magnetic field 
and frequency change.  This has the effect of rephasing the transverse signal forming an 
echo at a time equal to TE.  Both field inhomogeneities and spin-spin relaxation will 
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contribute to the loss of phase coherence over a TE and will not be eliminated in the 
process of echo formation.  The decay of the transverse magnetisation at echo time is 
driven by T2* and can be calculated using Equation 13.  The lack of a refocusing pulse 
means that flip angles other than 900 may be used in gradient echo sequences.  The use of 
lower flip angles increases the longitudinal magnetisation retained after excitation allowing 
a quicker recovery of signal and rapid acquisitions using lower TRs.  Therefore in addition to 
the parameters of TE and TR that control the signal in spin echo sequences, gradient echo 
acquisitions can be manipulated using the flip angle.  The relationship between these three 
controllable parameters in gradient echo sequences is described by(90) 
          
      
 
 
           
               
 
Equation 16  
 
2.4 Relaxometry 
The measurement of relaxation time constants T1, T2, and T2* can be performed using 
variations of the spin echo and gradient echo pulse sequences.  In the case of T2*, 
measurement of a multi echo gradient echo sequence can be used to capture the 
transverse decay curve.  Bipolar gradients can be used sequentially after excitation to 
rephase the transverse magnetisation and a monoexponential fit (Figure 7) can be used to 
estimate T2* using Equation 13.  A similar process can be used to measure T2 by fitting the 
decaying signal using a multi echo spin echo sequence using 1800 RF pulses to continuously 
refocus spins to generate echoes of decreasing magnitude. 
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Figure 7. T2* measurement 
Formation of echoes using a multi echo gradient echo sequence.  Rephasing of the 
transverse signal generates echoes of decaying magnitude that can be used for 
monoexponential fitting to estimate T2*. 
 
A popular method by which to measure T1 is using an inversion recovery sequence.  A 1800 
RF pulse is used to invert the longitudinal magnetisation(in the negative direction in the z 
axis) which then recovers towards its equilibrium value.  A time after inversion(TI) a 90 
degree pulse can be used to tip the magnetisation into the transverse plane to allow  a 
measurement of the longitudinal magnetisation recovery.  Repeating this process at 
multiple TIs provides multiple measurements of the T1 recovery curve that can be fit using 
a monoexponential function to estimate the T1 recovery constant.  The signal for an 
inversion recovery spin echo acquisition is given by(91) 
          
  
  
  
 
  
  
  
  
 
         
Equation 17  
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2.5 Spatial encoding 
To generate images using the NMR signal, spatial encoding is required to separate 
components from the different locations in a sample.  In MRI this is accomplished by 
introducing inhomogeneities in the main magnetic field using gradient coils.  The spatially 
varying magnetic field causes the frequency of spin precession to change with position.  
The signal strength at a particular position can then be determined via measurement at the 
corresponding frequency.  The spatial frequencies are mapped in three dimensions by 
application of pulsed gradients in the three axes of the scanner frame of reference. These 
can be described mathematically as 
    
   
  
             
   
  
           
   
  
 
Equation 18  
Where Gi is the gradient magnitude in axis i, Bz is the strength of the magnetic field in the z 
direction and x,y, and z are displacements in the direction of the respective axes. 
The raw MRI data acquired is arranged to form a spatial frequency domain known as ‘k-
space’ which can be transformed into an image space using a mathematical tool called the 
Fourier Transform(FT).  To reconstruct images from sampled data a special version of this 
technique is used called the discrete Fourier transform(DFT).  In order to resolve spin 
isochromats precessing at different frequencies, the DFT requires that they must possess a 
phase difference of at least 2π radians in the sampled signal(92).  The spatial dependence 
of frequency in the presence of an applied gradient in the x direction is given by 
                  
Equation 19  
And using Equation 14 we can express this relationship in terms of signal phase : 
                    
Equation 20  
So the phase at position x is dependent on both the magnitude of the gradient along the x 
axis as well at its duration, t.  It is the product of the gradient amplitude and gradient 
duration that determines the phase offsets between spin isochromats and therefore the 
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final spatial resolution.  Sampling the MR signal as time increases in the presence of a 
gradient field provides information about smaller and smaller volumes in the final image.  
In k-space this corresponds to filling locations further and further out from the centre 
which represent higher spatial frequencies.  The cumulative gradient time product, known 
as k is defined as 
              
Equation 21  
Where i denotes both the axis on which the gradient was applied and the axis along which 
the k-space matrix is filled with the sampled spatial frequency data.  By sampling in 
multiple directions, a matrix representing the distribution of spins at various spatial 
frequencies can be produced that yield an imaging slice(2D) or volume(3D) after Fourier 
transformation.  The conventional methods of spatial localisation of signal in 2D MRI 
acquisitions involve application of linear gradients for slice selection, frequency encoding, 
and phase encoding.  These gradients, are applied in a 2D gradient echo sequence as 
shown in Figure 8. 
 
Figure 8. 2D Gradient Echo pulse sequence 
2D gradient echo pulse sequence with slice select(SS), phase encode(PE), readout(RO) 
gradients. 
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A slice of the volume to be imaged is acquired by simultaneous application of a linear 
gradient along the desired axis (z in this case) and excitation using a frequency selective RF 
pulse.  The position of the slice is determined by the centre frequency(ωrf) of this RF pulse 
which corresponds to a point in space along direction of the applied gradient where spins 
are precessing at this frequency,  This relationship is described by 
             
Equation 22  
 and the slice thickness, Δz, is dependent on bandwidth of the pulse(Δω), given by 
    
  
   
 
Equation 23  
After slice selection, the combination of frequency encoding and phase encoding in the 
remaining two orthogonal axes (in this case, x and y respectively) is used to produce ‘in 
plane’ k-space data.  In the frequency encoding or ‘readout’ direction, the MR signal is 
sampled in the presence of a pulsed gradient with position encoded as in Equation 19.  The 
zeroth gradient moment is equal to zero at the central point of k-space and represents a 
component of the acquired signal that is uniform throughout the volume.  The filling of 
Cartesian k-space follows the pattern similar to that depicted in Figure 9.  For each line in 
the readout direction a dephase gradient is applied prior to acquisition to move to one 
edge of k-space.  A rephase gradient is then applied in the opposite direction and the MR 
signal is sampled as the whole width of k-space is traversed. 
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Figure 9. K-space 
Example of k-space being filled from left to right by sampling the echo during a rephase 
readout gradient (thick blue arrows).  The phase encode gradient and the dephase readout 
gradients are used to traverse to the start point (thin blue lines) before acquisition.  Figure 
adapted from (92). 
 
In the axis perpendicular to readout, known as the phase direction, data is acquired by 
application of a relatively short pulsed gradient prior to readout.  This generates an 
accumulation of phase by the time of acquisition that is position dependent described by 
Equation 20. The magnitude and duration of this phase encode gradient determine the 
point on the phase k-space axis that is traversed during signal readout.  Due to the decay of 
the signal due to relaxation processes, the signal is refreshed for each line of k-space in the 
phase encode direction after one TR.  The whole of k-space can be filled by varying the 
phase encoding gradient for each TR. 
The spacing between points in k-space determines the Field of View (FOV) imaged.  The 
relationship between spatial frequency resolution Δki  and the image domain is described 
by the following equations(92) 
           
 
    
 
Equation 24  
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Equation 25  
where =γ/2π . 
We can rewrite these equations in terms of image domain resolution: 
  
    
    
  
  
 
  
 
Equation 26  
where   can be substituted for x,y, or z axes. 
For 3D MRI acquisition, the slice selection is applied to the whole volume in the required 
FOV, referred to as ‘slab selection’.  This is followed by the application of phase encoding 
gradients in the slice selection axis and  k-space can be extended to a third dimension that 
is traversed a similar manner to the in-plane phase encoding dimension in 2D acquisition.    
2.6 Echo Planar Imaging 
2.6.1 Single and multi-shot acquisitions 
The filling of k-space line by line in the conventional MRI acquisition described in the 
previous section is accomplished by refreshing the transverse magnetisation over multiple 
TRs.  Advances in modern hardware performance allow faster switching of gradients with 
larger amplitudes and rapid sampling of the MR signal.  This has enabled k-space to be 
completely traversed after a single excitation using Echo Planar Imaging (EPI).  The readout 
gradient is repeatedly switched to rephase the transverse magnetisation which can be 
sampled many times before decaying away.  EPI sequences commonly use ‘blipped’ phase 
encoding gradients to step through k-space in the phase direction incrementally.  A 
gradient echo single shot or ‘true’ EPI pulse sequence is shown in Figure 10 along with the 
trajectory in k-space. 
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Figure 10. Single shot EPI 
Pulse sequence for single shot EPI (a) and diagram describing trajectory through k-space(b).  
Figure adapted from (92). 
  
The long readout time in EPI makes the resultant images vulnerable to distortion from 
magnetic field inhomogeneities and signal drop out from T2* decay.  The limitations on the 
amplitude and slew rates of the gradients both limit the achievable resolution as well as 
preventing reductions in readout time to minimize susceptibility effects.  An alternative 
approach is to take an interleaved multi-shot approach to fill k-space using multiple 
excitations (Figure 11).  Although less time efficient and more sensitive to artifacts from 
motion, less demands are placed on the gradients so a greater spatial resolution can be 
achieved.  Multi shot approaches have shorter readouts and are therefore less affected by 
T2* effects and artifacts arising from low bandwidth in the PE direction in true EPI are 
reduced.   
44 
 
 
Figure 11. Multi shot EPI 
Diagram of k-space trajectory of a multi shot EPI acquisition with three excitations.  Figure 
adapted from (92). 
 
2.6.2 Artifacts 
The time between signal samples in the PE direction in EPI is equal to the time between 
echoes formed from consecutive rephrase gradients, known as echo spacing(ES)(Figure 
10a).  This sampling occurs at a much lower rate than in the frequency encoding direction 
and the bandwidth per pixel in the PE direction can be calculated by 
     
 
     
 
Equation 27  
which is lower than the bandwidth per pixel in the frequency encoding direction by 
approximately a factor of approximately     .  This is particularly important when 
considering the effects of the chemical shift phenomenon in MRI.  The electronic 
environment of nuclei can modulate the magnetic field experienced by a spin (Beff) given by 
              
Equation 28  
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Where σ is the shielding constant and is approximately 3.3ppm for fat.  Consequently, the 
protons in fat will precess at a shifted frequency that may cause mislocalisation of the 
signal to neighbouring voxels.  The size of the spatial displacement of the signal is inversely 
proportional to bandwidth per pixel and may be calculated by 
     
   
    
  
Equation 29  
The use of an interleaved multi-shot sequence means that k-space is traversed at an 
increased rate and combining Equation 27 with Equation 29 it is apparent that reducing Npe  
will reduce the pixel shift of fat by a factor of 1/Nshot, where Nshot  is the number of shots 
used in the EPI acquisition.  The spatial shift of fat in tissue can cause significant artifacts in 
EPI images and further measures may need to be taken such as the use of frequency 
selective RF pulses to saturate the fat signal prior to excitation.   
EPI images can often suffer from geometric distortion caused by sources of magnetic 
susceptibility differences between regions in the volume of interest.  The magnitude of 
distortion, d, is increased in the PE direction due to low bandwidth and is given by(92) 
   
    
 
  
       
    
  
Equation 30  
where G is magnitude of the PE gradient blips and    is the resolution in image space in 
the phase encode direction.  The k-space steps in the PE direction in multi shot EPI are 
larger than in single shot acquisitions as can be seen in Figure 11.  The gradient-time 
product of the blips must therefore be greater, and as shown by Equation 30, this will have 
the effect of decreasing distortion.   
Gradients arising from magnetic field inhomogeneities may cause signal loss and blurring in 
addition to geometric distortion.  Consequently, the pulse train length is limited by T2* 
decay which is given by 
 
  
   
 
  
      
Equation 31  
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The readout time in single shot EPI is long relative to the T2* of tissue making it more 
sensitive to effects of signal dephasing when  compared with the truncated echo trains 
used in multi shot acquisitions. 
Both single shot and multi shot EPI acquisitions are susceptible to N/2 or nyquist ghosting 
artifacts.  These are caused by misalignments of echoes along the PE k-space axis which 
manifest in images as faint ‘ghost’ images displaced by half of the field of view.  This 
problem stems from the necessity to acquire each consecutive line of k-space with read 
gradients of alternating polarity.  Echoes acquired with negative gradients are reversed 
with respect to time and effects of eddy currents and processing of the signal by the RF 
receiver produces differences between odd and even lines in k-space(Figure 12). 
The rapid switching of gradients in the MRI scanner causes a fluctuating magnetic field that 
may induce electrical currents into conducting scanner components known as eddy 
currents.  These eddy currents cause a lag between the current in the coil and the gradient 
field and this delay causes the rephasing of the echo to be time shifted with respect to the 
centre of the acquisition window.  After time reversal of the odd echoes, this shift is in the 
opposite direction in k-space creating a zigzag pattern along the phase encode axis in k 
space.  If the eddy currents induced are asymmetric, B0 field modulation occurs and echo 
delays are not consistent across the field of view.  This may be caused by misalignments 
between the gradient coil and the structures in which eddy currents occur.  Another source 
of time delay is introduced during the low pass filtering of the signal in the receiver to 
remove noise from the MR signal. 
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Figure 12. Echo misalignment 
Echo misalignment in k-space caused by time delay between gradient current and gradient 
waveform.  A discrepancy between echo peaks in k-space is caused by time reversal of even 
echoes.  Figure adapted from(92). 
 
2.6.3 Nyquist ghost reduction 
The effects of eddy currents on the gradient waveforms may be reduced by scanner 
manufacturers through the use of pre-emphasis of the gradient waveforms as well as 
hardware to actively shield the gradient coils.  However, further techniques are required to 
remove the residual offsets of odd and even echoes in EPI.  A simple method is to delay to 
the start of the signal acquisition by a time that is equal to the lag between the current and 
the gradient waveform.  This aligns the echoes with the centre of the acquisition window.  
Reference scans are an alternative method used to correct for phase and time shifts 
between odd and even echoes.  Navigator echoes are acquired without phase encoding 
and the position of the echo peaks are detected.  Phase and timing adjustments are then 
calculated to align echoes along the PE k-space axis.  In the case of full reference scans, 
navigator echoes are collected for all lines of k-space in the EPI image which also has the 
effect of doubling the scan time. 
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2.7 Diffusion MRI  
2.7.1 Diffusion weighting of the MR signal  
Diffusion is a process by which molecules travel from areas of high concentration to areas 
of low concentration by way of random thermal motion.  Ficks first law describes the net 
flux of particles from regions of high concentration to low concentration(93): 
        
Equation 32  
Where J is the net particle flux, C is the particle concentration, and D is the diffusion 
coefficient.  Einstein later related the mean displacement of an ensemble of particles that 
occurs as a result of Brownian motion to the diffusion coefficient by the equation(93) 
         
Equation 33  
Where <x2>  is the mean-squared displacement of the ensemble, and Δ is the time over 
which diffusion occurs, known as ‘diffusion time’.  Diffusion weighted (DW) MRI is used to 
measure the amount of displacement of water molecules in tissue.  This can be achieved 
by the addition of ‘diffusion weighting’ gradients to a standard sequence.  In the simple 
case of a spin echo sequence, two identical DW gradients can be added, one between the 
90 degree excitation and the 180 degree refocusing RF pulses, and one after the 180 
degree pulse(Figure 13).  This method developed by Stejskal and Tanner is known as a 
pulsed gradient spin echo sequence. 
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Figure 13. Pulsed gradient spin echo pulse sequence 
Stejkal and Tanner diffusion weighted sequence.  Pulsed gradients are added to a spin echo 
sequence to generate diffusion weighting. 
 
The effects of these additional gradients can be best understood in a ‘narrow pulse’ regime, 
where the separation between the two pulses(Δ), is much greater than the pulse duration 
(δ).  Under these circumstances, diffusion taking place during the pulses is ignored, and the 
calculation describing the attenuation of the MR signal of a populations of spins caused by 
diffusion is much simplified(94).  The application of the first pulsed gradient will induce a 
spatially dependent phase shift, Ф1, in the transverse component of the MR signal of a spin 
that can be described by 
Ф1 = γ.G.z1.δ 
Equation 34  
where G and δ are the magnitude and duration of the gradient pulses and z1 is the position 
of the spin along the z axis in this example.  Likewise, the phase accumulation, Ф2 , of a spin 
generated by the second diffusion gradient is given by 
Ф2 = γ.G..z2.δ 
Equation 35  
The effect of the 1800 RF refocusing pulse is to reverse the direction of the phase induced 
by the second gradient, and therefore the aggregate accumulated phase caused by 
diffusion weighting using this sequence is 
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dФ = Ф2 - Ф1 =  γ.G.δ( z2 - z1) 
Equation 36  
It is apparent from this relationship that stationary spins will experience zero net phase 
change. Since the phase accumulation from the first gradient is flipped in polarity by the 
refocusing pulse, the second gradient has the effect of generating an equal and opposing 
phase change.  Spins that experience a displacement component in the direction of the 
gradient between the pulsing of the gradients will not experience equal phase shifts and 
will therefore have a net phase change at echo time.  The incomplete cancellation of 
induced phase increments will cause a spread of phases that will attenuate the cumulative 
transverse MR signal of a population of spins.  This effect can be described by signal 
attenuation, A, which is equal to the diffusion-attenuated signal, S, divided by the 
unweighted signal, S0, which can be expressed as(94) 
  
 
  
          
                               
Equation 37  
The term       is the spin density at the time of the first gradient pulse and describes the 
inital concentration of spins at location   .              is called the diffusion propagator 
and is the conditional likelihood that a spin at location    will have diffused to location   , 
in diffusion time Δ.  Where D is the diffusion coefficient, and diffusion is isotropic(94) : 
            
 
     
  
          
 
    
Equation 38  
By combining Equation 37 with Equation 38 the attenuation can be calculated as  
          
    
Equation 39  
Sometimes all gradient effects are summarised using a term known a ‘b value’ or ‘b factor’ 
which describes the magnitude of diffusion weighting :  
        
Equation 40  
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In practical situations, the ‘narrow pulse’ assumption is violated and diffusion will occur 
during the application of diffusion gradients.  The diffusion time then becomes less trivial to 
define although            is commonly used instead of Δ.  The b-value is therefore 
calculated as(94) 
                        
Equation 41  
Attenuation of the MR signal may be calculated by division of MRI images acquired with 
diffusion weighting gradients by spatially corresponding unweighted images, known as B0 
images in DW-MRI.  The pulsed gradient parameters can then be used to provide an 
estimate of Diffusion Coefficient.  When applied to measurements in tissue, this is referred 
to as the Apparent Diffusion Coefficient (ADC) and can be used to infer the presence of 
structures that restrict diffusion.  In some cases where microstructural arrangements in 
tissue cause highly anisotropic diffusion of spins, sampling in multiple directions may be 
necessary to characterise the environment.   
 
2.7.2 Diffusion Tensor Imaging 
Some tissues such as the white matter in the brain, have shown diffusion estimates to be 
highly dependent on direction (95) due to the highly ordered nature of their diffusion 
restricting structures.  The spin diffusivity in these environments is direction dependent 
and cannot be fully characterised using the scalar ADC value.  The diffusion tensor model 
(96,97), was developed to describe diffusion in three dimensions.  The diffusion tensor, 
given below, is a 3 x 3 matrix describing displacement in three dimensions, which can be 
calculated at each voxel in the images acquired. 
 
    
         
         
         
  
Equation 42  
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The ‘on diagonal’ elements     ,    , and     indicate the diffusivity along each of the 
three principle orthogonal axes(x,y,z), and the off-diagonal elements give a measure of the 
correlation between them.  The diffusion tensor can be described in terms of an ellipsoid 
(Figure 14), the surface of which represents the distances from the origin that a molecule 
will diffuse.  The principle axes of the ellipsoid are given by the eigenvectors of the tensor 
and diffusion distance along each axis over time t is given by the eigenvalues.   In an 
isotropic medium with equal diffusion in all directions, this ellipsoid will be spherical.  For 
environments where diffusion is more favourable in a particular direction, the ellipsoid will 
become more stretched in this direction.   Since the tensor is symmetric, there are only six 
unknown elements to determine and therefore, we need to image with diffusion weighted 
gradients applied in six different directions to generate the six simultaneous equations 
necessary to solve using linear algebra.    
 
 
Figure 14. The diffusion tensor ellipsoid 
A depiction of the ellipsoid representation of the diffusion tensor labeled with eigen 
vectors,i, and eigenvalues, .  Figure adapted from (93). 
 
A number of clinically useful measures can be derived from the diffusion tensor that are 
rotationally invariant.  The Mean Diffusivity (MD) is simply the mean of the diagonal 
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elements of the tensor, known as the trace of the tensor, and gives a scalar value of the 
average diffusivity in a voxel(93):   
 
   
     
 
 
Equation 43  
The MD can be used in combination with eigenvalues of the tensor to provide a measure of 
the anisotropy of diffusion in the voxel that is rotationally invariant.  The most popular 
anisotropy measure used in the literature is Fractional Anisotropy (FA), which normalizes 
the variance of the eigenvalues to the magnitude of the tensor and is scaled to take values 
in the range zero to 1.  It gives a measure of the fraction of the tensor that can be 
attributed to anisotropic diffusion and is given by(93) 
    
  
  
  
                           
   
    
    
 
 
Equation 44  
where λ1, λ2, and λ3 are the primary, secondary, and tertiary eigenvalues of the diffusion 
tensor.  In white matter tracts of the brain, where highly anisotropic diffusion is observed, 
these eigenvalues can be interpreted as measures of axial diffusivity in the direction of the 
fibres and radial diffusivity perpendicular to fibres across the tract(98).  Axial diffusivity(DA) 
is given by 
DA = λ1 
Equation 45  
and Radial diffusivity(DR) is calculated as 
DR =  (λ2, + λ3)/2 
Equation 46  
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2.8 Quantitative Susceptibility Mapping 
2.8.1 Magnetic susceptibility 
Magnetic susceptibility, χ, is a quantitative property which determines a materials 
tendency to interact with and distort a magnetic field.  A materials magnetization, M, is 
linearly related to the applied magnetic field, H, by the formula 
M= χH 
Equation 47  
Diamagnetic materials have χ < 0 and paramagnetic materials have χ >0, with 
ferromagnetic materials having  χ >> 1.  In the case of human tissue, values of |χ| << 1 are 
typical in MRI, with values close to that of water (χ~-9ppm).    
2.8.2 Magnetic susceptibility from the phase of the MR signal 
The phase of a gradient echo MRI signal at echo time(TE) is sensitive to magnetic 
susceptibility effects that cause variations in the main magnetic field, B0. This relationship is 
described by 
                   
Equation 48  
Where ΔФ is the difference observed in the phase of the net magnetic vector (relative to 
larmor frequency) and ΔB is the difference in magnetic field from the scanner B0 field 
strength.  Equation 48 can be used to calculate changes in the magnetic field, which have a 
functional dependence on the magnetic susceptibility distribution, using the phase of the 
MR signal.  It has been shown that signal phase can be calculated through the convolution 
of the magnetic susceptibility distribution with a magnetic dipole field(99,100). 
                     
   
 
 
  
  
 
  
             
Equation 49  
Where K is the k-space vector, and  
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Equation 50  
This convolution becomes a pointwise multiplication in the Fourier domain and by 
rearrangement of the Equation 49 we can express the magnetic susceptibility in terms of 
the measured MRI phase signal. 
 
                  
        
        
      
Equation 51  
 
where            
 
 
 
 
  
  
 
  
 
 
Equation 52  
This method of calculation  of the magnetic susceptibility distribution from the image phase 
is underdetermined as the k-space filter, F, requires a division by zero on the surface of a 
cone at the magic angle in the Fourier domain.  The simplest method by which to remove 
the division by zero is by regularisation using a thresholded K-space division(TKD) 
technique(101), which sets the value of the filter to a constant at these discontinuities.  
Thresholded k-space division provides a computationally efficient method of calculating the 
susceptibility distribution in an imaging volume from the phase of the MRI signal 
generating a Quantitative Susceptibility Map (QSM). 
By thresholding the K-space filter, magnetic susceptibility maps can be reconstructed from 
phase field maps that have had background contributions removed.  However, 
unfavourable side effects of the regularisation include streaking artifacts, noise 
amplification and systemic underestimation of magnetic susceptibility.  In the case of the 
underestimation errors, this can be corrected using a method suggested by schweser et 
al(102).  By dividing the original k-space filter (F) by the thresholded version (F’), the 
modulation transfer function(MTF) of the filter modification can be calculated as 
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Equation 53  
The point spread function (PSF) is equal to the Fourier transform of the modulation transfer 
function which can then be deconvolved with the susceptibility map to perform the 
correction.  The PSF can be approximated by a delta function, scaled by a factor dependent 
on the TKD threshold, tF.  The Fourier transform of a delta function is a constant value.  A 
property of the FT is that point-wise division in the Fourier domain is equivalent to 
deconvolution in the spatial domain.   Therefore the correction can be applied by a simple 
rescaling of susceptibility estimates from TKD by a factor calculated using the TKD 
threshold,tF, to approximate the PSF. 
2.8.3 Phase unwrapping 
3D gradient echo is currently the most commonly used pulse sequence for acquisition of 
data to perform QSM(103,104).  Complex data is reconstructed from the acquired k-space 
matrix using a 3D discrete Fourier transformation.  The signal phase, Ф, can then be 
calculated as 
            
     
     
  
Equation 54  
where Z is the complex reconstructed imaging data.  A volume of phase values called a field 
map is generated from this calculation that can take values in the limited range [-π, π] 
radians for which the arctan function is defined.  The phase of a spin is dependent both on 
the magnetic field experienced at its location and the time period over which it is measured 
as indicated in Equation 20.  Therefore, the presence of field gradients across the field of 
view due to large field inhomogeneities or poor shimming will cause phase values to fall 
outside of this range giving rise to ‘phase wraps’ in the image.  Where a phase value 
exceeds ±π it will be aliased back to this range by effectively adding or subtracting multiples 
of 2π(Figure 15).  This causes the appearance of fringe lines across the image where phase 
wrapping occurs. 
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Figure 15. Phase aliasing 
A plot of true phase vs. output from the arctan function.  Values of true phase that fall 
outside of  [-π, π] are aliased back into the range.  Figure adapted from (90). 
 
Path based and laplacian based algorithms are commonly used to spatially unwrap aliased 
images.  In the path based approach, as the name suggests, unwrapping is done by 
following a discrete path adding or subtracting multiples of 2π where aliasing is 
encountered.  These algorithms unwrap regions of ‘high quality’ voxels first to prevent 
error propagation in the unwrapping process.  The quality of a voxel may be established 
using multiple criteria such as estimated noise levels and spatial connectivity.  Unwrapping 
by taking the Laplacian of the phase can be accomplished using properties of Fourier 
transforms with trigonometric functions as described by Schofield and Zhu(105) 
           
               
       
Equation 55  
where Фw is the wrapped field map and the laplacian terms can be calculated using the 
properties of Fourier transforms(106).  In chapter 5, both path based and laplacian 
methods are applied and evaluated for in-vivo and ex-vivo field maps in the mouse brain. 
2.8.4 Removal of background field contributions 
Field maps of unwrapped phase can be considered to contain both data sensitive to the 
magnetic susceptibility of tissue in the volume of interest as well as what are known as 
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background field contributions.  These unwanted effects come from field inhomogeneities 
that may occur from sources such as boundaries between air and tissue such as the sinuses 
in the head.  In Susceptibility Weighted Imaging(SWI), homodyne (high pass) filtering is a 
popular way of separating the low frequency background contributions from the high 
frequency local susceptibility distribution in tissue.  However, this technique is prone to 
through plane banding artifacts and struggles to remove background effects from tissue 
boundaries of large susceptibility difference(104).  More sophisticated methods of 
background field removal have been developed recently called Projection onto dipole fields 
(PDF) and sophisticated harmonic artifact reduction for phase data (SHARP) that make use 
of the fact that the background field is harmonic within the region of interest.  
The PDF method requires the generation of a mask around the region of interest.  All voxels 
outside of this ROI are assumed to be responsible for the harmonic background 
susceptibility distribution inside, χB.  The strength of a magnetic dipole is then fit at each of 
the voxels outside of the ROI using a weighting matrix W(107): 
  
                       
  
Equation 56  
Where b is the total field and d is the unit dipole field.  The background field is then 
calculated as d   χB
* and removed. 
The harmonic nature of the external field contributions inside the ROI, χB , means that it 
satisfies Laplace’s equation(108): 
         
Equation 57  
In SHARP, the background field is removed from the local field, bL, by convolving the total 
field, b, with the Laplace operator, L.  Next an eroded mask, M, is applied to the data to 
remove unreliable convolution results around the edge of the brain.  In the final step, an 
inverse Laplacian operator, L-1, is applied to the data to compensate for the signal loss 
caused to the local field by the original convolution.  This process can be described by the 
following equation(108): 
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Equation 58  
After removal of the background contributions from the field map by either PDF or SHARP 
methods, quantitative susceptibility maps can be generated using thresholded k-space 
division described in section 2.8.2. 
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3 Development of a gradient calibration 
protocol for pre-clinical imaging at high 
resolution 
3.1 Overview 
As outlined in chapter 1, the study of animal models of AD in-vivo using MRI may offer new 
insights into disease progression and therapeutic response.  This chapter will describe a 
calibration protocol that was developed to ensure accuracy and consistency in the system 
imaging gradients for acquisition of longitudinal multi-parametric MRI data in the mouse 
brain.   The 9.4T MRI scanner at the Centre for Advanced Biomedical Imaging (CABI) was 
calibrated using this technique and data was acquired to evaluate the stability of the 
system.  The importance of such quality assurance protocols for high resolution, pre-clinical 
imaging is demonstrated.  This work lays the foundation for development and robust in-
vivo acquisition of MRI techniques that are highly sensitive to errors in imaging gradients, 
such as Diffusion Tensor Imaging which is the subject of Chapter 4. 
3.2 Background 
Pre-clinical, high-field MRI systems are now widely used to provide high-resolution images 
of animal models of human disease.  Such phenotyping studies have enhanced our 
understanding of numerous disease processes and, when used in combination with 
advanced computational methods, have been used to detect subtle differences in tissue 
structure, particularly in the brain (109).  To perform accurate, longitudinal, phenotyping 
studies, both in-vivo and ex-vivo, requires careful calibration of the MRI scanner, in 
particular of imaging gradients, so that microscopic changes in tissue structure can be 
robustly measured.   
Imaging gradients are generally calibrated via linear scaling factors in each principal 
imaging axis, and any error in their values results in a global compression or expansion of 
acquired images.  Furthermore, imaging gradients are assumed to be spatially linear, and 
complex image distortions can be introduced by gradient non-linearity, which rapidly 
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manifest with increasing distance from the magnet isocentre.  Gradient calibration is 
typically performed annually during routine maintenance by the scanner manufacturers.  
Scaling factors and linearity are assessed using a structural phantom.  Distances between 
structures are measured on a single slice of an MRI image of the phantom and compared to 
those of the original CAD design.  This approach is highly vulnerable to error due to 
operator variability, the small number of measurements taken and the large slice thickness 
(1 mm) used.  Neither drift of applied gradients over time due to hardware instability 
between maintenance visits nor deformations in the phantom structure over time are 
accounted for.  Additionally, acceptance limits specified (≤5% linearity over a 40 mm 
diameter of spherical imaging volume (DSV)) are potentially unsuited to the degree of 
accuracy required for phenotyping studies.   
Whilst several strategies for calibrating imaging gradients have been proposed for clinical 
scanners (110-113), these may not translate to pre-clinical scanners which differ from 
clinical scanners in several fundamental ways.  For example, the maximum imaging 
gradient strengths are typically an order of magnitude greater than those found on a 
clinical system, scanners have a much smaller bore size, and field strengths are typically 
between 7 and 11.7 T, compared with 1.5 or 3 T for clinical systems.  Due to the challenging 
design considerations, large distortions can be observed in pre-clinical gradient sets.  In 
these scenarios, control point or spot matching algorithms employed in clinical protocols to 
unwarp distorted images have been shown to fail and require operator intervention(114).  
Furthermore, the level of accuracy required for phenotyping studies (of the order of 10s of 
microns) outweighs that typically required for clinical in-vivo studies.   
The aim of this work was to develop a gradient calibration and quality assurance protocol 
for pre-clinical MRI scanners, which can be customised to individual systems and RF coils, 
and that aims to reduce geometric distortions and ensure stability over time in both in-vivo 
and ex-vivo longitudinal phenotyping studies.  Moreover, studies using imaging techniques 
that also rely on accurate gradients (such as diffusion MRI) would also benefit.   
The protocol is based on a structural phantom that was constructed and designed in-house.  
3D printing was used to construct the phantom which is a fast, straightforward and cost-
effective method to build bespoke components(115), particularly of the size required for 
pre-clinical systems.  Materials were chosen to be susceptibility matched, robust, and 
62 
 
usable in successive studies.  CAD plans for the phantom are open-source, and have been 
published online: https://www.ucl.ac.uk/cabi/publications/open_source.   
The calibration protocol consists of two stages: i) a system calibration method for absolute 
scaling of imaging gradients; ii) a post-processing correction of gradient non-linearity, 
achieved through non-rigid image registration.  All post-processing software is feely 
available to download (NifTK, http://cmic.cs.ucl.ac.uk/home/software/), making this simple 
protocol easy to adopt as part of a pre-clinical quality assurance (QA) procedure.   
In the following sections, the protocol is introduced and it is evaluated to what extent it can 
improve the accuracy of imaging gradients, compared with the values derived from the 
standard calibration procedure performed by the scanner manufacturer.  The variation in 
the calibration parameters were monitored across a six-month period, alongside a serial 
assessment of the structural stability of the phantom.   
Here follows, a brief, step-by-step description of the calibration protocol.   
3.3 Gradient calibration protocol description 
The calibration protocol is shown schematically in Figure 16.  Firstly, a 3D grid phantom is 
constructed using 3D printing, with dimensions set according to the size of the RF coil 
and/or scanner bore to be used.  The phantom is then scanned using X-ray CT to provide a 
set of image data that is free from image distortion(114,116,117) (although for 3D printers 
with a high printing accuracy, the CAD plans for the phantom could be used as a fall back 
option if an X-ray CT system is not available).  Next, scaling errors in the imaging gradients 
are corrected by performing a linear system calibration (Figure 16a).  Here, high-resolution, 
3D gradient echo MR images of the grid phantom are acquired and are overlaid on the CT 
data using affine registration (i. e. scaling, translation, rotation and shearing).  The 
registration parameters are then used to adjust the system gradient scaling values.   
After system calibration of the scaling values, a second set of MR data is acquired, in order 
to perform a post-processing correction of gradient non-linearity.  These data are 
translated into the CT imaging space using a rigid registration and then unwarped by non-
rigid registration.  This removes distortions caused by gradient non-linearity and any 
residual scaling errors that remain after the linear system calibration.   
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Figure 16. Gradient calibration protocol flowchart 
Flowchart detailing the processes involved in the protocol and the order in which they 
should be implemented.  The two major subdivisions of the technique are the system 
calibration (a) and the post-processing correction (b).  Expected image deformations are 
illustrated using schematics. 
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3.4 Methods 
3.4.1 3D Grid phantom 
A phantom containing a three dimensional grid structure was designed in SolidWorks (DSS 
Corp, Concord, MA) computer aided design (CAD) software and was 3D printed using a 
Formiga P100 plastic laser-sintering system (EOS Electro Optical Systems Ltd., Warwick, UK) 
at a layer thickness of 100 µm.  It was manufactured using fine polyamide (PA-2200 nylon), 
a material with low water absorption properties (0.41% over an initial 24hr period) and 
ability to withstand high mechanical and thermal load (EOS, PA 2200 Material Data Sheet).  
Nylon has a magnetic susceptibility that is close to that of water (< 3ppm) and so should 
not cause artifacts in either spin-echo or gradient-echo images (118).   
For the current study, the dimensions of the phantom were 3D-printed to fit into a 35 mm 
birdcage coil that is routinely used for in-vivo phenotyping of mice (Rapid Biomedical 
GmbH, Germany).  The grid pattern occupied 75% of the diameter of the coil and its length 
(60 mm) encompassed its entire sensitive region (50 mm) and extended beyond the 40mm 
DSV of linearity specified by the manufacturer.  To enable removal of waste material 
generated during production, the phantom was formed in four pieces (Figure 17).  After 
cleaning, the grid section was inserted into the outer chamber, where it was sealed by 
attaching a chamber cap with epoxy resin.  Also incorporated into the phantom design is a 
positioner with a thread for a nylon screw that allows consistent placement within the coil.   
The walls of the three-dimensional grid pattern in the phantom were 0.5 mm thick to 
enable adequate sampling at the imaging resolution, and spaced 2.5 mm apart.  An 
irregular prism (Figure 17f) was included in the design of the phantom, at the centre of the 
grid, to aid orientation during post-processing.  When inserted, the centre of the grid 
structure aligned with the isocentre of the magnet.   
The phantom was filled with a solution of copper sulphate (1.25 g/L) and sodium chloride 
(5.3 g/L) in water (measured T1, 245 ms).  The filling tube contained an s-bend shape to 
ensure air bubbles that accumulated at the top when stored in its vertical position were 
prevented from travelling into the main chamber during imaging.  
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Figure 17. 3D grid phantom design  
CAD drawing of phantom sections and photograph of the assembled phantom, which was 
created using 3D printing.  To assemble, the grid section (a) was inserted into the outer 
chamber (b) which was sealed by the chamber cap (c).  It can then be filled through the s-
bend (d) and sealed using a cap (e).  An irregular prism (f) in the centre of the grid structure 
aids in the orientation of images. 
  
3.4.2 CT and MRI imaging 
CT images of the phantom (Figure 18a,b) were acquired prior to filling with solution using a 
Bioscan nanoSPECT/CT system (Mediso, Budapest, Hungary).  The Field of View (FOV) was 
selected to cover the whole grid section of the phantom and images were reconstructed 
using the vendor software to an isotropic resolution of 73 µm (system limit).  To verify that 
the CT data were accurate, 10 manual measurements of the phantom were made using 
digital calipers and compared to CT data using NiftyView software (UCL, London, UK).  
Prior to MRI acquisition, the phantom was filled and placed into the RF coil.  An imaging 
gradient set with a 60 mm inner diameter (SGRAD 115/60/HD/S, Agilent Technologies UK 
Ltd., Berkshire, UK) was used in all experiments (unless stated otherwise), with a maximum 
gradient amplitude of 1 Tm-1.  The gradient set is specified by the manufacturer to have a 
gradient sub-system rise time of 130 µs and a linearity of ≤ 5% within a 40 mm DSV.   
All measurements were performed using a 9.4 T Agilent scanner, and images were acquired 
using a 3D gradient echo sequence, optimized for high resolution imaging of ex-vivo murine 
brains (119).  The FOV was set to 26x30x30 mm3 in the central region of the phantom, 
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within the 40 mm DSV of specified linearity.  Voxel size was set to 40 µm, isotropic, and the 
readout gradient was 0.09 Tm-1, applied in the Z direction (parallel with the bore of the 
magnet).  Other acquisition parameters included TR = 17 ms, TE = 4.54 ms, and a flip angle 
of 51°.  Five averages were acquired, resulting in a total imaging time of 13 hours, 16 
minutes.  To investigate warping effects outside of the specified region of linearity and the 
possibility of reducing acquisition time for system calibration, data were also acquired at a 
reduced isotropic resolution of 100 µm over a larger FOV.  The readout gradient was 
reduced to 0.04 Tm-1 and the FOV was 60x40x40 mm3, imaging the whole grid structure 
(Figure 18c, d) in a reduced time of 3 hours, 46 minutes.   
 
Figure 18. CT and MRI images of phantom 
Axial (a) and coronal (b) slices from CT data and corresponding axial (c) and coronal (d) 
slices from 3D gradient echo MRI data.  Landmarks for distance measurements are shown 
(b) for Z axis (red) and Y axis (blue) (landmarks in X axis are orthogonal to those in the Y axis 
at same Z coordinates). 
 
Shimming was performed manually at the start of each imaging session.  The linewidth of 
the shim was monitored across imaging time points for consistency (40 ± 5 Hz) using a 
pulse and collect sequence and the temperature variation during a scan was measured by 
attaching a probe to the outer surface of the phantom.  
To investigate warping effects that may be specific to the gradient echo sequence 
implemented, 3D Fast Spin Echo images of the phantom were acquired over the larger FOV 
with an isotropic resolution of 100 µm.  Other acquisition parameters included TR = 200 
ms, Echo Train Length = 4, Echo Spacing = 6.86 ms, Averages = 5, and a read gradient 
strength of 0.11 Tm-1 applied in the Z direction (Acquisition time of 11 hours, 7 minutes).  
67 
 
To maintain consistency in the comparison between sequences, gradient echo data was 
acquired at an isotropic resolution of 100 µm as detailed above with the read gradient 
strength increased to 0.11 Tm-1. 
3.4.3 System Calibration 
NiftyReg software (120-122) was used for all image registration in this study.  The affine 
and rigid registrations were carried out using the reg_aladin algorithm(120,121) which 
employs  a two step process.  A block matching algorithm provides a set of corresponding 
points between a target and source image before the transformation is evaluated using 
normalized cross-correlation(123).  To reduce processing time, initial alignment is assessed 
based on down-sampled low resolution images before final registration using full resolution 
images.   
Prior to registration, the CT data was cropped reducing the FOV to include the grid section 
of the phantom only, providing initial alignment of the MRI and CT images.  An affine 
transformation matrix was output by the reg_aladin algorithm, which was decomposed 
into its constituent transformation parameters.  The gradient scaling values stored in the 
MRI console software were then adjusted through multiplication with the scaling 
parameters from the registration in the X, Y and Z directions.   
Phantom grid structures were segmented within MRI data by intensity thresholding to 
remove high signal intensity voxels occupied by the filling solution, and was further refined 
by manual segmentation to include only the grid structure.   
To evaluate the improvement in gradient scaling afforded by the affine registration, dice 
coefficients (124) of the segmented grid structures were compared, before and after 
adjustment.  The dice coefficient, s, was defined as 
 
  
               
                 
 
Equation 59  
where MRIG  and CTG  are the segmented grid structures of the MRI and the CT data.  s
ranges from 0 (indicating no overlapping voxels) to 1 (indicating that all voxels overlap 
completely).   
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3.4.4 Longitudinal assessment of calibration accuracy 
After the initial system calibration, MRI acquisitions were repeated at monthly intervals 
over a period of six months to measure stability over time.  Additionally, CT images of the 
phantom were acquired at the same time points to account for structural deformations.  To 
investigate global volume changes in the phantom, affine registrations of the CT data at 
each time point to the CT data acquired at the first time point were implemented, again 
using Niftyreg.  Distortion in the structure was evaluated by taking distance measurements 
(using NiftyView) between grid section landmarks in the CT data (Figure 18b), at three 
evenly spaced points along each axis.  The measurements taken spanned the full diameter 
of the grid section in the X, and Y direction and the full length of the phantom in the Z 
direction.  To test for a dependency between each of the measurements and longitudinal 
time point, a linear least squares regression analysis was performed to identify any 
significant correlation (P=0.05, ANOVA).   
3.4.5 Scaling measurements for correction of Total Brain 
Volume estimates 
Due to differences in experimental setup, structural imaging of the mouse brain in-vivo is 
carried out using a larger 120 mm diameter gradient set (SGRAD 205/120/HD/S, Agilent 
Technologies UK Ltd., Berkshire, UK) with a maximum gradient amplitude of 0.6 Tm-1.  The 
gradient set is specified by the manufacturer to have a gradient sub-system rise time of 180 
µs and a linearity of ≤ 5% within a 80 mm DSV.  The larger diameter facilitates use of a 
mouse bed with anaesthetic breathing apparatus and a two channel mouse brain surface 
coil (RAPID, Germany) for signal detection.  Scaling of the gradient magnitude values for 
each of the gradient sets is done independently which may be a source of error when 
comparing data collected across multiple hardware configurations. 
Prior to development of the protocol described here, in-vivo data was acquired in the larger 
diameter gradients that had been previously calibrated by the scanner manufacturers as 
part of an annual maintenance visit.  Ex-vivo structural imaging of the same mice was 
carried out in the smaller diameter gradient set, post system calibration.  To estimate 
scaling differences between the in-vivo data and ex-vivo datasets related to the hardware, 
the phantom was imaged in the larger diameter gradient set using the larger FOV protocol 
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described in section 3.4.2.  The system calibration protocol was used to calculate scaling 
factors for comparison with those from the smaller diameter set.  
Structural MRI datasets were acquired for a cohort of wild-type mice (n=8) at 7.5 months 
using previously described in-vivo(125) and ex-vivo(119) imaging protocols.  Total Brain 
Volumes (TBVs) were estimated by manually correcting brain masks generated 
automatically using a previously published multi-atlas label fusion algorithm(126).  These 
volumes were then rescaled using the values from the appropriate gradient set calculated 
by the system calibration. 
  
3.4.6 Post-Processing Correction 
The MRI data (defined as the source) was transformed into the imaging space of the CT 
data (defined as the target) by rigid registration using the reg_aladin algorithm in NiftyReg.  
NiftySeg segmentation software was used to automatically generate a registration mask 
that encompassed the area within the outer casing of the phantom in the CT data.  This 
prevented intensity changes outside of the grid section of the phantom affecting the 
registration.  The reg_f3d algorithm(122) in NiftyReg was used to carry out a non-rigid 
registration to warp the MRI data, post rigid registration (source), to the CT data (target).   
The reg_f3d algorithm(122) uses cubic B-splines to generate a deformation field.  The local 
displacement of control points in an equally spaced lattice causes warping that modifies 
mapping between source and target images.  The registration is assessed through 
Normalised Mutual Information as an indication of correspondence between images and 
warping is constrained through bending energy and elastic energy terms(123).  Input 
parameters were optimized to generate a smooth deformation field.  A spline grid spacing 
of 20 voxels was implemented and the weight of the linear elastic energy penalty term was 
increased to [0.01 0.01].   
To investigate the reproducibility of the results, the phantom was imaged four times, back-
to-back, and displacement fields were generated for each scan.  The first acquisition was 
taken as a reference and the absolute displacement differences at each point were 
calculated in the X, Y, and Z orthogonal directions (Z is aligned with the axis of the scanner 
bore), for each subsequent acquisition.   
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3.5 Results 
3.5.1 Phantom stability measurements 
The structural stability of the phantom was assessed over a six month period from CT data 
acquired every month.  The maximum change in scaling identified on any axis was 0.28%.  
Phantom length measurements showed no significant correlation between variables, which 
suggests that there were no gradual changes in the phantom structure over time.  The 
comparison of manual measurements in the CT imaging data to those made using digital 
callipers at a single time point showed a mean percentage difference of 0.27±0.17%, 
indicating a close agreement.  The temperature of the phantom recorded during an MRI 
acquisition ranged between 19.9 °C and 20.2 °C (melting point of PA 2200 is 184 °C).   
3.5.2 System Calibration 
Prior to the start of the study, the imaging gradients of the 9.4 T scanner had been 
calibrated using the scanner manufacturer’s standard protocol described in the 
introduction.  Details of this protocol are published in a user manual supplied with their 
structural phantom.  By comparing the CT phantom images with 100 µm-resolution MRI 
data (acquired with the manufacturer’s calibration) after rigid registration, marked 
discrepancies were observed between CT and MRI images  (white and black structures, 
respectively, in Figure 19(a and b).  Relative to CT, MRI images were globally compressed in 
the Y direction and expanded in the Z direction.  This can be seen most clearly in a central 
section of the phantom, within the 40 mm DSV specified by the manufacturer, where 
gradient linearity is optimal (Figure 19b).  Figure 19e demonstrates the magnitude of these 
global changes, which varied with direction (scaling: X = 100.4%, Y = 105.3%, Z = 97.6%).  
This experiment was defined as scaling time point -1.   
Outside the 40 mm DSV, it was clear that discrepancies between MRI and CT data markedly 
increased due to gradient non-linearity.  To reduce the impact of this distortion when 
comparing image distortion before and after calibration, dice coefficients were only 
calculated in a region of interest corresponding to the central section of the phantom, 
within the 40 mm DSV (Figure 19b).  Correction of image distortion due to gradient non-
linearity is the purpose of the post-processing correction evaluated later in the study.   
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The system was then calibrated using our proposed protocol (scaling time point 0), a new 
set of MRI data was acquired, and rigid registration to the CT data was repeated.  The 
accordance between these data and CT prior to and following calibration (Figure 19) was 
assessed by comparing dice coefficients, s: in the central region of interest, s was 0.73 
before calibration and 0.84 afterwards (0.57 and 0.67, respectively, over the whole FOV).  
Affine registration of the MRI data acquired after the system calibration to the CT data 
produced scaling factors of 99.6%, 99.9%, 100.5% in the X, Y, and Z axes (Figure 19e), which 
is a marked improvement over the pre-calibration values.  The mean scaling factor error 
(relative to unity) across all axes after correction was reduced from 2.7% to 0.3%.   
Using the same approach as described above, the mean and standard deviation of the 
scaling factors measured every month, for a total of six months, were 99.7±0.1%, 
100±0.2%, and 100.1±0.1% in the X, Y and Z directions.   
The scaling factors calculated by registering the MRI data acquired at an isotropic 
resolution of 40 µm to the CT data followed a very similar pattern to the 100 µm MRI data 
(Figure 19e).  The mean percentage difference between the 40 µm and the 100 µm scaling 
factors taken across all time points was 0.52±0.23%.   
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Figure 19. Gradient scaling values before and after system calibration 
Sagittal slices of CT phantom images (white) overlaid on MRI images (filler inside phantom 
shown in green, phantom structure shown in black, 26x60 mm FOV ) showing alignment 
before (a,b) and after (c,d) system calibration.  The errors in the scaling factors (e) prior to 
calibration (time point -1) are reduced after system adjustment (TP 0) and the factors 
calculated using 100 µm data (X,Y,Z) are in good agreement with the 40 µm data 
(x40,y40,z40).  
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3.5.3 Post-Processing Correction 
Alignment of MRI and CT data was further improved after non-rigid registration (Figure 
20a), especially in regions further from the magnet isocentre.  The dice coefficient 
calculated from the whole grid structure in the phantom increased from 0.62 before post-
processing correction, to 0.88.   
A displacement field, generated from the deformation field output by the non-rigid 
registration, shows the magnitude of voxel displacements applied to the MRI data to 
unwarp and register it to the CT data (Figure 19b-f).  The displacements along the Z axis 
(Figure 19b) were less than 0.1 mm at a distance of less than ±10 mm from the isocentre.  
At a distance of ±20 mm, and greater, the displacements increase rapidly to more than 0.35 
mm.  The displacements along the X and Y axes show small displacements of less than 0.1 
mm in central slices (Figure 19c,d) at distances of less than ±5 mm from the centre.  For 
slices located further from the isocentre (in the Z direction) (Figure 19e,f), the magnitude of 
displacements markedly increases.  Outside the central region of relatively low 
displacement, there is a rapid increase to values larger than 0.25 mm in the X and Y 
direction within the walls of the grid section of the phantom.   
Within the central 40 mm DSV, where linearity is specified by the manufacturer, the 
maximum displacement was 0.72 mm, 0.87 mm and 0.6 mm in the X, Y, and Z axes, 
corresponding to a linearity of 3.6%, 4.35%, and 3% respectively.  The maximum 
displacements in the phantom outside of this volume were 3.51 mm, 3.81 mm, and 2 mm 
in the X, Y and Z axes.  The repeated generation of displacement fields to test 
reproducibility revealed the mean discrepancy between calculated displacements to be 
11.8±10.2 µm across all axes for the whole FOV.   
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Figure 20. Displacement fields generated from post-processing correction 
Projection along the X axis from CT phantom data (white) overlaid on MRI images (filler 
inside phantom shown in green, phantom structure shown in black) show good alignment 
after post-processing correction (a).  Displacement fields generated from the non-rigid 
registration show that Z displacements increase along the Z axis (b) as distance from the 
centre increases.  Increased X and Y displacements are observed in the X (c) and Y (d) axes 
respectively for central slices.  Slices taken further from the centre show these 
displacements in the X (e) and Y (f) directions increase more rapidly with distance from the 
slice centre. 
 
 
 
3.5.4 MRI sequence comparison 
Images acquired using the fast spin echo and gradient echo sequences were similar in 
appearance (Figure 21).  Scaling factors calculated using a gradient echo sequence and a 
fast spin echo sequence showed a percentage difference of 0.06%, 0.02%, and 0.03% in the 
X, Y, and Z axes respectively.  The mean displacement difference taken across the whole 
grid structure was 19±30 µm. 
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Figure 21. Sequence Comparison 
Representative axial and sagittal slices of MRI phantom images acquired using the FSE 3D 
sequence(a,b) and GRE 3D sequence(d,e).  Displacement fields generated for each 
acquisition were of similar appearance (c,f). 
 
3.5.5 Scaling of Total Brain Volume estimates 
Scaling factors calculated for the larger diameter gradient set at the in-vivo imaging time 
point were 93.4%, 95.9%, and 92.1% in the X,Y, and Z axes respectively.  The equivalent 
measurements for the ex-vivo data acquired in the small diameter gradient set were 99.5%, 
99.9%, and 100.4% (Figure 22a).  The percentage difference in the mean of the axis scaling 
factors between the small and large diameter sets was -17.4%. 
 The mean estimated total brain volume for the in-vivo samples was 634 mm3 compared to 
484 mm3 in the ex-vivo data.  This corresponded to a 30.8% larger mean volume 
measurement of the brains in-vivo.  After adjustment of the individual volume 
measurements, this mean difference was reduced to 8% (Figure 22b). 
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Figure 22. Scaling factor adjustments of TBV estimates 
Gradient scaling factors calculated using the system calibration protocol for large diameter 
and small diameter gradient sets(a) and TBV estimates for in-vivo and ex-vivo data before 
and after scaling correction. 
 
 
3.6 Discussion 
The precision and stability of a pre-clinical MRI system are of paramount importance when 
performing quantitative, comparative and longitudinal measurements in imaging subjects 
over time.  A gradient calibration protocol has been developed, specific to pre-clinical 
imaging systems, that can quantify and correct for these errors.  Moreover, it has been 
shown that, for the accuracy required for the detection of microscopic changes in tissue 
structure and size, significant measurement errors can be introduced through imperfect 
gradients, particularly when relying on calibration protocols with low acceptance limits.  
Our protocol is based on a 3D-printed geometric phantom, featuring a three-dimensional 
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grid structure.  The plans for the phantom have been published online and can easily be 
adapted for individual RF coils and scanner bore sizes.  The phantom design contains novel 
features such as an s-bend in the filling pipe to prevent air bubbles in the main cavity, and 
the ability to attach as a single piece directly to the RF coil to improve consistency in 
phantom positioning between measurements. 
Monitoring of relative gradient scaling factors using MRI data has been reported 
previously(115).  In this study, high-resolution CT and MRI imaging data were used to 
validate the structural stability of the phantom over time and provided a simple method for 
the absolute scaling of the system gradients.  The ability to reduce errors in scaling values 
will improve accuracy of measurements acquired on the system and invites the possibility 
of reuse of control group data reducing animal numbers.  A post-processing technique has 
been introduced for the correction of image distortions caused by gradient non-linearity.   
Relative to the scanner manufacturer’s standard calibration, the system calibration 
developed here reduced the mean gradient scaling factor error from 2.7% to 0.3%.  Errors 
of the magnitude found prior to our calibration have the potential to be a significant 
confounder to detection of structural volume changes in the mouse brain, which can be 
less than 2% (109).   
The calibration requires the acquisition of three-dimensional gradient echo data, and a 
comparison was made of the accuracy of acquiring at 40 and (more rapid) 100 μm isotropic 
resolution.  There was close agreement between the scaling parameters calculated from  
gradient echo data acquired  at two different resolutions and fast spin echo data, indicating 
that accurate system calibration can be performed using the gradient echo protocol with 
reduced scan time for inclusion in a routine QA protocol.  Application of such a protocol on 
pre-clinical systems is clearly important, particularly given the magnitude of gradient errors 
that resulted from the manufacturer’s standard calibration.  A  5.3% scaling error was 
found in the Y direction prior to calibration, which, for example, would result in a 9.8% 
error in apparent diffusion coefficient (ADC) estimates, calculated from DWI data (due to 
the inverse square relationship between b-value and gradient magnitude).  The scaling 
values, once corrected with our protocol, were stable over the six month period, indicating 
that it may be satisfactory to carry out as few as two system calibrations per annum.   
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Previous pre-clinical structural MRI studies have compared volumetric measurements from 
in-vivo and ex-vivo data sets (127,128) using multiple hardware configurations.  To 
investigate effects of gradient scaling on TBV estimates, in-vivo and ex-vivo imaging was 
performed using different gradient sets for the same cohort of wild-type mice.  The mean 
difference in scaling factor of 17.4% was shown to cause a 22.8% increase in the in-vivo 
volumes measured.  After adjustment for scaling discrepancies, the difference in mean 
volume was reduced to 8% which may be due to dehydration and shrinkage of tissue 
caused by perfuse fixation for ex-vivo imaging(129,130).  These results highlight the 
importance of gradient scaling measurements when comparing data acquired on different 
systems or hardware configurations. 
The post processing correction showed that displacements near to the isocentre of the 
magnet, following calibration, can be less than 0.1 mm.  The deviation from linearity of the 
small diameter gradient set used was specified by the manufacturer as ≤5% within a central 
40 mm DSV region.  The linearity, measured as the maximum spatial deviation as a 
percentage of the 20 mm DSV radius, was found to be within these limits in each axis.  
However, this tolerance corresponds to a maximum spatial deviation of 1 mm which may 
not be satisfactory for phenotyping applications and a correction may be required.  Outside 
of this region, image distortion increases rapidly, with displacements of 0.3 mm and larger.  
With the application of non-rigid registration during post-processing, the dice coefficient 
improved by 26%.  The strong correspondence between the CT data and the corrected MRI 
indicates that non-rigid registration approach is a robust solution to unwarping data in 
regions of large distortion.   
The use of the generated deformation field may reduce distortions significantly, especially 
when imaging samples such as multiple embryos or anatomy that is positioned at a 
distance from the magnet isocentre.  Therefore, the post-processing correction for gradient 
non-linearity can increase the effective FOV over which biological samples can be 
accurately imaged, markedly increasing the efficiency of high resolution scans that are 
often acquired overnight.  Assuming satisfactory stability of the gradients, the deformation 
field from a single time point could be used to correct multiple datasets collected over a six 
month period for animal phenotyping studies (131).   
In this study, MRI acquisition parameters were based on an ex-vivo murine structural 
neuroimaging sequence with the aim of correcting this data using the deformation field.  
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The use of a 3D gradient echo sequence to characterise gradient field distortion is in line 
with previous clinical studies(110,114,116,132,133) and the agreement of scaling factors 
calculated from data acquired at two resolutions  and using a fast spin echo sequence 
indicate robustness of the methodology to changes in the read gradient magnitude and 
MRI sequence.  The mean difference in displacements between the gradient echo and fast 
spin echo data is within a single standard deviation of the reproducibility data mean 
difference, suggesting that the warping, caused by non-linearity of the gradients, is 
dominating any sequence specific effects in the scenario investigated. 
The deformation field could also be used to unwarp in-vivo data sets collected with the 
same imaging protocol although it should be noted that some variability in the accuracy of 
spatial displacement may be introduced by sample-dependent B0 perturbations.  These 
should be minimal in structural imaging and if necessary can be corrected for through the 
use of existing techniques (134).  Minor deviations from the protocol described here may 
be necessary such as adjustments to the phantom dimensions to fit specific hardware 
configurations and an alteration of the composition of the phantom filler solution to 
optimize SNR for the particular pulse sequence used.   
3.7 Conclusions 
In this chapter, a complete protocol has been presented consisting of a system calibration 
of MRI gradients and a post-processing correction for non-linearities away from the magnet 
isocentre.  The phantom design is open-source and can be adjusted as necessary for the 
specific imaging protocol, RF coil and scanner dimensions used.  The NiftyReg software 
used for the system calibration and the post-processing correction is also freely available to 
download and has been used to perform absolute scaling of gradients and an image 
correction of distortions caused by gradient non-linearity.  This simple step-by-step process 
can be integrated with or form the basis of a QA protocol that could be implemented 
during installation and as part of routine maintenance on any pre-clinical MRI system.  
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4  A Diffusion Tensor Imaging protocol for 
in-vivo multi-parametric MRI 
4.1 Overview  
In the previous chapter a gradient calibration protocol was developed to provide quality 
assurance for MR data acquired using the 9.4T MR system in CABI for the in-vivo 
measurement of phenotypic changes in mouse models of AD. The effects of gradient 
inaccuracies on MR measurements of anatomical volume and diffusion in tissue were 
discussed.  Diffusion Tensor Imaging is an MRI technique sensitive to the diffusion of water 
molecules from which the microstructural organisation of tissue can be inferred.  Changes 
to the diffusion environment may be indicative of white matter pathology, known to occur 
in neurodegenerative diseases.   
In this chapter, a time efficient DTI acquisition is developed with the aim of inclusion in a 
multi-parametric protocol.  The design and testing of this sequence is described and data is 
acquired in-vivo in the rTg4510 mouse model of tau pathology in AD.  DTI parameter 
measurements in both grey matter and white matter regions of the rTg4510 are presented 
and compared to those of wild-type controls.  Differences identified indicate the sensitivity 
of this DTI protocol to tau pathology and support its value within a multi-parametric MRI 
protocol to study mouse models of AD in-vivo. 
 
4.2 Background 
4.2.1 White matter pathology in AD 
The tissue of the nervous system consists of regions of grey matter and white matter 
named for the colour exhibited by their parenchymal make up.  Neuronal cell bodies 
(Figure 23c) in grey matter perform integrative functions or act as relays at junctions 
between synapses of axons and neighbouring cell bodies.  The white matter is a network of 
myelinated axons grouped into bundles called tracts that enable communication across the 
central nervous system through the propagation of electrical signals known as action 
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potentials.  Myelin sheaths wrap around the axons of neurons and are made up of 
membrane layers rich in phospholipids that are white in colour.  They provide a layer of 
electrical insulation that increases the speed of transmission of action potentials.  The 
millions of white matter tracts connect neurons across the nervous system to form a 
functional network.  In the human brain, white matter lies centrally, beneath a layer of grey 
matter on the surface known as the cortex (Figure 23b). 
 
Figure 23. Anatomy of the human brain 
Schematics of the human brain with key parts labeled(a) , a coronal slice with grey matter 
and white matter regions indicated(b), and neuronal cell features depicted(c). 
 
 
Damage to white matter that reduces nerve conduction will impact the ability and speed at 
which different parts of the brain communicate with each other, impairing sensory, motor 
and cognitive functions(135).  Although AD is defined by the presence of Aβ and NFT 
pathology in grey matter regions,  there is growing interest in white matter disease(WMD) 
which has been observed at neuropathological examination in over 50% of AD cases(136).  
Numerous white matter changes in AD have been reported in post mortem studies 
including  decreased myelin density(136), decreased myelin basic protein(137), loss of 
oligodendrocytes(138), activation of microglia(139), ventricular ependyma and gliosis, and 
loss of myelinated axons(140).   WMD in AD is mild and distributed throughout the brain, 
with the frontal lobes (Figure 23a) thought to be more severely affected(136).  This 
presentation is unlike other AD-vascular type dementias where focal infarcts occur(141).  It 
is currently unknown whether WMD is a direct result of protein misfolding and aggregation 
in AD or whether it is a secondary effect following connected regions of grey matter 
degeneration.   The former scenario is described by ‘Retrogenesis’, a theory which 
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hypothesizes that white matter regions that myelinate later in development are the first to 
be affected by AD(142,143).  The axons of these tracts have a smaller diameter and less 
oligodendrocytes associated with them when compared to earlier myelinating regions.  In 
supporting  a larger population of axons, a greater metabolic challenge may be placed on 
the oligodendrocytes making them more vulnerable to pathological processes(144).  
Alternatively, the white matter changes observed could be as a direct consequence of 
adjacent grey matter pathology, a process known as Wallerian Degeneration(145).  The non 
invasive nature of DTI offers the possibility to spatially map sequential white matter 
changes in the AD brain over time and may provide insight into the primary cause of white 
matter disease. 
4.2.2 DTI of white matter disease 
The directional arrangement of hydrophobic myelin in the white matter of the brain is 
reflected by a highly anisotropic diffusion environment.  Water molecules diffusing in this 
tissue will find their motion restricted by boundaries created by the walls of the myelin 
sheaths of axons aligned parallel to the orientation of the tract.  Bulk diffusion over time 
will be reduced in directions perpendicular to tracts of densely packed fibres since spins will 
be impeded by these boundaries and will undergo a rather tortuous diffusion trajectory.  
The relative diffusion along the direction of the tract will be much larger due to the 
reduced obstructions encountered.   
The ability of DTI to provide a multi-directional quantification of diffusion in three 
dimensions lends itself to the measurement of anisotropic diffusion in white matter.  
Values of Fractional Anisotropy(FA) and Mean Diffusivity (MD) calculated from the tensor 
can quantify the extent of anisotropy of diffusion and provide a measure of bulk diffusion 
in a voxel respectively.  In the case of white matter voxels, the ellipsoid described by the 
tensor will have much greater diffusivity in the direction of the fibre tract - described by 
Axial Diffusivity(DA), than in the two directions perpendicular to it – described by Radial 
Diffusivity(DR)(146).  By mapping these parameters, regional measurements can be taken 
in specific tracts of interest or fibre pathways can be traced using tractography image 
processing techniques(147). 
As AD progresses, NFT pathology spreads sequentially to different grey matter regions of 
the brain as defined by Braak staging(11).  Initially presenting in the transentorhinal region 
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of the temporal lobe including the entorhinal cortex and hippocampus, NFTs then become 
more widespread throughout the temporal lobe before severely affecting all neocortical 
association areas later in disease(11).  Atrophy of grey matter in the hippocampus has also 
been shown to correlate with this time course of distribution of NFT 
pathology(37,148,149).  The use of DTI to probe white matter tracts associated with 
regions implicated in these stages of disease may offer new insights into the link between 
neurodegeneration and WMD in AD.  
In a study by Huang et al(150) reductions in FA and altered diffusivity relative to healthy 
controls were observed to be greatest in AD patients in the temporal lobe followed by 
lesser changes in the parietal and frontal lobes following a regional pattern that parallels 
NFT pathology.  Furthermore, there was reduced DA and increased DR in the temporal 
white matter in patients with AD compared to reduced DA only in MCI cases.  This was 
attributed to early axonal damage in MCI and a complete loss of myelinated axons in AD.  
The authors concluded that the white matter changes are most likely secondary, following 
perikaryal degeneration, consistent with wallarian degeneration.  This hypothesis has been 
supported by other studies performing similar regional measurements (151,152) and 
correlating white matter damage measured by DTI with cognitive function(153,154).  
The retrogenesis hypothesis suggests WMD is a primary effect that occurs due to the 
formation of plaques and tangles in tissue and to explore this possibility, DTI comparisons 
have been made between early and late myelinating fibre tracts during initial stages of AD.  
Studies supporting retrogenesis have reported lower FA values in late-myelinating 
pathways (uncinate fasciculus, ILF, SLF), limbic pathways (fornix/stria terminalus, 
cingulum), and commissural pathways (splenium of the corpus callosum, forceps major) 
with no significant differences identified for early-myelinating regions included in these 
studies(155,156).  The anterior part(genu) of the corpus callosum myelinates later in life 
relative to the posterior part (splenium)(142) and studies have made comparisons between 
DTI measurements in these two structures.  Although reduced FA in the splenium appears 
to be more prominent in AD(157), reductions in the genu have been reported in MCI 
patients(158,159) indicating sensitivity to changes in this prodromal stage of the disease.   
These findings suggest an increased vulnerability of later myelinating regions to AD.  
However, connections from these white matter structures to other parts of the brain, such 
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as those between the splenium and the temporal lobe(157,160) may mean that results are 
confounded by wallerian degeneration.   
 
4.2.3 Potential of DTI as a disease biomarker 
The utility of DTI as a tool to interpret the order in which WMD and neurodegeneration 
occur is challenging due to  the difficulty in interpreting DTI parameters, conflicting results 
between studies, and the possibility of combined effects from multiple causes such as 
ischemic mechanisms, cerebrovascular disease and reactive gliosis(150).  Through the 
consensus of a number of studies there is a growing body of evidence of widespread 
increased MD and reduced FA in AD brain(144,161,162).  These differences have been 
observed in various white matter regions, using a number of acquisition protocols and 
analyses including ROI based, voxel-wise, and tract based.  Changes in diffusivity have also 
been consistently observed in AD with increased DR thought to represent myelin damage 
that increases with disease progression and DA as a measure of axonal integrity, more 
sensitive to early disease(150).  Correlation between DTI changes in white matter with both 
grey matter volume changes(163) and cognitive performances further support these 
parameters as indicators of disease progression(153,154). 
Sensitivity to early disease has been assessed through DTI studies in MCI cohorts as well as 
cases of increased risk factor of AD including carriers of APOEe4 and parental family 
history.  Patients diagnosed with MCI are considered to be in the prodomal phase of AD 
with increased risk of conversion.  Changes in MD and FA are remarkably similar to those 
observed in AD patients although less widespread(161).  DA has been suggested as a 
particularly sensitive marker to WMD in MCI(161) and that DTI measurements in the fornix 
may be  as useful as hippocampal volume(164,165) as a biomarker in conversion of MCI to 
AD.  In cohorts with an elevated risk factor of AD, reductions in FA in a number of white 
matter regions associated with AD have been observed in APOE e4 and subjects with a 
family history of late onset AD(166-168).   
It should be noted that there are a number of studies that report a lack of group 
differences in AD and MCI compared to healthy controls(162).  The source of these 
discrepancies are unclear with inconsistency in disease stage, low statistical power from 
small cohorts, and the variety of methods of data acquisition and analysis possible reasons.  
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The use of mouse models that mimic WMD found in AD may prove useful in controlling for 
some of these variables.  The ability to image large numbers of subjects and generate 
corresponding histology to analyse microstructural changes and quantify pathological 
burden may provide crucial insights into how to best optimise DTI protocols for AD 
biomarker applications. 
In comparison to white matter, DTI of grey matter is less commonly the subject of studies 
in AD literature.  Often only MD measures are reported due to the lack of anisotropy in the 
tissue.  An elevated MD has been reported in grey matter regions(169-171) as well as 
reduced FA in the hippocampus(171) and the thalamus(169).   
4.2.4 DTI in mouse models 
There may be multiple potential permutations of structural rearrangements in the tissue 
that give rise to a particular DTI contrast.  The lack of specificity makes it difficult to 
attribute a known abnormality to an observed change in a parameter.  MRI diffusion 
measurements in white matter originate from water molecules both within the axon and in 
the extracellular axonal spaces.  There are multiple intra-axonal structures that may 
influence diffusion within this compartment.  Both the axonal membrane and myelin 
sheath surrounding it act as barriers to diffusion, damage to which will cause changes to 
both intra and extra cellular diffusion environments(172).  Alterations to any of these 
structures in pathology may occur in combination with unpredictable effects on diffusion.  
To be able to use DTI parameters as markers of specific microstructural alterations, their 
relationships to the biology must be fully understood. 
DTI studies of mouse models that exhibit specific types of white matter abnormality may 
help to inform on root cause of signal changes.  A number of studies have tried to draw 
parallels between diffusivity parameters and histology in simple models of white matter 
pathology.  Studies in the shiverer mouse model of dysmyelination(98) and of 
demyelination using cuprizone treatment(173) suggest that reductions in myelination of 
the corpus callosum increase DR.  In more subtle white matter pathology induced by 
hypoperfusion, mice exhibited a lower FA in the corpus callosum that correlated with 
measures of reduced myelin integrity(174).  In some rodent models of axonal degeneration 
and injury, reduced DA has been observed in affected white matter regions(175,176).  In 
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other studies including more complex models, these findings have not been 
replicated(177,178) highlighting the need for further investigation of these relationships.   
Mouse models may also be used to better understand the relationship between DTI 
parameters and disease.  The careful breeding and housing of transgenic mouse models of 
AD may reduce group variability through the control of external factors such as diet and 
exercise that can affect human studies.  Histological analysis can be used to identify the 
physical tissue changes driving diffusion measurements and to draw correlations between 
DTI indices and presence of known pathologies in AD.  The expedient progression of 
pathology in models allows rapid longitudinal studies of DTI measurements in early and late 
stages of pathology.  Characterisation of the chronological order of myelination of white 
matter regions(179) will allow the testing of experimental paradigms to evaluate 
retrogenesis and wallerian degeneration hypotheses. 
A number of studies have focussed on beta-amyloid models of AD with varying 
characteristic levels of pathological burden.   Invariably, differences have been reported 
compared to wild-type controls but the nature of the changes in DTI parameters varies 
between studies.  In the corpus callosum, both reductions(81,82) and increases in 
anisotropy(180) have been observed at late time points after the appearance of amyloid 
plaques.  Likewise, grey matter FA increases(180) and decreases(181) have been reported 
for transgenic groups.  Inconsistencies may be due to variations in mouse models, DTI 
protocols, ROIs, and image analysis methods between studies and without strong 
correlations with histology, the cause of differences is speculative. 
 
4.3  Development of a time-efficient DTI protocol 
4.3.1 Introduction and aims 
The in-vivo imaging time for a mouse that is anaesthetised and then recovered is limited to 
protect for the toxic effects of prolonged anaesthesia. In the case of the phenotyping 
project licence (Phenotyping Transgenic Mice licence (PPL: 70/7474)) awarded to CABI by 
the UK Home Office, a maximum of 3 hours is specified.  The aim of this work was to 
develop a methodological protocol for the acquisition of DTI data in the mouse brain at a 
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suitable resolution with sufficient SNR, which runs within an allocated portion of the total 
imaging time(3 hrs).  As part of a multi-parametric MRI protocol that included 3D 
structural, ASL, and CEST, it was required that acquisition took no longer than 45 minutes. 
To resolve white matter structures in the murine brain, a  minimum in plane resolution of 
200µm2 is required(182).  When compared to human imaging, this high resolution 
requirement counteracts the SNR gain of the high field strength in dedicated small animal 
MRI scanners.  Furthermore, the combined lengthening of T1 and shortening of T2 times at 
high field further reduce the amount of signal available for a given DTI scan time(182).  Ex-
vivo imaging offers a less time restricted alternative, however measurements may not 
represent in-vivo diffusion accurately due to the tissue fixation process required for ex-vivo 
sample preparation.  Spin echo sequences have been used previously to measure diffusion 
in white matter of the mouse (183-185).  The relatively long scan times of these protocols 
prohibit their use in this particular application where it is necessary to employ a rapid 
acquisition technique.  Recently, multi-shot DW SE-EPI sequences have shown potential to 
provide high quality DTI data sets at high field with reduced imaging times (186,187).   
Single shot spin echo EPI sequences allow very fast acquisition of images after a single 
excitation making them robust to motion artifacts relative to multi shot acquisitions.  
However, the signal decays with T2* dependence during the image readout and is highly 
sensitive to B0 field inhomogeneities which can lead to distortion and signal loss at long TEs.  
In the brain, these are caused by discontinuities in bulk magnetic susceptibility at tissue 
boundaries where local magnetic field gradients are generated.  Due to its size (and thus 
relatively high surface area to volume ratio), these effects make imaging in the mouse brain 
with EPI particularly challenging.  Imaging at high field is favoured to capitalise on SNR 
increases, however susceptibility effects are worse(188).  Compared to human brains, the 
mouse brain has a much larger surface to volume ratio meaning susceptibility effects in 
images spread to a larger proportion of the brain(189).  There is also significant demand 
placed on the gradient hardware in the presence of a rapidly decaying signal, where high 
slew rates will be necessary to meet the resolution requirements.   
As described in section 2.6.2, the distortion and signal loss caused by off resonances effects 
can be reduced by decreasing the number of PE steps per excitation required to traverse k-
space in the PE direction.  In a multi-shot acquisition, data acquired over multiple 
excitations are combined (commonly in a mesh pattern) to fill the whole of k-space in the 
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PE direction.  This EPI technique places less stress on the gradient hardware whilst offering 
higher achievable resolution and reduced effects of field inhomogeneities and T2* decay.  
A multiple shot approach does necessitate acquiring data over multiple TRs which incur a 
penalty of increased scan time compared to the single shot method and motion between 
shots can introduce artifacts into the images. 
In this section, a multi-shot DW SE-EPI sequence is optimised at 9.4T for the investigation of 
white matter changes in mouse models of AD as part of a multi-parametric MRI protocol.  
Steps taken to mitigate effects of common artifacts in multi-shot EPI sequences are 
described and the rationale behind choices of diffusion weighting parameters discussed. 
Preliminary in-vivo data is acquired and the accuracy of DTI measurements is evaluated 
through comparison to those reported in the literature.    
 
4.3.2 Methods 
4.3.2.1 DW SE-EPI protocol description 
A four shot EPI sequence was developed for in-vivo imaging of the mouse brain based on a 
previously published protocol(187). Multi-shot EPI sequences are vulnerable to bulk 
motion.  To prevent introduction of artifacts due to motion, the head of the anaesthetized 
mouse must be immobilized during imaging.  This is usually achieved by securing the teeth 
of the animal using a bite bar and the use of ear bars to clamp a caudal section of the 
cranium.  This method is very effective but was not compatible with the mouse bed and 
coil setup used in these experiments.  A 72 mm inner diameter volume coil (Rapid 
Biomedical) was used for RF transmission and signal was received using a 4 channel array 
head coil (Rapid Biomedical).  When the four channel array was attached to the mouse bed, 
a standard ear bar setup was not possible due to space restrictions, leaving only the bite 
bar and nose cone to secure the head.  A nose cone attachment with arms that protruded 
outwards towards the caudal end of the mouse’s head was designed and 3D printed by 
collaborators (Figure 24).  Adjustable ear bars were inserted through holes drilled in the 
arms to secure the head from the sides.  The polyamide (PA2200) material used for 3D 
printing is flexible and the dimensions of the head holder were such that they would flex 
inwards as the upper RF coils were secured adding further pressure. 
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Figure 24. Images of mouse head holder 
CAD drawing of mouse head holder (a) and attached to nose cone with ear bars inserted 
(b). 
 
It may not be possible to remove effects of respiratory motion through immobilization of 
the head and in this scenario, gating has been used previously to provide further 
improvements (190,191).  Respiratory gating was added to a four shot EPI sequence to 
prevent acquisition during breaths.  I achieved this by configuring the respiratory 
measurement equipment and by modifying the core EPI sequence code in VNMRJ.  A 
respiratory pad (SA instruments) was used to monitor breathing of the animal and a gating 
output from the vendor software was read by the MR sequence prior to implementing each 
shot.  The gate was configured to open between resps after a delay equal to 10% of the 
previous inter-resp period (Figure 25).  It closed again after a time that was equal to 50% of 
the previous inter-resp period.  The EPI pulse sequence code was amended to read the gate 
output at the start of each shot.  If open, the sequence was played out and data acquired.  
If the start of the shot occurred during respiration, indicated by a closed gate, data was not 
acquired but all RF pulses and gradients would be played out as normal to retain the steady 
state of the MR signal with respect to T1 and T2* relaxation.  Acquisition of the next shot 
would then occur at the next open gate reading. 
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Figure 25. Respiratory gating for EPI sequence 
SA instruments software detects an inter resp. period based on the gradient of the 
respiration signal(a).  The gate is opened after a 10% inter-resp. period delay (b).  The gate 
closes again after a further 50% of the inter-resp. period(c).  Where the start of the pulse 
sequence for an EPI shot occurs while the gate is open, the echo is acquired.  If the gate is 
closed, the echo is not acquired.   
 
In acquiring each shot in an EPI sequence, gradients of alternating polarity are acquired to 
continually refocus the signal(Figure 10, section 2.6.1).  Alterations to desired application of 
imaging gradients from sources such as eddy currents can cause a mismatch in adjacent 
lines of k-space.  These may cause faint artifacts in the resulting images known as N/2 
ghosts (section 2.6.2).  To reduce these artifacts, timing delays were added to the pulse 
sequence to centre echoes in the acquisition window and calibration scans were acquired.  
Full triple reference scans were acquired prior to the EPI acquisition.  These include a scan 
without phase encoding, one with inverted readout polarity and no phase encoding, and a 
scan with inverted readout polarity and phase encoding.  To apply corrections using the 
reference scans, the phase of scans collected without phase encoding is negated and 
multiplied at each pixel with the phase encoded scans acquired with the corresponding 
gradient polarity.  The two sets of modified phase encoded images are then summed at 
each pixel to give the final complex image.      
To ensure sufficient directional diffusion sampling, gradients were applied in thirty 
directions (Table 1) spread equidistantly over a sphere using a Jones30 scheme(192).  This 
scheme has been shown to produce low and rotationally invariant noise in FA estimates 
(193) required for robust estimation of tensor orientation and anisotropy at a b-value of 
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1000 s/mm2 (194).  Collecting diffusion data in a high number of directions limited the 
acquisition to a single b-value due to time constraints.  Previous studies have indicated a 
difference in the optimal DTI b-value depending on diffusion environment in the tissue.  In 
estimating a single tensor in isotropic brain parenchyma, this has been found to be 
approximately 1200 s/mm2 (192).  When anticipating more anisotropic media such as 
white matter tracts, a lower b-value has been suggested  to be approximately 900 s/mm2 
(195).  The final b-value after sequence optimization was 1050 s/mm2 which falls between 
the isotropic and anisotropic values indicated by the literature and is similar to that used in 
previous studies in-vivo in the mouse(185,187).  A single unweighted image was acquired 
prior to collection of diffusion weighted images.  To increase SNR, five signal averages were 
collected for each image to give a scan time of 42 minutes and 41 seconds. 
Order Read Phase Slice 
1 0 0 0 
2 1 0 0 
3 0.166 0.986 0 
4 -0.11 0.664 0.74 
5 0.901 -0.419 -0.11 
6 -0.169 -0.601 0.781 
7 -0.815 -0.386 0.433 
8 0.656 0.366 0.66 
9 0.582 0.8 0.143 
10 0.9 0.259 0.35 
11 0.693 -0.698 0.178 
12 0.357 -0.924 -0.14 
13 0.543 -0.488 -0.683 
14 -0.525 -0.396 0.753 
15 -0.639 0.689 0.341 
16 -0.33 -0.013 -0.944 
17 -0.524 -0.783 0.335 
18 0.609 -0.065 -0.791 
19 0.22 -0.233 -0.947 
20 -0.004 -0.91 -0.415 
21 -0.511 0.627 -0.589 
22 0.414 0.737 0.535 
23 -0.679 0.139 -0.721 
24 0.884 -0.296 0.362 
25 0.262 0.432 0.863 
26 0.088 0.185 -0.979 
27 0.294 -0.907 0.302 
28 0.887 -0.089 -0.453 
29 0.257 -0.443 0.859 
30 0.086 0.867 -0.491 
31 0.863 0.504 -0.025 
Table 1. Diffusion gradient directions 
Unit vector directions for diffusion weighted gradients and the order they were applied in 
the DW SE-EPI sequence.  
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In order to analyse the data, I wrote software in Matlab to construct tensors at each voxel 
using a least squares fit method.(196).  Firstly, a gradient encoding matrix, g, is formed 
using the gradient unit vectors in Table 1.  A b vector, b, is calculated using the acquired 
imaging data and the scalar b value using the equation(196) 
   
       
   
   
 
 
  
Equation 60  
Where Idw is the intensity in the diffusion weighted images, IB0 is the intensity in the b=0 
images, and  b is the scalar b-value.   Once b has been calculated, it can be used with the 
gradient encoding matrix to solve the linear equation(196) 
     
Equation 61  
to give x, which can be rearranged form the diffusion tensor matrix at each voxel.  A least 
squares fit in matlab was used to solve the linear equation followed by an eigen 
decomposition of the diffusion tensor matrix.  Eigen values were used to calculate MD, FA 
and radial and axial diffusivity following standard methods(98,197).  Anatomical structures 
were delineated manually in the parameter maps produced to provide mean ROI 
estimates. 
4.3.2.2 Protocol evaluation in a diffusion phantom 
n-dodecane is a liquid alkane that has previously been identified as suitable for measuring 
the accuracy of DTI sequences(198).  It has a well defined diffusion coefficient over a range 
of temperatures that can be used to test the accuracy of measurements using DTI.  At room 
temperature, it is within the range of ADC  values (0.5 x10-3mm2/s to 0.8 x10-3mm2/s) 
measured in-vivo in the corpus callosum of the developing mouse(185) and T1 and T2 
values are close to those of human white matter. 
A cylindrical diffusion phantom was constructed using 3 ml of Dodecane (Sigma-aldrich, UK) 
in a 5ml plastic syringe.  It was imaged at 9.4T in a 26mm diameter birdcage RF coil used for 
signal transmission and reception.  A temperature probe was attached to the outer surface 
of the phantom to monitor temperature during experiments (SA instruments).   Images 
were acquired using the DW SE-EPI protocol described previously in a central region of the 
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phantom. A ROI was drawn in the centre of the phantom across all 16 slices (20 x 20 x 16 
voxels) and the mean and standard deviation of the MD values was calculated to assess the 
accuracy of estimates, given the known diffusion coefficient of the phantom. 
Misalignments of adjacent echoes in k-space caused by eddy currents can cause both 
distortions and translations in images.  In DTI sequences, these effects may vary with the 
direction in which the diffusion weighting gradients are applied.  The presence of these 
artifacts were investigated by applying the DW- SE-EPI protocol in the central slices of the 
dodecane phantom.  The diffusion weighted image acquired first in the sequence was then 
subtracted from all other images to provide a set of difference images.  The presence of 
spatial shifts or distortion should be visible by prominent intensity changes along the edges 
of the phantom.  
4.3.2.3 Protocol evaluation in-vivo 
All of the in-vivo imaging in the protocol evaluation was performed using C57BL/6 mice 
with a 9.4 T VNMRS horizontal bore scanner (Agilent Inc.).  A 72 mm inner diameter volume 
coil (Rapid Biomedical) was used for RF transmission and signal was received using a 4 
channel array head coil (Rapid Biomedical).  Mice were anaesthetised under 2% isoflurane 
and positioned in a MRI compatible head holder to minimise motion artifacts. Anaesthesia 
was then maintained at 1.5% isoflurane in 100% O2 throughout imaging. Core temperature 
and respiration were monitored using a rectal probe and pressure pad (SA instruments). 
Mice were maintained at ~ 37 °C using heated water tubing and a warm air blower with a 
feedback system (SA instruments). 
A four shot Spin Echo EPI sequence was used to acquire sixteen slices.  The olfactory bulbs 
were used as an anatomical landmark to maintain consistency in slice positioning between 
animals(Figure 26). The FOV was 20 × 20 mm with a matrix size of 100 × 100 and a slice 
thickness of 0.5 mm.  Diffusion gradients were applied in thirty directions with the 
following parameters G = 0.25 T/m, Δ = 9.3 ms, δ = 5.5 ms, and b = 1050 s/mm2 to generate 
30 diffusion weighted images in addition to a single unweighted b=0 image.  Acquisition of 
5 averages with a TR of 2000 ms and TE of 24 ms gave a total imaging time of 43 min.  
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Figure 26.  Slice positioning for DW SE-EPI protocol 
Sagittal view of a mouse brain images with positioning of sixteen imaging slices overlaid. 
The junction between the olfactory bulbs and cortex was used as an anatomical landmark for 
the most rostral slice. 
 
A single mouse was imaged to investigate the sensitivity of the DTI sequence to chemical 
shift and motion artifacts.  Due to the low bandwidth in the phase encode direction, EPI 
sequences are highly susceptible to chemical shift artifacts(199).  A frequency selective RF 
pulse was used to saturate the signal from fat to mitigate artifacts.  The pulse was Gaussian 
shaped, non slice selective, and centred at 3.3ppm, the chemical shift of fat relative to 
water.  Images were also collected in-vivo (n=1), without the saturation pulse to investigate 
the severity of chemical shift artifacts.  An unweighted, single shot EPI image was acquired 
at the same resolution in a comparable imaging time (TR=8000ms, TE=24ms) to the multi 
shot sequence to compare distortion artifacts.  Data was also acquired using the multi shot 
sequence to test the efficacy of the respiratory gating added to the sequence and 
customised head holder to reduce motion artifacts. 
To investigate the accuracy of the DTI protocol in-vivo, data was acquired(n=1) and 
compared to  previously published values for C57BL/6 mice during early development (P15 
to P45)(185).  The animal was imaged and DTI parameters were calculated using the 
protocol described earlier.  To compare FA and MD measurements, mean values in ROIs in 
three regions were measured (Figure 27).  A white matter region in the corpus callosum 
and a grey matter regions in the caudate putamen and in the somatosensory section of the 
cortex were manually segmented in three slices to replicate the ROIs in the previous study.  
Low SNR has been shown to reduce both precision and  accuracy of DTI-based contrasts in 
FA(200).  SNR calculations were made using the cortical ROI (Figure 27) by dividing the 
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mean signal intensity by the standard deviation of the signal measured in the four corners 
of the image.   
 
Figure 27. ROIs for study comparison 
ROIs in the corpus callosum (CC), the forelimb region of the somatosensory cortex (S1FL), 
and the Caudate Putamen(CP) are shown for calculation of mean diffusion parameter 
estimates and SNR (corpus callosum and cortex only). 
 
4.3.3 Results 
4.3.3.1 Protocol evaluation in a diffusion phantom 
A dodecane diffusion phantom was used to investigate the accuracy of ADC estimates using 
the DW SE-EPI protocol as well as potential issues of echo misalignment.  The mean and 
standard deviation of MD measurements at a b-value of 1050 s/mm2 was 0.743±0.043 x10-
3mm2/s.  The measured temperature of the phantom during imaging was 18.5±0.30C.  At 
this temperature, the MD was within the range of specified diffusion coefficient values 
previously published (0.708 x10-3mm2/s and 0.788 x10-3mm2/s  measured at 150C and 200C 
respectively )(198).   
Difference images were generated by subtracting the first diffusion weighted image from 
the other diffusion weighted images.  In the case of eddy current induced distortion, it 
would be expected that visible differences would be observed at the periphery of the 
phantom.  The signal magnitude observed in the difference images was very low compared 
to that in the raw diffusion weighted image (Figure 28).  This is expected in such a phantom 
where diffusion should be isotropic and therefore attenuation of the signal should be equal 
in all weighting directions.  Furthermore, the lack of noticeable signal at the edge of the 
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images of the phantom images indicate a lack of direction dependent distortion or 
translation of signal as might be produced in the presence of eddy currents in the gradient 
coils. 
 
Figure 28. Dodecane diffusion weighted difference images 
The first DW images from a central slice of the phantom followed by difference images 
generated by subtracting this image from the twenty nine subsequent DW images.  The DW 
value differences are very small compared to the DW signal magnitude and the lack of large 
differences around the periphery of phantom suggest the eddy current distortions are 
minimal.    
 
The use of calibration scans can reduce the appearance of N/2 ghosting with the 
disadvantage of increasing scan time to acquire the extra data.  Images of the dodecane 
phantom were acquired with and without a full triple reference scan (Figure 29).  Ghosting 
was observed in the images acquired without a reference that disappeared when the full 
triple calibration scan was added to the sequence. 
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Figure 29. Effect of reference scan on EPI images 
SE-EPI images of n-dodecane phantom acquired with no reference scan (a) and with a full 
triple reference scan (b). Intensities were windowed [0 10000].  Ghosting is visible in the 
image acquired without the full triple reference scan. 
 
4.3.3.2 Protocol evaluation in-vivo 
EPI images were acquired in-vivo in a mouse to assess chemical shift artifacts and 
differences in distortion between single shot and multi shot images.  Chemical shift 
artifacts were found to be present in the multi-shot EPI acquisitions (Figure 30a).  These 
were markedly reduced by the addition of a fat saturation RF pulse (Figure 30b).  Significant 
distortion in the phase encode direction was observed in images acquired using a single 
shot EPI sequence (Figure 30c).  Mislocalisation of the MR signal resulted in a smearing 
across the image and a loss of contrast that is particularly apparent at the edges of the 
brain.  
 
Figure 30. Multi-shot EPI with RF fat saturation 
Single image slice for four shot EPI acquisition, chemical shift artifacts are observed(a) that 
are removed by the addition of a fat saturation pre-excitation RF pulse(b).  The single shot 
EPI acquisition(c) exhibits significant mislocalisation of signal in the phase encode direction 
(L to R). 
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Motion artifacts were evident in the multi-shot EPI images in the phase encode direction 
using only the manufacturer supplied nose cone to secure the mouse head(Figure 31a).  
Ghosting was most apparent in the diffusion weighted images(Figure 31a) which is likely to 
be due to the lower SNR and greater susceptibility to motion introduced by the diffusion 
gradients compared to the unweighted images.  Marked improvements were observed in 
the images when respiratory gating was added to the EPI acquisition (Figure 31b) indicating 
that some of the motion was due to the breathing of the animal.  A small time increase of a 
few minutes was caused by the necessity to repeat EPI shots that occurred during 
respiration.  When using the head holder designed to immobilise the animals head, motion 
artifacts in images were further reduced without respiratory gating (Figure 31c).   
 
Figure 31. Respiratory motion artifacts in EPI images 
Single slice b=0 images and six diffusion weighted images acquired without (a) and with(b) 
respiratory gating(NSA=1)(without custom head holder).  Artifacts were found to be 
reduced using the custom head holder with no respiratory gating(c) (NSA=5).  
 
A single wild-type mouse was imaged in-vivo using the optimised DW SE-EPI protocol to 
compare SNR, and MD and FA in with previously published values in selected ROIs(185).  
Sixteen coronal images were generated for a single unweighted b=0 image, followed by 
thirty diffusion weighted images with gradients applied following a Jones30 scheme.  
Images were observed to be free from distortion and motion artifacts (Figure 32).   
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Figure 32. DW SE-EPI in-vivo images 
Representative b=0 and thirty diffusion weighted images for a single coronal slice acquired 
in a wild-type mouse. 
 
DTI parameter maps were generated from tensor calculations at each voxel in the images 
(Figure 33).  It was observed, as expected, that MD values were greater in the CSF filled 
ventricular regions.  White matter regions are clearly visible as areas of increased FA and 
DA and reduced DR in comparison to surrounding grey matter regions.   
 
 
Figure 33. DTI parameter maps 
Maps of MD (a), FA(b), DR(c), and DA(d) acquired in-vivo in the mouse brain  (Diffusivity 
values given in mm
2
/s).   Increased MD can be observed in the ventricles(a) and white 
matter regions display increased FA(b) and reduced DR(c). 
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The SNR value calculated in the cortex of the b=0 images was 55 in the cortex.  This equates 
to an SNR of 35 dB which is less than the value of 46 dB measured in the somatosensory 
cortex by Chahboune et al(185) which is likely due to differences in the imaging parameters 
used.  In the diffusion weighted images, the mean SNR measured across all thirty diffusion 
weighting gradient directions in the cortex was 24.2±1.5. 
The FA and MD measured in the corpus callosum ROI were 0.53±0.07 and 0.75± 0.11 x10-
3mm2/s respectively.  These estimates were in good agreement with values reported in the 
earlier study taken during early development.  The values in the grey matter regions of the 
caudate putamen ( FA = 0.19±0.05 / MD =0.75± 0.07 x10-3mm2/s ) and the somatosensory 
region of the cortex ( FA = 0.13±0.05 / MD =0.77± 0.07 x10-3mm2/s ), also fell within the 
ranges of these parameters measured previously. 
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4.3.4 Discussion 
In this section a multi-shot DW SE-EPI acquisition was optimised and tested for in-vivo 
acquisition in the mouse brain at 9.4T.  The sequence runs in less than 43 minutes making it 
suitable for inclusion in an imaging protocol containing other MRI techniques to be 
performed within the maximum imaging time for an in-vivo murine recovery experiment.  
The protocol was evaluated through comparison of phantom and in-vivo diffusion 
measurements to published values and effects of artifacts known to plague this type of EPI 
acquisition were analysed. 
Distortion experienced by single shot EPI acquisitions at high field can be seen clearly in 
Figure 30c, and are less apparent in the multi-shot sequence implemented.  Artifacts in 
images caused by increased sensitivity to motion of multi shot sequences were reduced by 
introducing gating of the pulse sequence to acquire data between breaths in the 
respiratory cycle.  However, a head holder was subsequently developed to immobilise the 
animal that proved to be a highly robust solution to motion artifacts.  Consequently, the 
respiratory gating was removed from the sequence due to the extra scan time it incurred.  
The use of an RF pulse to saturate fat was successful in removing chemical shift artifacts in 
the phase encode direction. 
The addition of a calibrated time delay was employed to reduce Nyquist or N/2 ghosting 
that can be caused by misalignments of consecutive echoes in k-space.  Despite the 
increased time necessary to acquire them, it was found that full triple reference calibration 
scans provided a significant reduction in ghosting.  The contribution of eddy currents in 
gradient coils due to the rapid switching of current in EPI sequences were investigated 
through the use of difference images in diffusion weighted images.  Phantom images 
appeared to show minor changes in magnitude or spatial localisation in signal between 
images weighted by gradients applied in different directions.  The gradient sets used in 
these experiments are self shielded to reduce eddy currents outside of the set.  Effects of 
any remaining currents are reduced through the use of pre-emphasis or digital eddy 
current compensation that is employed by the console software.   Post processing 
correction techniques can be employed which may involve registration and resampling to 
realign erroneous spatial localisation of signal in images.  These were not employed in this 
study due to the apparent lack of severity of errors induced. 
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The accuracy of the DTI protocol was tested in-vivo and through the use of a diffusion 
phantom and parameter estimates were shown to be in good agreement with values 
previously published.  Repeating the in-vivo experiments with a larger cohort of mice would 
have been desirable to provide a measure of precision of the technique.  Although in-vivo 
SNR estimates in the cortex were lower than those reported, the values measured in both 
the b=0 and the diffusion weighted images were well above the noise floor(201).  
Furthermore, the  increased number of DW gradient directions used in this protocol should 
reduce noise in FA estimates(193).  Varying the number of gradient directions, b-value 
magnitude, and signal averages will have impacts on image SNR, accuracy of DTI parameter 
estimates, as well as scan time of this protocol and further investigation to establish 
optimal balance of these components would be beneficial. 
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4.4 Diffusion Tensor Imaging in a mouse model of 
Tau Pathology 
4.4.1 Introduction 
In recent years, tau has emerged as a potential target for therapeutic intervention in 
AD(25,26).  Tau plays a critical role in the neurodegenerative process: aggregates of 
hyperphosphorylated tau forming neurofibrillary tangles (NFTs) are a major hallmark of AD 
and correlate with clinical disease progression(11).  In the absence of amyloid-beta, NFTs 
are also implicated in several other neurodegenerative diseases (frontotemporal dementia 
with parkinsonism, progressive supranuclear palsy, corticobasal degeneration), further 
supporting the role of tau in the dementing process(202).  The rTg4510, a mouse model of 
tauopathy has been developed that specifically expresses tau in the forebrain but without 
amyloid plaques, enabling dissection of the unique role of tau in AD pathology(203,204).  
Behavioural and histological studies of the rTg4510 mouse have demonstrated cognitive 
deficits in learning and motor tasks and marked atrophy of brain regions known to be 
selectively vulnerable to AD such as the hippocampus and frontal cortex(204). 
In this study, diffusion tensor imaging (DTI) (a sensitive measure of local tissue 
inflammation and cellular integrity) was implemented to probe changes in microstructural 
compartmentation in the rTg4510 mouse.  As part of a multi-parametric protocol, data was 
acquired in a limited scan time and sensitivity to tissue pathology in selected white and 
grey matter regions was evaluated against histological measures.  Diffusion parameters 
were sampled in different sub regions of the corpus callosum.  Differences identified 
between the earlier myelinating splenium(92) and the genu, may indicate a vulnerability to 
disease that is dependent on development.      
It is shown that this DTI protocol can unambiguously discriminate tau pathology from 
healthy control subjects, providing a platform for the longitudinal assessment of 
experimental treatments in combination with other MRI techniques.  Furthermore, we 
demonstrate that DTI metrics are sensitive to tau-pathology in regions of low NFT density, 
providing evidence that these data may inform the development of a multi-parametric 
imaging biomarker for early detection of tau pathology in the clinic.   
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4.4.2 Materials and Methods 
4.4.2.1 Transgenic mice 
Generation of homozygous rTg4510 transgenic mice has been reported previously(203).  
Female rTg4510 mice were licensed from the Mayo Clinic (Jacksonville Florida, USA) and 
bred for Eli Lilly by Taconic (Germantown, USA).  Mice were imported to the UK for imaging 
studies at CABI.  All studies were carried out in accordance with the United Kingdom 
Animals (Scientific Procedures) act of 1986. 
4.4.2.2 Magnetic Resonance Imaging 
All imaging was performed with a 9.4 T VNMRS horizontal bore scanner (Agilent Inc.).  A 72 
mm inner diameter volume coil (Rapid Biomedical) was used for RF transmission and signal 
was received using a 4 channel array head coil (Rapid Biomedical).  Mice were 
anaesthetised under 2% isoflurane and positioned in a MRI compatible head holder to 
minimise motion artifacts.  Anaesthesia was then maintained at 1.5% isoflurane in 100% O2 
throughout imaging.  Core temperature and respiration were monitored using a rectal 
probe and pressure pad (SA instruments).  Mice were maintained at ~37 °C using heated 
water tubing and a warm air blower with a feedback system (SA instruments). 
In this study, rTg4510 and wild-type litter matched control mice at 8.5 months of age were 
imaged.  DTI was conducted on N = 9 rTg4510 mice and N = 17 wild-type controls as part of 
a multi-parametric MRI protocol(125).  The brains of each of the rTg4510 and wild-
type(WT) mice were perfuse fixed for histology which was carried out by collaborators 
directly after imaging.  The reported p-values are from standard t-tests for differences in 
parameters between the rTg4510 and WT groups, unless stated otherwise. 
4.4.2.3 Diffusion Tensor Imaging (DTI) 
A four shot Spin Echo EPI sequence was used to acquire sixteen slices as described in 
section 4.3.  The olfactory bulbs were used as an anatomical landmark to maintain 
consistency in slice positioning between animals.  The FOV was 20 × 20 mm with a matrix 
size of 100 × 100 and a slice thickness of 0.5 mm.  Diffusion gradients were applied in thirty 
directions with the following parameters G = 0.25 T/m, Δ = 9.3 ms, δ = 5.5 ms, and b = 1050 
s/mm2 to generate diffusion weighted images in addition to a single unweighted b=0 
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image.  Acquisition of 5 averages with a TR of 2000ms gave a total imaging time of 43min.  
Software written in Matlab was used to construct tensors at each voxel through a least 
squares solution approach (196).  The parameters MD, FA as well as radial and axial 
diffusivity were calculated from the tensors following standard methods.  Three slices 
posterior to the bregma were selected for comparison to histology in the unweighted 
images and ROIs were manually drawn in the corpus callosum and grey matter areas of the 
hippocampus, cortex and thalamus (Figure 34).  White matter ROIs were also taken in 
single slices located in both a rostral and caudal location(Figure 34a) in the external capsule 
to compare measurements in the Genu and Splenium regions of the corpus callosum 
respectively.  Mean Diffusivity and Fractional Anisotropy values were measured for all 
regions and radial and axial diffusivity were also calculated in white matter structures.  
Mean values were calculated for the ROIs in each group for comparison of the DTI 
parameters. 
 
Figure 34. DTI Regions of Interest 
Location of slices (a) in the rostral (a,r) and caudal (a, c) white matter of the external 
capsule, and in slices posterior to the bregma (a, pb) where ROIs(b) were drawn in the 
cortex(Ctx), Hippocampus(Hp), Thalamus(Th), and corpus callosum(CC)for comparison with 
histology. 
4.4.2.4 Histology and Immunohistochemistry 
Following in-vivo imaging, the brains were perfusion fixed and histology was performed by 
collaborators.  Animals were terminally anaesthetised with Euthanal (0.1 mL) administered 
via intraperitoneal injection.  The thoracic cavities were opened and the animals perfused 
through the left ventricle with 15–20 mL of saline (0.9%) followed by 50 mL of buffered 
formal saline at a flow rate of 3 mL per minute.  Following perfusion, the animal was 
decapitated, defleshed, and the lower jaw removed.  All brains were stored in-skull at 4 °C 
before being dispatched for histology. 
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Brain samples were then processed using the Tissue TEK® VIP processor (GMI Inc,MNUSA).  
After processing, sections were embedded in paraffin wax to allow coronal brain sections 
to be cut.  Serial sections (6-8 µm) were taken using HM 200 and HM 355 (ThermoScientific 
Microm, Germany) rotary microtomes.   
Immunohistochemistry (IHC) was performed using a primary antibody for tau 
phosphorylated at serine 409 (PG-5; 1:500 from Peter Davies, Albert Einstein College of 
Medicine, NY, USA).  Secondary antibody was applied and slides were then incubated with 
avidin biotin complex (ABC) reagent for 5 min (M.O.M.  kit PK-2200, Elite ABC rabbit kit PK-
6101, or Elite RTU ABC PK-7100 Vector Labs).  After rinsing, slides were treated with the 
chromogen 3,3′-diaminobenzidine (DAB; Vector Laboratories, SK-4100) to allow 
visualisation.  The slides were then cover slipped, dried and digitised using an Aperio 
Scanscope XT (Aperio Technologies Inc., CA, USA). 
4.4.3 Results 
4.4.3.1 Regional correlations of diffusion parameters to NFT density 
Immunohistochemistry was performed on each of the individual rTg4510 (n = 9) and WT (n 
= 17) control animals to estimate the density of PG-5 positive NFTs in cortical, hippocampal 
and thalamic regions (Figure 35).  No PG-5 positive cells were observed in any of the 
control mice and quantitative measures were made in the hippocampus, cortex and 
thalamus for each rTg4510 mouse.  There was high pathological burden detected in the 
cortex and hippocampus (mean NFT density = 229 cells/mm2 and 83 cells/mm2 respectively) 
of the transgenic group.  The positive cell count observed in the thalamus was much lower 
in comparison (mean NFT density 2.3 cells/mm2) (Figure 35).   
The DTI measurements in the cortex and hippocampus, areas of high density of tau 
pathology, showed increased FA and MD in the transgenic group (Figure 36).  Significant 
differences in both FA and MD were observed in the cortex.  The FA in the transgenic and 
wild-type groups were 0.18±0.03 and 0.15±0.01 (p=2.1×10-4) and the MD was 
8.24±0.49x10-4 mm2/s and 7.64±0.35x10-4 mm2/s (p = 7.46 × 10-3).  The Hippocampus 
measurements of FA were 0.21±0.04 and 0.17±0.03 for the transgenic and wild-type groups 
respectively and the MD values were 9±0.49x10-4 mm2/s and 7.7±0.59x10-4 mm2/s, only 
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the MD group differences were significant (p=4.75 × 10-2).  In the thalamus, a region of low 
tau pathology, a significant increase was observed in the MD only (p=4.83 × 10-2).   
 
Figure 35. Immunohistochemistry to estimate regional PG-5 positive NFT 
density 
 a) Single histology slice from a representative rTg4510 mouse  with staining for PG-5 
positive NFTs.  Marked regional  dependence  of NFT density is  observable  (see  inset(b-d) 
for example s of  cortical, hippocampal and thalamic NFT distribution).  E) Quantitative  
regional estimates of NFT density for each of the 17 WT and 9 rTg4510 mice  that were 
used for MRI studies   
108 
 
 
Figure 36. DTI measurements in Grey Matter regions 
Mean Diffusivity(a) and Fractional Anisotropy (b) in grey matter regions in WT and rTg4510 
mice. A significant increase in MD was observed across all regions in the rTg4510.  The 
cortex was the only grey matter regions to exhibit a significant increase in FA. Red crosses 
indicate outliers defined as values that lie greater than ±2.7σ from the mean. 
 
 
No significant correlations between DTI parameters and tau pathology measurements were 
observed within ROIs.  Therefore, a secondary correlation analysis was performed in which 
regions were ranked based on their pathological burden.  The cortex and hippocampus 
were ranked as “high” density while the thalamus was ranked as “low” density.  The 
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relationship between percentage difference in MRI parameters from WT controls (ranked 
as 0 tau burden) and tau density was examined.  A significant correlation of FA and MD to 
the ranked data was observed (Figure 37).  There was a positive correlation of FA 
(Spearman's CC = 0.48, p = 1 × 10−5) and MD (Spearman's CC =0.57, p=1.2 × 10−7) to group 
ranked tau density.  However, there was no statistical difference in the percentage 
difference from control between the cortex and hippocampus (the “high” ranked regions) 
in each of the MR measures, despite the cortex presenting with a threefold increase in NFT 
density relative to the hippocampus.  This finding suggests a monotonic relationship exists 
between measures of MD and FA and NFT density within a degree of tau burden which 
dissociates between regions of “high” tau burden (the cortex and hippocampus) in the 8.5 
month rTg4510 mice. 
 
Figure 37. DTI correlates to histological ranking of tau density  
Percentage change (normalised to control) in a)MD and b) FA as a function of histological 
ranking of PG-5 positive NFT density.  Spearman's non-parametric correlation coefficient 
was used to investigate a possible correlation of DTI measures to histological ranking (p-
value and correlation coefficient (CC) reported in figure inset).  Box plots represent median, 
interquartile range and range of quantitative MR estimates. Red crosses indicate outliers 
defined as values that lie greater than ±2.7σ from the mean. 
   
4.4.3.2 DTI of white matter regions of high pathology 
DTI was employed to investigate microstructural changes in the white matter of the 
rTg4510 mice relative to the normal brain.  Intensity of PG-5 staining in images of histology 
slices was used to calculate a staining density in the corpus callosum ROI as a ratio of the 
area of positive stain divided by the total area of the region.  The staining density in the 
rTg4510 (3.5 ± 1.37) was significantly greater than that of the wild-type group (0.01 ± 0.01, 
p = 6.12 × 10−5).  The mean ROI measurements of FA and MD in the corpus callosum taken 
posterior to the bregma showed significant differences between the transgenic and control 
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groups (Figure 38).  The transgenic group exhibited a reduced FA of 0.32 ± 0.05 compared 
to the controls (0.48 ± 0.07, p = 4.5 × 10−6, effect size = 2.7).  In contrast, the MD of 9.4 ± 
0.8 × 10−4 mm2/s observed in the transgenic group was greater than in the controls (7.7 ± 
0.4 × 10−4 mm2/s, p = 6.3 × 10−8, effect size = 3).   
 
Figure 38. MD and FA measurements in the Corpus Callosum 
Mean Diffusivity (a) and Fractional Anisotropy measurements in the corpus callosum 
posterior to the bregma.  MD is increased and FA is reduced in the rTg4510 group. Red 
crosses indicate outliers defined as values that lie greater than ±2.7σ from the mean. 
 
 
Most marked was the change in radial diffusivity, where a clear discrimination between the 
wild-type and the transgenic groups was observed (p = 1.5 × 10−8, effect size = 3.8) (Figure 
39).  No significant difference was observed in axial diffusivity values (rTg4510 = 11.1 ± 0.9 
× 10−4 mm2/s, control =10.7 ±0.9 × 10−4 mm2/s, p = 0.36).  
 
Figure 39. Radial Diffusivity in the corpus callosum 
Measurements of Radial Diffusivity in the corpus callosum posterior to bregma (a) showed 
elevated values in the rTg4510 group.  Representative parameter maps are shown for a 
wild-type (b) and rTg4510(c) mouse.  Red arrows highlight regions of  reduced contrast in 
radial diffusivity between the corpus callosum and surrounding grey matter in the 
transgenic map. 
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4.4.3.3 Comparison of rostral and caudal regions in the corpus callosum 
 
The measurements in regions of the genu and the splenium of the corpus callosum 
displayed a number of significant differences in DTI parameters between the wild-type and 
rTg4510 groups (Figure 40).  In the rostral ROI containing the genu, there was a significant 
FA reduction in the rTg4510 (rTg4510 =0.31±0.07, control =0.51±0.1, p = 8.91 × 10-10).  DR 
and DA were also significantly different with increased DR (rTg4510 = 5.95 ± 1.1 × 10−4 
mm2/s, control =4.6 ±0.8 × 10−4 mm2/s, p = 3.86 × 10-5) and decreased DA measured in the 
rTg4510. 
In the caudal ROI containing the Splenium of the corpus callosum, the DTI parameters 
followed a similar pattern to measurements taken for the histology comparison.  There 
were significant increases observed in MD in the rTg4510 (rTg4510 = 7.58 ± 1.1 × 10−4 
mm2/s, control =6.58 ±0.8 × 10−4 mm2/s, p = 3.6 × 10−4) and DR (rTg4510 = 6.35 ± 1.2 × 10−4 
mm2/s, control =5.2 ±1.1 × 10−4 mm2/s, p = 6.5 × 10−5).  Like the genu measurements, a 
reduced FA was observed in the rTg4510 (rTg4510 = 0.32 ± 0.1, control =0.41 ±0.2, p = 7.4 × 
10−4) decreased.  DA was slightly increased in the transgenic groups but the difference was 
not significant(rTg4510 = 10.05 ± 1.5 × 10−4 mm2/s, control =9.56 ±2.0 × 10−4 mm2/s, p = 
0.12).   
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Figure 40. DTI in rostral and caudal slices 
DTI parameter values measured in a rostral slice (a-d) and a caudal slice(e-h).  MD (a,e), 
FA(b,f), DR(c,g) and DA(d,h) are presented for both slice ROIs.  Calculated p-values are 
presented beneath box plots with group differences found not to be significant displayed in 
red. Red crosses indicate outliers defined as values that lie greater than ±2.7σ from the 
mean. 
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4.4.4 Discussion 
In this study, a time efficient acquisition DTI protocol has been deployed to probe distinct 
aspects of AD pathophysiology in the rTg4510 mouse.  The sensitivity of non-invasive DTI 
imaging to provide brain tissue correlates of tau pathology in white matter and in regions 
of high NFT density in the grey matter has been demonstrated.  Increased MD was 
observed in a region of low NFT pathology highlighting the value of DTI for the 
identification of tau-driven pathological processes, suggesting its utility as a biomarker for 
the early assessment of novel tau therapeutics. 
A number of clinical studies using DTI have observed increased MD and reduced FA in the 
white matter of the brains of AD patients when compared to healthy controls(18,65).  
These findings of increased MD and reduced FA in rTg4510 mice relative to wild-type 
controls are consistent with this and suggest that the aberrant white matter microstructure 
observed in AD may be, at least in part, a consequence of the tau pathology underlying the 
disease.  The increase in radial diffusivity in the presence of unchanged axial diffusivity in 
the corpus callosum of the rTg4510 mice suggests a reduction in myelination, mirroring 
previous observations in sub regions of the corpus callosum in AD sufferers(39).  These 
findings are highly concordant with an earlier longitudinal study by Sahara et al.  that 
applied DTI methods to investigate the white matter of the rTg4510 model(205).  Electron 
microscopy measures were performed and demonstrated the presence of tau inclusions in 
the white matter and subsequent micro-structural disorganisation relative to WT controls 
at later time points(205).  The effects of amyloid plaques, the other hallmark pathology of 
AD, have been investigated in previous studies (81,82) where differences in DTI parameters 
have been observed at late time points after the appearance of amyloid plaques.  
Abnormal myelination patterns have been identified prior to appearance of NFTs and 
amyloid plaques in a mouse model exhibiting both pathologies(206).   
To investigate the effects of tau pathology on white matter that matures at different stages 
of development, measurements were taken in the genu region of the corpus callosum and 
the earlier myelinating region of the splenium.  Changes in the splenium mimicked those in 
the white matter region of high tau pathology, exhibiting reduced FA and increased MD 
and DR in the rTg4510.  In the genu, reduced FA and increased DR was observed with 
greater significance than in the splenium and  axial diffusivity was also significantly lower in 
than in the control group.  No differences were detected in genu of the rTg4510 at this time 
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point in the study by Sahara et al..  The increased statistical significance of the diffusion 
changes in the genu compared to the splenium region of the external capsule may offer 
support to the retrogenesis hypothesis, that the later myelinating structures are affected 
more severely by pathology.  However, the rostral location of the genu may make it more 
susceptible to the neurodegeneration that occurs preferentially in the 
forebrain(125,203,204) under the CaMKII promoter in the rTg4510.  Additionally, it should 
be noted that a limitation of this study is the relatively late time point (8.5 months) may 
restrict evidence for specificity of DTI parameters to abnormal tau within and connected to 
the high ranked regions, as marked neurodegeneration is likely to have already occurred.  
Tracking the DTI changes from an early time point using this protocol alongside structural 
MRI atrophy measurements may provide more information on the temporal order of 
changes in white matter regions and their relationship with neuronal cell loss in connected 
grey matter tissue.   
The MD findings in grey matter regions are in good agreement with previous studies that 
have detected elevated values in the brains of AD patients (169,171,207) and in mouse 
models exhibiting amyloid pathology at late stages of progression(82).  In the previous 
longitudinal DTI study in the rTg4510 by Sahara et al(205), no differences in MD were 
observed in any of the ROIs at later time points.  This may be due to the increased animal 
numbers as well as enhanced sensitivity of the DTI protocol used here.  The positive 
correlation between the increased MD and the tau density ranking suggest that the 
disruption to the cytoarchitecture indicated by these increases may be driven by the 
pathology.  Furthermore, the positive correlation of FA with tau density may indicate that 
the structural reorganisation that occurs may have directional specificity.  FA has been 
found to be reduced in AD patients in the hippocampus (171) and the thalamus (169) which 
contradicts the findings in this study where the FA was increased significantly in the cortex 
and hippocampus in the transgenic mice and there is no significant difference in the 
thalamus.  These differences may be due to the addition of amyloid-beta pathology present 
in the brains of AD patients or the inherent differences in murine grey matter tissue 
structure.   
The thalamus of the rTg4510 mice was found to have relatively low NFT density (mean=2.3 
cells/mm2), mirroring human tissue at early Braak staging with low NFT density(208).  We 
observed an increased MD in this region relative to WT controls.  This finding suggests that 
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microstructural changes that occur with little pathology present can be detected in this 
brain region with DTI.  These imaging changes may reflect very early local markers of tau 
pathology in the thalamus, but it cannot be ruled out that some of these differences may 
also be secondary to the large tau pathology in the forebrain structures, many of which are 
known to project to the thalamus.  This may be important as we know that tau aggregates 
can transfer and propagate/spread within synaptic circuits(209,210).  There is post-mortem 
evidence in AD for this regional spread(11) and more recent neuroimaging studies in 
human AD suggest “epicentres” (211) or “nodes” (212) that may link to network 
dysfunction. 
Histological measures of pathological tau burden in the rTg4510 mice demonstrated a 
strong regional dependence of NFT density ranging from low (2.3 counts/mm2 in the 
thalamus) to high (229 counts/mm2 in the cortex) (Figure 35).  This is to be expected as 
expression of tau is driven by a forebrain specific promoter in the rTg4510 mouse (87).  We 
sought to exploit this marked dynamic range of NFT density (as quantified using PG-5, 
pS409 tau) between regions to investigate correlations between ranked tau burden and 
difference in MR parameters from control (to account for intrinsic regional differences).  
We observed significant correlations between the percentage change from control in MD 
and FA across regions free of NFTs (wild-type), low NFT density (rTg4510 thalamus) and 
high NFT density (rTg4510 cortex and hippocampus), indicating a monotonic relationship 
between NFT density and diffusion changes between different regions of varying tau load 
at this time point.  This observation provides encouragement that DTI could be used to 
broadly classify regions of negligible, low and high NFT density for non-invasive staging of 
AD.  The percentage change in MR parameters in rTg4510 from control were very similar 
between the cortex and hippocampus (high ranked data), despite the marked difference in 
the overall NFT density between these two brain regions.  This may be a feature of the 
rTg4510 model at this time point or reflect the greater and more selective vulnerability (or 
different inherent composition) of the hippocampus, a region known to present with 
marked abnormality in AD patients.  We observed limited within-region correlations of NFT 
density to other DTI parameters in grey matter which may be due to the relatively narrow 
distribution of NFT density within each region (Cortex: 229 (±28), Hippocampus: 82.9 (±15), 
Thalamus: 2.3 (±0.8)(PG-5 positive neurons per mm2)) at this time point.   
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4.5  Conclusions 
This study has demonstrated the value of non-invasive DTI MRI for sensitive detection of 
tau pathology in the rTg4510 model of AD.  These novel data represent a platform for 
future longitudinal and therapeutic evaluation studies in this model.  The time efficient 
acquisition has been integrated into a multi-parametric protocol and merits application in 
clinical populations to investigate the pattern of MR changes in regions known to follow the 
well-defined stages of NFT progression.  Estimates of diffusion can detect changes in 
healthy tissue in a region of low NFT density (2.3 cells/mm2) which provides promise for the 
use of these markers to identify and track subjects early in the Alzheimer's disease 
continuum. 
White matter DTI measurements showed significant changes in the corpus callosum of the 
rTg4510.  Reductions in FA and increases in DR were observed in all measurements and 
may be attributed to a reduction in the presence of hydrophobic myelin in this tract 
suggested in a previous study using Electron Microscopy(205).  However, the 
microstructural rearrangements that occur in disease may not always be straight forward 
and there have been studies that call into question the specificity of FA and DR to 
abnormalities in myelination(177,178).  Quantitative Magnetic Susceptibility 
Mapping(QSM) is an MRI technique sensitive to the diamagnetic properties of myelin and 
has shown increased sensitivity over DTI to the maturation of white matter tracts in the 
developing mouse brain(213).  In the following chapter, a protocol is developed and 
applied in the rTg4510 to investigate the sensitivity of QSM to tau pathology.  
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5 Quantitative Susceptibility Mapping in the 
rTg4510 mouse model 
5.1 Overview 
In the last chapter, an SNR time efficient DTI protocol was developed for integration into a 
multi-parametric MRI protocol and applied to the rTg4510 mouse model of AD.  Differences 
in diffusion parameters relative to wild-type controls indicated a reduction in the 
directional diffusion of spins in white matter tracts which may be due to degradation of the 
myelin sheaths of axons.  Neuroinflammation and oxidative stress in AD are associated with 
NFT pathology and dysfunction of oligodendrocytes - myelin generating glial cells.  
Disruption to the homeostasis of iron in the brain may be a trigger for neuroinflammation 
and excess accumulation of iron in the basal ganglia has been observed(214).  Quantitative 
Susceptibility Mapping (QSM) is an emerging MRI technique that has demonstrated 
sensitivity to the concentration of myelin(diamagnetic) and iron(paramagnetic) which may 
represent an early biomarker of AD. 
In this chapter, a QSM protocol is developed and data is collected both in-vivo and ex-vivo 
in the rTg4510 and WT controls.  Firstly, the phase data from a previously acquired ex-vivo 
dataset was processed and used to carry out a pilot experiment to identify regions of 
reduced magnetic susceptibility contrast between white matter and grey matter.   Gradient 
echo acquisitions were then optimised for collection of both in-vivo and ex-vivo data and a 
post processing software pipeline was developed to generate susceptibility maps from this 
data.  Magnetic susceptibility and T2* estimates in regions of interest in rTg4510s and wild-
type controls are presented and discussed. 
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5.2 Background 
5.2.1 Introduction 
Despite its role in a variety of metabolic processes, iron can take on a reactive ferrous form 
in the body that may lead to tissue damage in the brain caused by the generation of 
biologically toxic Reactive Oxygen Species(ROS) (215,216).  The storage of iron, in its ferric 
form, is disrupted in Alzheimer’s Disease where deposition occurs in excess of the global 
increases associated with healthy ageing(217).  Abnormal accumulation has been shown to 
occur in the iron rich regions of the basal ganglia(214) and co localised with plaque and 
tangle pathology(216).  Oxidative stress is associated with the dysfunction of 
oligodendrocytes in AD(218) and the consequent breakdown of axonal sheaths in white 
matter tracts may lead to the release of myelin-associated iron(219).  It has been 
hypothesized that a breakdown in iron homeostasis is responsible for an increase in the 
harmful redox-active iron population(216).  The use of chelating agents to target these 
reactive species has shown neuroprotective value in mouse models of AD(220). However, a 
causal relationship between iron accumulation and the pathobiological cascade in AD has 
not been demonstrated.  In-vivo biomarkers sensitive to tissue iron concentration may play 
a key role in tracking the progressive iron accumulation that occurs in AD pathogenesis and 
provide a means by which to measure the efficacy of therapeutics.  
5.2.2 Role of Iron in Neurodegenerative disease 
Iron is crucial for the healthy function of neural tissue, it is involved in DNA synthesis, 
mitochondrial respiration, myelin synthesis, and the synthesis and metabolism of 
neurotransmitters.  It occurs in ferric (Fe3+) and ferrous (Fe2+) forms that constitute a redox 
couple, important in its functions of electron and oxygen transport.  Iron is absorbed from 
food in the gastrointestinal tract and is transported through the body in the bloodstream.  
It enters the brain by passing through the vascular endothelial cells of the blood brain 
barrier into the extracellular space.  It can then be taken up by neurons, microglia, 
astrocytes and oligodendrocytes and is stored in the brain in its ferric form bound within 
the proteins ferritin and neuromelanin.  Iron levels need to be tightly regulated in the brain 
but homeostasis can become disturbed during neuroinflammation which is thought to 
increase iron levels in neurons and microglia(221).  Ferritin containing reactive microglia 
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have been found to be present alongside neuroinflammatory AD pathology(222) as well as 
reactive astrocytes, known to express haemochromatosis, a protein linked with congenital 
iron overload(220).  Increased iron levels are associated with ROS generated through the 
Fenton reaction between hydrogen peroxide and ferrous iron.  Oxidative stress can be 
caused if ROS exceed a cells detoxification level leading to cell death. 
The ability to spatially map iron stores in-vivo would provide insight into their link with 
pathology in AD.  The insoluble beta-amyloid plaques and neurofibrillary tangles of tau that 
form in the AD brain have both been found to contain iron(223,224).  The Amyloid 
Precursor Protein(APP) gene is a known to be mutated in familial forms of AD and its 
genetic translation has been shown to be highly sensitive to intracellular iron 
concentration(225).  Genetic studies indicate an association between several iron related 
genes and AD risk factor(226).  Furthermore, previous studies investigating the appearance 
and location of plaques in transgenic mouse models of familial forms of AD have shown a 
co localisation with iron deposition(216).  Aggregation and phosphorylation of tau and iron 
accumulation has been observed in a mouse model over expressing heme oxygenase(HO-
1), which is a haem degrading enzyme that is upregulated in the hippocampus and 
temporal cortex of patients with AD and MCI(216).  Additionally, in vitro experiments have 
shown that aggregation of phosphorylated tau can be mediated by transitions of iron 
between its ferric and ferrous forms(227).  Iron accumulation has also been observed in 
MAPT knockout mice due to impairment of APP mediated iron export(228).  Iron 
accumulation in mouse models that over express tau forming NFT pathology(such as the 
rTg4510) have not been characterised. 
5.2.3 Iron measurement in-vivo using MRI 
The relationship between excess iron deposition and ROS in the brain suggests that iron 
measurement may act as a surrogate marker of oxidative stress(229).  The interaction of 
iron with magnetic fields is due to its paramagnetic susceptibility and is therefore, 
theoretically, detectable in tissue by MRI.  The magnetic properties of haemoglobin in the 
blood are mostly due to the presence of heme iron.  The transition from oxyhemoglobin to 
deoxyhemoglobin during oxygen consumption increases the paramagnetism of the heme 
iron ions and the balance of oxyhemoglobin/deoxyhemoglobin forms the basis of the BOLD 
effect in fMRI(230).  Non-heme iron is found in cells throughout the body and in the brain is 
distributed heterogeneously with greater density found in regions associated with 
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movement such as the globus pallidus, the putamen, the caudate nucleus, and the red 
nuclei(231).  The variations in tissue concentration generate measureable changes in the 
local susceptibility that can be measured using MRI(231).   Non-heme iron stored as ferritin 
and hemosiderin (found in broken down blood products) are the only types present in 
great enough concentrations to be detected(232). 
Perturbations in the B0 field caused by materials with high magnetic susceptibility have a 
shortening effect on the relaxation time constants of the transverse MR signal.   
Hypointensities in T2 and T2* weighted images have been observed in brain regions such 
as the basal ganglia, a structure associated with a greater iron content (229,233).  Iron may 
also cause hyper intensities in T1 weighted images due to shortening of the longitudinal 
relaxation time(231).  A more quantitative correlate of iron concentration in tissue can be 
gained by measurement of transverse relaxation constants T2, T2’, and T2*, where T2* is a 
combination of spin-spin relaxation(T2), and reversible relaxation(T2’) caused by in 
homogeneities in the main magnetic field(see Equation 11).  T2 measurement is robust 
from background susceptibility effects and is reduced in the presence of high iron content 
in tissue(234).  However, its sensitivity to changing water content in tissue may affect iron 
estimates, especially in the presence of inflammation(231).  This issue can be overcome 
using field dependent rate increase (FDRI) technique which requires T2 measurements at 
two different magnetic field strengths(235). 
The reversible relaxation constant, T2’, is directly related to signal phase and shortening of 
this parameter is thought to more accurately relate to iron in brain tissue when compared 
with T2(231,236).  Increased scan times are necessary for the acquisition of both T2 and 
T2* relaxation datasets to calculate T2’ and its relatively small magnitude make it 
vulnerable to noisy estimates due to field inhomogeneities. Consequently, T2* 
measurements are more frequently used(229).  T2* incorporates T2 and T2’ relaxation 
mechanisms and the errors in iron estimation associated with them.  Nevertheless, values 
correlate well with post mortem measurements of iron in human brain samples(237) and 
data can be acquired using a simple multi echo gradient echo acquisition that is fast and 
widely available making this the most established MRI method for this application(233).  
The techniques described so far use the magnitude of the MRI signal to provide a measure 
that is sensitive to magnetic susceptibilities of materials that are both paramagnetic and 
diamagnetic relative to water.  Calcifications and myelin in white matter are diamagnetic 
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and like iron will have the effect of reducing transverse relaxation constants.  Using the 
phase of the signal from gradient echo acquisitions, it is possible to discriminate between 
tissue types that are either diamagnetic or paramagnetic relative to water. 
The phase of the transverse MR signal in a gradient echo acquisition is directly related to 
the magnetic field experienced by the spins.  The interaction with the B0 field is dependent 
on the bulk magnetic susceptibility of the tissue and is proportional to off resonance effects 
on signal phase.  The polarity of the phase of the complex signal allows differentiation 
between positive and negative susceptibility effects on the signal and the size of the phase 
shift has been shown to correlate with iron concentration in the brain(238).  Phase 
measurement at a voxel is complicated by the non local effects from sources at other 
locations within the volume of tissue imaged, peripheral air/tissue/bone interfaces at the 
edge of the brain, as well as any other sources of field inhomogeneity such as poor 
shimming of the B0 field.  The latter two sources are known as background field 
contributions and can cause severe distortion artifacts and signal drop out in affected 
regions.  The relationship between magnetic susceptibility and field strength means 
artifacts related to magnetic susceptibility are exacerbated in high field applications.  
Furthermore, signal phase is only defined between the values of ±π radians and the 
occurrence of values outside of this range cause aliasing, known as phase wrapping in the 
reconstructed images. 
Image post-processing methods can be used to remove wraps and background field 
contributions and the resulting phase images can then be combined with magnitude 
images to generate Susceptibility Weighted Images(SWI).  SWI  enhances T2* contrast with 
phase information to improve visualisation of small blood vessels within the brain(239), 
Cerebral Microbleeds (CMBs)(240), as well as identification of iron and improved grey 
matter/white matter contrast(241).  To remove the effects on phase estimates from non 
local contributions that persist in SWI, a further post-processing step is applied that 
requires deconvolution of the phase map with a magnetic dipole field.  This technique is 
known as Quantitative Susceptibility Mapping.  Magnetic susceptibility estimates using 
QSM correlate well with iron measurement at post mortem(242).  Unlike relaxometry 
techniques, QSM provides contrast between diamagnetic tissue such as calcifications and 
myelin, and paramagnetic iron through negative and positive susceptibility values 
respectively.  One drawback of this method is that the deconvolution calculation is ill-posed 
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and consequently requires regularisation to reduce noise and streaking artifacts.  The 
susceptibility estimates are dependent on the centre frequency used in acquisition and 
values are given relative to reference tissue regions that often vary between studies.  
Additionally, there are a number of alternative methods for the QSM processing of phase 
data reported in the literature with few comparisons made between them.  These 
inconsistencies are due, in part, to the novelty of the QSM technique.  Non-local 
contributions that cause blooming artifacts in T2* maps may impact accuracy and mean 
that QSM offers an improved estimation of iron concentration(103,243).  Conveniently, 
both can be generated from the same multi-echo gradient echo acquisition enabling QSM 
to be validated against the more established T2* method. 
In early studies of iron deposition in AD, focal hypointensities were observed around beta-
amyloid plaques in ex-vivo T2* weighted images(244), and lower regional intensities in the 
putamen and red nucleus were found in AD patients(245).  Relative to healthy subjects, 
regional quantitative measurements of T2 have shown reductions in the caudate 
putamen(246) as well in the cortex, and globus pallidus(231) and a  recent study found 
reductions in T2* in the pulvinar nucleus(247) in AD patients.  MRI phase contrast studies 
also suggest increased iron concentrations in the caudate putamen as well as in the 
hippocampus, frontal and parietal regions in the cortex(248,249).  In a recent QSM study of 
AD the increased magnetic susceptibility measured in the putamen of patients was as 
statistically significant as the differences in atrophy of the hippocampus in this region, a 
measure seen as the ‘gold standard’ MRI biomarker in AD(250). 
High resolution T2 and T2* weighted imaging of APP and PS1 mouse models of AD have 
been used to visualise beta-amyloid plaques and study their distribution in-vivo. 
Hypointensities observed were validated using histological stains sensitive to iron and beta-
amyloid(72-78).  Studies have also shown T2 shortening in amyloid pathology models 
where no iron was detected, suggesting this effect may be due to other plaque 
characteristics, especially in younger mice(251,252).  T2 is thought to better delineate 
these plaques than T2* which may overestimate their size, and T2 relaxation has shown a 
longitudinal relationship with plaque load in the hippocampus and cortex of mice(253).  
T2* and T1 shortening has been observed in plaque-containing structures of the brain in 
APP/PS1 mice but not in pathology free regions (78,254).  Studies using phase based 
methods include the visualisation of plaques using SWI(255) and CMBs using QSM(256).  
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Thus far, QSM group comparisons have only been applied in the ArcBeta model of AD with 
significant differences observed longitudinally(257) but not in a cross sectional study(256).  
There have been no studies using MRI to investigate iron accumulation in models of tau 
pathology of AD.  
5.2.4 Motivation and aims 
Despite the link between iron and tau pathology in neurodegeneration, there have been no 
attempts to use MRI as a measure of non invasive iron quantification to explore this 
relationship.   In this chapter, a QSM protocol is developed and applied in the rTg4510 
mouse in-vivo.  Previous work has shown that reactive microglia and astrocytes, associated 
with neuroinflammation and iron accumulation, are present in higher quantities in this 
model than in controls(258,259).  Abnormalities in myelination in the corpus callosum have 
been observed using DTI and EM in previous studies(125,205) and aggregated tau protein 
has been found to be present in oligodendrocytes(260).  I hypothesized that QSM might 
provide a sensitive in-vivo method to alterations in myelin and potentially iron 
accumulation that may be occurring in the rTg4510. T2* and high resolution ex-vivo 
measurements are presented with histological staining of markers of tissue inflammation 
and white matter integrity to aid the interpretation of in-vivo findings. 
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5.3 An ex vivo pilot study of contrast enhanced 
QSM in the rTg4510 
5.3.1 Introduction 
Quantitative susceptibility maps can be generated from the phase of MRI data acquired 
using a gradient echo sequence.  High resolution gradient echo imaging of the ex-vivo 
mouse brain has been previously optimised in CABI for the study of structural changes in 
disease(119).  Protocols have been designed to maximise contrast between white matter 
and grey matter in fixed tissue.  Voxel sizes of the order of 40µm x 40µm  x 40µm  have 
been achieved using a 12 hr “overnight scan” enabling fine structures in the mouse brain to 
be resolved.  To achieve this resolution, gadolinium, a paramagnetic contrast agent is 
added to the fixative which shortens the longitudinal relaxation time constant for the tissue 
and permits a reduced time to repeat for enhanced SNR efficiency per unit time.  The 
selective uptake of contrast agent in grey matter provides an added benefit of increased 
CNR between grey matter and white matter(261). 
The effects on magnetic susceptibility of ex-vivo mouse brain tissue caused by the addition 
of gadolinium to the perfuse fixation process was the subject of a recent study by Dibb et al 
(261).  As the concentration of the contrast agent was increased, an increased difference in 
magnetic susceptibility between white matter and grey matter tissue was observed.  It was 
suggested that this may be due to a barrier to penetration created by the myelin sheaths in 
white matter restricting the uptake of Gd molecules to the extracellular space.  This 
produces a relatively lower Gd content per unit volume of tissue in white matter compared 
to the grey matter.  Gd is paramagnetic and therefore the greater concentration in grey 
matter generates an increased magnetic susceptibility relative to the white matter.   
As a preliminary investigation into magnetic susceptibility in the rTg4510, data from a 
previous volumetric study was used(data acquired by a collaborator).  This data was 
acquired at high resolution using brains doped with Gadolinium.  I hypothesized that 
disrupted white matter in the rTg4510(205) may be less resilient to penetration from the 
paramagnetic contrast agent, thus reducing differences between QSM estimates between 
grey and white matter in this animal modal (relative to healthy controls).  Deformation 
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fields generated from the non-rigid registration of the magnitude data were used to 
transform magnetic susceptibility maps into a common space for analysis.  A voxel-wise 
group comparison was used to identify differences in magnetic susceptibility between the 
rTg4510 and controls.  This automatic technique expedited analysis, removing the time 
consuming process of manual segmentation. 
5.3.2 Methods 
5.3.2.1 Magnetic Resonance Imaging 
Imaging data was acquired previously by collaborator to perform a high resolution tensor 
based morphometry(TBM) comparison of the rTg4510 mouse with Wild-type controls.  10 
rTg4510 mice and 8 wild-type littermates were culled at 7.5 months and perfuse-fixed with 
0.9% saline (15 – 20 mL) followed by 10% Buffered Formalin (50 mL) doped with Magnevist 
(8 mM).  High resolution ex-vivo images of three brains were acquired simultaneously at 
9.4T (Agilent Inc. Palo Alto, CA, USA) by securing brains in a purpose built holder. A 35 mm 
diameter birdcage RF coil was used for RF transmission and signal detection using a 
gradient echo sequence with the following parameters: FOV = 32 mm x 25 mm x 25 mm; 
resolution = 40 μm x 40 μm x 40 μm; TR = 17 ms; TE = 4.54 ms; flip angle = 51o; NSA= 6. 
Total imaging time was approx. 11 h and was typically performed “overnight”. 
5.3.2.2 Magnetic susceptibility mapping and non-rigid registration 
The post processing of the MRI data involved reconstruction of phase data and generation 
of magnetic susceptibility maps using a combination of software that I developed alongside 
algorithms made freely available by other research groups online.  Corresponding 
magnitude data had already been reconstructed and registered by a collaborator for TBM 
using an automated software pipeline.  The deformation fields from this registration were 
used to transform magnetic susceptibility maps into this common space for voxel-wise 
group analysis.  The data processing protocol is described in the flowchart in Figure 41.     
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Figure 41. Flowchart of image processing 
Flowchart detailing the post processing of the gradient echo to register magnetic 
susceptibility maps into the same space for voxel-wise analysis in SPM. 
 
The first step of the registration pipeline performs automatic separation of the three brains 
in each reconstructed magnitude image.  This separation was then applied by a 
collaborator to the corresponding phase images and I then conducted susceptibility 
mapping processing on these individual brains.  FSL Prelude (fsl.fmrib.ox.ac.uk/fsl/fsl-
4.1.9/fugue/prelude.html) was used to perform spatial unwrapping of the phase images.  
The background field effects were then removed using the Projection on to Dipole Fields 
method (PDF.m, MEDI toolbox, Cornell MRI Research Lab) (107,262). Susceptibility maps 
were calculated by thresholded k-space division (TKD)(101) using a low truncation value 
tF=1 to limit streaking effects in the final susceptibility maps.  This was to limit artifacts that 
might be caused by large susceptibility differences at tissue boundaries due to the 
Gadolinium contrast agent in the fixative. 
After the brain separation, further steps to register the magnitude images were carried out 
by a collaborator (Figure 41).  These included the automatic orientation to a standard atlas 
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followed by an intensity non-uniformity correction (N3 algorithm(263)) before automatic 
skull stripping using the STAPLE algorithm(264) which also generated masks for each brain.  
Group-wise registration was then performed using NiftyReg software(120,122). Firstly, all 
subjects were rigidly aligned to a randomly chosen target member of the group followed by 
five iterations of affine registration producing a matrix describing the transformation of the 
registration for each brain.  Finally, there were 20 iterations of non-rigid registration (NRR).  
After each iteration, the intensity average image was found and used as the target for the 
subsequent registration.  Deformation fields describing the transformation from the affine 
registration were generated for each brain. 
To register susceptibility maps, I applied the rigid, affine, and non-rigid transformations 
from corresponding magnitude image registrations to the susceptibility maps.  Firstly, the 
orientation matrix was added to the header of the nifty file containing the susceptibility 
map.  Next this header matrix was multiplied by the affine registration matrix to combine 
transformations.  Using niftyreg software, the modified affine matrix in the file header was 
used to transform the susceptibility map in the file before a further transformation was 
applied using the deformation field generated from the non-rigid registration.  The 
combination of affine and non-rigid transformations in niftyreg ensured that resampling 
was performed only once on the data in the final step.  
Prior to group comparisons, all susceptibility values were calculated relative to a reference 
to account for differences in centre frequency in the MR acquisitions.  The mean 
susceptibility in the grey matter of each mouse brain was used as a reference and was 
subtracted from each voxel value.  A grey matter mask (Figure 42) was generated 
automatically for this purpose by intensity thresholding in the magnitude atlas image. 
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Figure 42. Grey Matter Mask 
Axial slice of grey matter mask used to generate reference magnetic susceptibility values. 
 
5.3.2.3 Statistical Parametric Mapping 
Statistical Parametric Mapping (SPM) (SPM, http://www.fil.ion.ucl.ac.uk/spm/) was used to 
investigate susceptibility differences between the wild-type and transgenic groups.  Images 
were smoothed to with a 0.1 mm FWHM Gaussian kernel to account for registration error 
and to bring image values closer to a normal distribution.  A two sample, two-tailed, t-test 
at each voxel was carried out for statistical significance.  The results were corrected for 
multiple comparisons using the False Discovery Rate(FDR) method (q=0.05)(265). 
 
5.3.3 Results 
Marked, region-specific,  increases in susceptibility were observed in a rostral section of the 
corpus callosum (less diamagnetic in the rTg4510) as shown in the Statistical Parametric 
Map in Figure 43(a - c).  Mean images of the registered susceptibility maps were calculated 
for the wild-type (Figure 43d-f) and rTg4510 mice (Figure 43g-i).  In both the coronal and 
axial slices presented in Figure 43, a reduction of white matter contrast is observed from 
visual inspection of the rTg4510 susceptibility maps in regions that correspond to increases 
in the comparative SPMs.  This appears to be due to an increase in the mean susceptibility 
in these white matter regions in the rTg4510.  Increased magnetic susceptibility was also 
observed in the striatum (more paramagnetic in the rTg4510) (Figure 43b). 
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Figure 43. Increases in magnetic susceptibility in the rTg4510 
SPM (FDR corrected,q=0.05) overlaid on magnitude image atlas(a-c), showing increases in 
magnetic susceptibility in the corpus callosum and anterior commissure (less diamagnetic), 
and the striatum(more paramagnetic) in the rTg4510 mice in comparison to WT.  
Corresponding slices in mean magnetic susceptibility images display greater contrast 
between the white matter and grey matter in the external capsule in the WT mice (d-f) in 
comparison to the rTg4510 mice (g-i).  
 
 
To investigate the possibility of registration errors causing the loss of contrast in the white 
matter, magnitude images were inspected.  The visible reduction in contrast in the corpus 
callosum in the mean susceptibility maps (Figure 44a) of the rTg4510 mice was not 
observed in the mean magnitude image (Figure 44b).  This finding was replicated in an 
unregistered susceptibility map and magnitude image in a representative mouse (Figure 44 
c,d). 
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Figure 44. White matter contrast in mean images 
Contrast between white matter and grey matter reduced in the rTg4510 mean susceptibility 
maps (a) was not observed in the corresponding mean magnitude images(b).  This finding 
was consistent with comparisons between susceptibility maps in individual rTg4510 mice 
(c), and magnitude images (d) prior to registration. 
 
Decreased magnetic susceptibility was detected in various regions throughout the rTg4510 
brain.  Most notable, bilateral changes appeared to co localise to the motor cortex, 
striatum, the amygdala, the substantia nigra and the dentate gyrus (Figure 45). 
 
Figure 45. Decreased magnetic susceptibility in the rTg4510 
SPM (FDR corrected, p<0.05) overlaid on magnitude image atlas, indicating decreases in 
magnetic susceptibility in the rTg4510 mice.  Significant bilateral decreases were observed 
in the rTg4510 in regions including the motor cortex and caudate putamen (a), the nucleus 
of the posterior commissure and the amygdala(b), and the substantia nigra and the 
polymorph layer of the dentate gyrus(c). 
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Histological staining (n=1) was carried out by collaborators in a coronal slice in the frontal 
cortex to identify any abnormalities in the regions of increased susceptibility (Figure 43 b).  
White matter integrity was probed using a stain consisting of solochrome cyanin sensitive 
to myelin combined with cresyl violet, a neuronal counter stain. To identify reactive 
microglia and astroctyes that are thought to mediate neuroinflammation(221), a GFAP and 
an IBA-1 stain were also used.  In comparison to the WT, the solochrome staining in the 
genu of the corpus callosum showed a more disorganised arrangement of cell bodies and 
myelin with large gaps evident in the rTg4510(Figure 46d,e).  This was accompanied by an 
increased density of reactive microglia in this region (Figure 46b,f,g).  Astrocytic staining 
was also more dense across the corpus callosum in the rTg4510(Figure 46c), with increased 
activity also observed in the striatum(Figure 46h,i). 
 
 
Figure 46. Histology in rTg4510 
Solochrome cyanin / cresyl violet(a), IBA-1(b), and GFAP(c) staining of  a coronal slice 
0.74mm rostral to the bregma for a WT(left) and rTg4510(right) mouse. ROIs are magnified 
at x100 for inspection of the corpus callosum(d,e,f,g) and the striatum(h,i) 
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5.3.4 Discussion 
Magnetic susceptibility maps of the ex-vivo mouse brain were registered using the 
transformations from the non-rigid registration of the magnitude data.  Significant relative  
increases in susceptibility in the white matter of the rTg4510 mouse were observed using a 
voxel-wise group comparison.  A loss of contrast was evident from visual inspection of the 
QSM maps between the white matter of the corpus callosum and the surrounding grey 
matter.  This may be due to a reduction in diamagnetic myelin, which has been shown to be 
disorganised in this model in histology and in previous studies(205).  In the previous 
chapter, increased diffusion perpendicular to the direction of the white matter in the 
rTg4510 tracts was observed, with greater significance observed in the rostral regions of 
the brain.  This further indicates the possibility of reduced myelination which has also been 
observed using EM(205).  However, rather than a decrease in diamagnetic tissue present, it 
may be the case that an increase in paramagnetic components are being observed.  The 
increased presence of reactive microglia and astrocytes suggest neuroinflammation in the 
corpus callosum and striatum and have been linked to iron accumulation(220,221), as has 
the presence of NFT pathology(224) which is present in these regions in the rTg4510 at the 
age imaged(203).  In this study, only a single animal from each group was analysed 
histologically.  Staining for gliosis and iron in a greater number of animals would enable a 
more quantitative group analysis to be conducted as well tests for correlations with MRI 
parameters.   
The use of gadolinium in the preparation of the ex-vivo tissue may have amplified the QSM 
changes in the rTg4510 and possibly masked the underlying pathological changes.  The 
neurodegeneration that occurs in this model may cause damage to tissue in the rTg4510 
that alters the uptake of the paramagnetic contrast agent.  In the case of the rostral white 
matter, a greater concentration of Gd may be present due to disruption to myelin sheaths 
which may be responsible or be contributing to the increased magnetic susceptibility in the 
rTg4510.  Interestingly, a loss of contrast with grey matter was not observed in the 
magnitude images which might be expected if an increased signal in the white matter were 
generated by the T1 shortening effect of an elevated Gd concentration.  Since there is 
marked atrophy in the rTg4510 at the timepoint imaged, an irregular distribution of the 
contrast agent may also be the cause of both paramagnetic increase and decreases 
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observed in the striatum as well as decreases in magnetic susceptibility in other grey 
matter regions.  
This preliminary study indicates that there may be changes in the magnetic susceptibility of 
tissue in the rTg4510 mouse model of Tau pathology that are detectable using QSM.  It is 
unclear whether group differences stem from differences in the magnetic susceptibility in 
the tissue or alterations to contrast agent distribution.  The following sections of this 
chapter attempt to answer this question by optimising and performing QSM in ex-vivo 
rTg4510 tissue omitting Gadolinium from the perfuse fixation process.  This data is also 
used to validate data collected using an in-vivo protocol which suffers from a lower SNR 
and is acquired at a lower spatial resolution.   
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5.4  Development of gradient echo acquisitions 
for QSM in the mouse 
5.4.1 Introduction 
The biological interpretation of the differences in magnetic susceptibility in the rTg4510 
relative to controls identified in the last section was confounded by the presence of 
Gadolinium.  In order to repeat this experiment without contrast agent, the parameters of 
the gradient echo sequence used to acquire data must be adjusted to allow for the 
different MR relaxation properties of the tissue.  The expected increase in the longitudinal 
relaxation constant will cause a reduction in the MRI signal at an echo time given the same 
time to repeat.  The goal of the design of a gradient echo sequence for QSM is to provide 
pristine phase data.  The precision of this data can be estimated by the uncertainty or 
variance of the estimated phase.  Greater variance may reflect noisy estimates that will 
propagate through the susceptibility processing and manifest as artifacts in the maps 
produced.  The variance of the phase is inversely proportional to the SNR of the magnitude 
of the MRI signal(104) as described by the formula(266) 
       
 
      
 
Equation 62  
Where σphase is the standard deviation of the phase in radians and SNRmag is the signal to 
noise ratio of the magnitude of the MRI signal.  So by maximising the SNR of the signal 
magnitude, the uncertainty in phase estimation and noise in the susceptibility maps 
produced will be reduced.  In spoiled gradient echo sequences, commonly used for QSM, 
the signal SSGRE is given by the following equation(90) 
       
            
       
                
        
 
 
Equation 63  
Where M0 is the longitudinal equilibrium magnetisation and   is the flip angle, known as 
the Ernst Angle when maximum signal is generated.  This relationship can be used calculate 
the Ernst Angle in tissue of given T1 and T2* for a given TE and TR.  Selection of TR will 
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depend on the total scan time, desired resolution and FOV of the acquisition and the 
number of signal averages taken.  Longer TRs allow longitudinal relaxation to occur over a 
greater time period and more signal available for RF excitation.  For a 3D spoiled GRE 
(SGRE) acquisition, the longest TR possible will be calculated by the division of the scan 
time limit by the number of excitations necessary to cover the FOV at the desired 
resolution.  However, SNR is proportional to the square root of the number of signal 
averages(NSA)(266), assuming uncorrelated noise between transients, and TR will need to 
be reduced if extra averages are collected.  This additional factor can be added to the 
equation above to incorporate the trade off between TR and NSA to calculate the Ernst 
Angle and provide optimal SNR as follows to select the SGRE sequence parameters that will 
yield lowest phase uncertainty. 
          
            
       
                
        
 
        
Equation 64  
The phase contrast generated by off resonance due to magnetic susceptibility will increase 
with time after excitation.  Optimal phase CNR is achieved when the echo time is equal to 
the T2* of the tissue imaged (267,268).  Where limitations due to scan time or spatial 
distortion at later echo times in T2* weighted sequences require earlier acquisition, a 
minimum of TE = T2*/2 may be used to provide an acceptable CNR for QSM 
applications(104).  In this section, the T2* measured in the white matter in the corpus 
callosum of ex-vivo mice, was used to calculate the Ernst Angle that would maximise 
magnitude SNR and provide the most accurate phase estimates for QSM.  T1 and T2* 
mapping of fixed ex-vivo mouse brains provided regional estimates that could be used in 
Equation 64 to simulate different combinations of TR and NSA within a 12hr overnight scan. 
A main aim of this thesis is to investigate the potential of new pre-clinical MRI techniques 
for in-vivo imaging of AD mouse models for inclusion in a multi-parametric protocol.  To 
this end, the mapping of relaxation parameters and Ernst angle calculations were also 
carried out to calculate optimal sequence parameters for an in-vivo acquisition.    Phase 
estimation in-vivo is complicated by the presence of flow, most prominent in blood vessels.  
The flow of spins in the direction of an applied magnetic field gradient will cause them to 
accumulate phase and may lead to an error in signal phase as well as mislocalisation of 
signal in phase encoding directions.  To improve accuracy of phase estimates, first order 
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gradient moment nulling was added to the SGRE sequence to provide flow compensation in 
three dimensions.   
 
5.4.2 Methods 
The experimental methods in this section are described in three parts: T1 and T2* mapping 
and regional estimates in ex-vivo and in-vivo animal cohorts; ernst angle simulations; and 
development and testing of a flow compensated 3D SGRE sequence. 
5.4.2.1 T1 and T2* mapping and regional estimates 
Animals 
Ex-vivo animals had been culled at 8 months and perfuse fixed previously by collaborators 
as described in section 5.3.2.1 with the exception of the addition of Magnevist contrast 
agent which was omitted.  The de-skulled brains of wild-type rTg4510 littermates (n=3) 
were rehydrated in 50ml PBS (Sigma-Aldrich, UK) for three weeks to increase proton 
density and T2 in the tissue(for increased SNR)(184,269,270).  They were transferred to 
20ml syringes filled with 10ml of proton MR signal-free, non-viscous Fomblin 
perfluoropolyether (PFS-1, Solvay Solexis SpA., Bollate, Italy) and imaged individually in a 
26mm diameter birdcage coil (Rapid Biomedical GmbH, Germany) at 9.4T (Agilent 9.4 T 
VNMRS 20 cm horizontal-bore system / Agilent Inc. Palo Alto, CA, USA).       
For in-vivo experiments, wild-type littermates (n=8) of a J20 AD mouse model were imaged 
at 15.5 months.  Mice were secured in a cradle under anaesthesia with 1-2% isoflurane in 
100% oxygen using a custom-built head holder to reduce motion.  Body temperature was 
maintained at 36 – 37.5 °C using a water-heating system and warm air fan.  Core body 
temperature and respiratory rate were monitored using a temperature probe and pressure 
pad (SA Instruments, NY).  Scans were performed on an Agilent 9.4 T VNMRS 20 cm 
horizontal-bore system (Agilent Inc. Palo Alto, CA, USA).  A 72 mm birdcage radiofrequency 
(RF) coil was used for RF transmission and a 2 channel mouse brain surface coil (RAPID, 
Germany) was used for signal detection.    
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T1 mapping and image acquisition 
A single slice 4-shot segmented spin echo echo-planar imaging (EPI) readout was 
implemented with the following parameters: slice thickness = 0.5 mm, FOV =15 × 15 mm, 
matrix size = 100 × 100, slice selective inversion pulse width = 100 mm, 16 inversion times, 
TR=16.6 seconds. For the ex-vivo acquisition,   TI = 9, 14, 22, 34, 52, 81, 126, 196, 304, 471, 
732, 1140, 1760, 2700, 4300, and  6600ms, TE = 11 ms.   For the in-vivo acquisition, TI = 30, 
44, 65, 96, 141, 208, 306, 451, 664, 979, 1442, 2124, 3129, 4609, 6789, and 10000 ms, and 
TE=13ms.  T1 maps were calculated using a conventional three parameter fit(271) at each 
pixel across magnitude values for all TIs using a non linear least squares curve algorithm in 
matlab.  Mean T1 values were calculated for each mouse in ROIs in the cortex and 
hippocampus. 
T2* Mapping and image acquisition 
A Spoiled 3D Gradient Recalled Multi-Echo sequence was used to acquire data for both in-
vivo and ex-vivo T2* mapping.  The ex-vivo dataset was acquired with the following 
parameters 16 TEs (TE1 = 2.27ms, ΔTE=2.37ms), TR = 600ms, flip angle =440, NSA=3 at a 
resolution of 80µm x 80µm x 80µm , FOV = 18mm x 12mm x 12mm.  Eight echoes were 
acquired for the in-vivo data: TE1 = 2.33ms and ΔTE=2.3ms, with a flip angle of 270 and 
TR=210ms, at a resolution of 150µm x 150µm x 150µm  (FOV = 15mm x 15mm x 15mm).   
T2* estimates were calculated at each voxel using a non linear least square fitting 
algorithm in matlab using a two parameter fit function.  ROIs were drawn in the cortex and 
corpus callosum and mean T2* values were calculated. 
5.4.2.2 Ernst angle simulations 
The T1 and T2* measured in the corpus callosum was used to optimise values of flip angle, 
TR, and NSA using Equation 64.  Software was written in matlab to estimate maximum SNR 
and optimal flip angle for varying TR and NSA.  For the ex-vivo scan, a time limit of 11 hrs 
was necessary to complete the scan within an overnight time slot on the 9.4T MRI scanner 
in CABI.  At the desired resolution of resolution of 80µm x 80µm x 80µm  and FOV = 18mm 
x 12mm x 12mm, the maximum TR was 1000ms for a single average.  To optimise SNR, 
simulations were run for ten to one signal averages by varying the TR (100, 111.11, 125, 
142.86, 166.66, 200, 250, 333.33, 500, and 1000 ms respectively) to complete in the 
desired scan time.  Each TR/NSA combination was run for integer flip angles from 1 to 90 
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degrees) with the measured T1/T2* in the white matter (952ms and 32ms respectively) 
with TE=T2*.  
The target time for the in-vivo scan was to run in approximately an hour, at a 150µm x 
150µm x 150µm  resolution FOV = 18mm x 18mm x 18mm, a single average could be taken 
with TR=250ms.  To optimise SNR, simulations were run for ten to one signal averages by 
varying the TR (25, 28, 31, 36, 42, 50, 62.5, 83, 125, and 250ms respectively) to complete in 
the desired scan time.  Each TR/NSA combination was run for integer flip angles from 1 to 
90 degrees with the measured in-vivo T1/T2* in the white matter (1533ms and 29ms 
respectively).  Due to poor SNR and distortion at late echo times, TE = T2*/2 of white 
matter was used for in-vivo simulations which is preferred in situations when TE = T2* 
cannot be achieved (104). 
 
5.4.2.3 Flow compensation development and testing  
To reduce error in phase estimates caused by flow in the in-vivo acquisitions, first order 
gradient moment nulling was added to the gradient echo sequence to provide flow 
compensation in three dimensions.   Bipolar gradients were added to null the first moment 
for slice select, readout, and both phase encoding gradients.  I achieved this by modifying 
the core 3D GRE sequence code in VNMRJ.  As shown in Figure 47, the nulling of the slice 
select gradient is carried out by addition of a bipolar gradient immediately after the slice 
select gradient and nulling of readout and phase encoding gradients was implemented 
simultaneously, immediately before the start of the readout rephase gradient.  Bipolar 
gradients were trapezoidal in shape and magnitudes and duration were calculated using 
equations previously published(272).  These values were not ‘hard coded’ and calculated 
based on the imaging gradient dimensions generated by VNMRJ.  This flexibility means that 
the bipolar gradients are automatically adjusted in this sequence if the user changes any 
sequence parameters such as the TE and enables easy portability of this functionality into 
other 3D sequence code. 
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Figure 47. Flow compensation gradient diagram 
Sequence diagram showing the placement of bipolar gradients to implement first order 
gradient moment nulling.  Slice select gradient is nulled using the bipolar gradient in 
interval a, and all other bipolar gradients are implemented in interval b, prior to read 
refocus gradient. 
 
A flow phantom (Figure 51a) was constructed to test the 3D gradient moment nulling 
added to the sequence.  A section of plastic tubing of 2.5mm inner diameter was 
embedded in a 20ml falcon tube filled agar (1%).   The ends of the tubing were connected 
at each end to a water heating system (Haake Circulator DC30 with B3 bath, Thermo Haake, 
Newington NH, USA). The system was configured to pump water through the tubing at a 
flow rate of 12.5 l/min at room temperature.  The effects of phase accumulation of the 
flowing spins can be observed in MRI phase images as disruptions to wrapping in the 
direction perpendicular to flow(266).  The phantom was imaged in a 26mm diameter 
birdcage coil (Rapid Biomedical GmbH, Germany) with a 3D gradient echo sequence with 
the following parameters: TE = 18.5ms, TR=250ms, flip angle =29, FOV = 18mm x 18mm x 
18mm, matrix = 96 x 32 x 32.  Data was acquired without flow compensation with water 
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flow on and off to observe the effects on phase.  This experiment was then repeated with 
flow compensating gradients implemented in the sequence. 
 
5.4.3 Results 
5.4.3.1 T1 and T2* mapping and regional estimates 
Parameter maps of T1 and T2* in ex-vivo and in-vivo mice are shown in Figure 48.  Mean 
values in ROIs were in good agreement with published relaxation measurements at 9.4T 
(273,274).  Ex-vivo estimates of T1 in the cortex and corpus callosum were 1063±66 ms and 
952±32 ms respectively. T2* values measured were 65±3ms in the cortex and 32±7 ms in 
the corpus callosum.  In-vivo measurements of T1 were higher than their ex-vivo 
equivalents.  Unlike the cortex, where the T1 (1917±109 ms) was similar to reported 
values(274), a reduced T1 was found in the corpus callosum (1533±107 ms) possibly due to 
discrepancies in the age and breed of the mice used.  The T2* measured in the cortex 
(37±2ms) and in the white matter (29±2ms) were lower than the ex-vivo estimates and 
similar to  previous high field measurements(275). 
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Figure 48. Ex vivo and In-vivo T1 and T2* maps 
Single slice coronal images of Ex-vivo (a,b) and In-vivo (c,d) T1 and T2* maps. 
 
5.4.3.2  Ernst angle calculations 
The simulated SNR calculated in the ex-vivo data using the relaxation parameters calculated 
for white matter (T1 =952 ms, T2*=32ms) is shown in Figure 49. The optimal flip angle 
decreased as TR was reduced in the simulation and SNR was found to increase with the 
number of averages (Figure 49a).  The percentage gain in SNR decreased with the addition 
of each average (Figure 49b).  The SNR increased by 3.1% by increasing NSA from 1 to 2.  
However, increasing the number of signal averages beyond 5 resulted in percentage 
increases of less than 0.1%.  In light of such minimal gains in SNR, it was decided to limit 
NSA to 5 so as to maintain as long a TR as possible.  This maximises the scanner “dead 
time” built into each repetition, reducing heating in the scanner coils and amplifiers(276).  
The combination of 5 signal averages with a TR of 200ms gave and optimal flip angle of 36 
degrees in white matter and 34 degrees in grey matter in simulations (Figure 49c).    
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Figure 49. Ex vivo signal estimates 
Simulations using the gradient echo equation to estimate SNR for different TR and NSA 
combinations using white matter relaxation parameters(a).  The percentage gain in SNR 
decreases with increasing NSA(b).  Signal for grey matter and white matter is plotted 
against flip angle for TR =200ms and NSA = 5(c). 
 
The simulated SNR calculated in the in-vivo data using the relaxation parameters calculated 
for white matter (T1 =1533 ms, T2*=29ms) is shown in Figure 50.  The flip angle at which 
maximum SNR is achieved, decreased as TR was reduced in the simulation and there was 
only a slight gain in SNR observed for the extra averages acquired (Figure 50a).  The 
percentage increase in SNR by taking two averages over a single average was less than 
0.1%.   The signal in grey matter and white matter was simulated for a single average and a 
TR of 250ms indicating an optimal flip angle of 32 degrees in white matter and 29 degrees 
in grey matter (Figure 50b).   In-vivo data acquired (n=1) with at a TE of 15ms repeated at 
multiple flip angles was in good agreement with simulations indicating a maximum signal at 
a flip angle of 32 degrees in white matter (Figure 50c). 
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Figure 50. In-vivo signal estimates 
Simulations using the gradient echo equation to estimate SNR for different TR and NSA 
combinations using white matter signal relaxation parameters(a).  Simulated signal for grey 
matter and white matter is plotted against flip angle for TR =250ms and NSA = 1(b).  In-vivo 
measurements of white matter signal plotted against flip angle(c). 
 
5.4.3.3 Flow compensation development and testing 
Magnitude images of a cross section of the flow phantom indicate the flowing water region 
within the water bath tubing surrounded by agar (Figure 51a).  When the water bath flow is 
turned off, the phase images display complete phase wrap lines that pass through the 
water tube horizontally across images (Figure 51 b,c).  When the flow was turned on, the 
wrap lines are disturbed in the flowing section of the phantom as the phase of spins in the 
flowing water accumulate phase in the direction of flow (Figure 51d).  This accumulation 
was corrected and the artifacts markedly reduced when the flow compensation gradients 
are turned on and complete phase wrap lines can be observed in the presence of flow 
(Figure 51e). 
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Figure 51. Flow compensation phantom 
Magnitude image of flow phantom(a) with phase images of the same slice where the water 
is not flowing (b,c) and when the flow is switched on(d,e).  The effect on the phase of the 
flowing water can be observed by the disruption to the wrapping pattern(d) that is 
corrected by addition of flow compensation gradients(e).  
 
5.4.4 Discussion 
In this section, ernst angle simulations were carried out to optimise the SNR of the signal 
magnitude of a 3D spoiled gradient recalled echo sequence both in-vivo and ex-vivo.  T1 
and T2* mapping was conducted to provide estimates in white matter and grey matter 
regions that could be used to calculate the flip angle to generate greatest signal at the 
desired echo time.  Optimal values for TR and NSA were calculated for given scan times to 
maximise SNR.   
The signal relaxation values used in simulations were generated through T1 and T2* 
mapping and ROI estimates.  These were in good agreement with values reported in 
previous studies(261,274,275).   The T1 estimates were greater in-vivo than ex-vivo which 
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may be due to both differences in the imaging temperature and fixation effects.  The in-
vivo imaging was conducted at body temperature compared to the room temperature at 
which ex-vivo imaging was carried out.  There is a known increasing relationship between 
spin-lattice relaxation and temperature(277). T1 has also been shown to be reduced in 
tissue fixed using aldehydes thought to be due to the chemical reactions that occur during 
fixation(269).  Increases in temperature and use of formaldehyde fixative have been shown 
to also decrease T2(269,277).  However, it has been shown that the reduction due to 
fixative can be reversed through rehydration of tissue using PBS(269) as carried out in this 
study.  The increased T2* observed in the ex-vivo tissue is contradictory to the expected 
decrease in the T2 component due to temperature.  The use of smaller voxels and 
improved field homogeneity reduce dephasing of the transverse MR signal(278)  and in 
addition to greater tissue hydration may be responsible for the elevated T2*  
measurements in the ex-vivo data. 
To maximise phase SNR, the ex-vivo simulations used an echo time equal to the T2* of 
white matter. At this echo time, maximum magnitude SNR was produced with a flip angle 
of 36 degrees, a TR of 200ms and five signal averages.  An echo time of half of the T2* 
measured in white matter was used in the in-vivo ernst angle simulations and a maximum 
SNR was calculated at a flip angle of 32 degrees for a single average with a TR of 250ms.  
This simulated experiment was in good agreement with empirical data collected.  First 
order gradient moment nulling improves phase estimation of spins moving with a constant 
velocity.  However, it should be noted that there may be extra phase components not 
accounted for from the acceleration of spins (caused by turbulent flow in vessels) and 
inconsistent field gradients in the direction of movement.  Techniques to correct for these 
effects have been reported and are a subject of current research (279,280).  Nevertheless, 
the flow compensation implemented here will improve phase estimation caused by 
mislocalisation of signal and accumulation of spins due to motion at a constant 
velocity(104,279,281).  Spoiled gradient recalled echo acquisitions that include this flow 
compensation, in combination with the optimised parameters from the ernst angle 
simulations carried out in this chapter, should provide ideal data for QSM under these in-
vivo / ex-vivo experimental conditions. 
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5.5 In-vivo and Ex vivo QSM in the rTg4510 
5.5.1 Introduction 
Quantitative Susceptibility Mapping has been shown previously to correlate to iron 
concentrations in tissue(242,282) and myelin in white matter(213,275), both of which are 
thought to be altered in AD(161,216).  In a recent clinical study, significant increases in 
magnetic susceptibility were detected in AD patients relative to controls in the putamen, a 
sub region of the striatum(250).  There have been few studies in mouse models of AD but 
in common with T2* studies of iron, none have been performed in mice exhibiting tau 
pathology.  The magnetic susceptibility findings and histology in the preliminary study in 
section 5.3.3 suggest that QSM may be sensitive to white matter damage and 
neuroinflammation in grey matter regions in the rTg4510.  The loss of contrast between 
rostral white matter and surrounding grey matter that was visually apparent in the mean 
magnetic susceptibility maps may be due to reduced myelin.  This is supported by the 
increased radial diffusivity and reduced FA measured in the genu region of the corpus 
callosum of the rTg4510 presented in chapter 4.  Furthermore, abnormalities in 
myelination in the rTg4510 have been observed at 4 months of age using electron 
microscopy(205).  Magnetic susceptibility measurements have been shown to be more 
specifically related to myelin concentration than measures of diffusion using DTI(213). QSM 
may therefore provide a non invasive method to measure myelin content in tissue and to 
track early white matter damage in-vivo in the rTg4510. 
The increased presence of reactive microglia and astrocytes known to occur in regions of 
NFT pathology in the rTg4510(70,87) were observed in the corpus callosum and striatum in 
section 5.3.3.  Gliosis is associated with oxidative stress and the accumulation of iron which 
may be responsible for the increases in magnetic susceptibility in these regions.  The 
rTg4510 may provide the opportunity to further understand the relationship between iron 
accumulation and tau pathology in the absence of plaques.  Measurement of iron 
concentration in-vivo using QSM may constitute a novel biomarker of neuroinflammation in 
the rTg4510 and a means by which to test iron chelating therapeutics.  
In this study, the sensitivity of QSM to NFT pathology in the rTg4510 is investigated.  In-vivo 
and ex-vivo data are acquired using the gradient echo acquisitions optimised in the 
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previous section.  Commonly used methods for phase unwrapping and background field 
removal are evaluated and a QSM post processing software pipeline is developed. 
Magnetic susceptibility maps are generated and group comparisons are made between 
rTg4510 mice and wild-type controls.  Regions of interest were selected to be comparable 
to those used in the DTI study (Figure 34, section 4.4.2.3) and based on the voxel-wise 
increases detected in the striatum and rostral section of the corpus callosum in the pilot 
study(Figure 43, section 5.3.3).  T2* mapping estimates were taken in corresponding 
regions and comparisons are presented between QSM measurements and this more 
established MRI method of estimation of iron concentration in-vivo. 
5.5.2 Methods 
Animals 
Generation of homozygous rTg4510 transgenic mice has been reported previously(203).  
Female rTg4510 mice were licensed from the Mayo Clinic (Jacksonville Florida, USA) and 
bred for Eli Lilly by Taconic (Germantown, USA).  Mice were imported to the UK for imaging 
studies at CABI.  All studies were carried out in accordance with the United Kingdom 
Animals (Scientific Procedures) act of 1986. 
Imaging 
All imaging was performed with a 9.4 T VNMRS horizontal bore scanner (Agilent Inc.).  In-
vivo imaging was conducted on N = 10 rTg4510 mice and N = 10 wild-type controls.   A 72 
mm inner diameter volume coil (Rapid Biomedical) was used for RF transmission and signal 
was received using a 2 channel array head coil (Rapid Biomedical).  Mice were 
anaesthetised under 2% isoflurane and were immobilised by securing the head using a bite 
bar within the anaesthesia nose cone and ear bars that protruded inward from the sides of 
the mouse bed apparatus (Rapid Biomedical).  Anaesthesia was then maintained at 1.5% 
isoflurane in 100% O2 throughout imaging.  Core temperature and respiration were 
monitored using a rectal probe and pressure pad (SA instruments).  Mice were maintained 
at ~37 °C using heated water tubing and a warm air blower with a feedback system (SA 
instruments).  Shimming was performed using an automatic 3D gradient echo shim 
function (VNMRJ, Agilent Inc.) with a voxel containing the cortex (linewidths were 47±7 Hz).  
Data for QSM was collected using a 3D single echo spoiled gradient recalled echo sequence 
with flow compensation in three dimensions.  Subsequently, a multi-echo sequence was 
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run without flow compensation to acquire data for T2* mapping.  Parameters for both 
sequences are provided in Table 2.  
In preparation for ex-vivo imaging, perfusion fixation was carried out by laboratory 
collaborators.  Animals were terminally anaesthetised with Euthanal administered via 
intraperitoneal injection immediately after in-vivo imaging.  Fixation was then carried out 
by perfusion through the left ventricle: first with 15 – 20 mL of saline (0.9%) and heparin; 
second with 50 mL of buffered formal saline, at a flow rate of 3 mL per minute.  Brains 
were then removed and stored in-skull at 4 oC in buffered formal saline.  After 4 weeks, 
brains were transferred to PBS (50ml refreshed weekly, Sigma-Aldrich) for rehydration 
(184,269,270) for a further 3 weeks.  Ex-vivo imaging was conducted on N = 8 rTg4510 mice 
and N = 8 wild-type controls using a 3D spoiled GRE acquisition with parameters given in 
Table 2.  Brains were secured individually in a 20ml Syringe filled with 10ml proton MR 
signal-free, non-viscous Fomblin perfluoropolyether (PFS-1, Solvay Solexis SpA., Bollate, 
Italy) prior to imaging in a 26mm diameter birdcage coil (Rapid Biomedical GmbH, 
Germany) at 9.4T.  Shimming was conducted using a pulse a collect sequence generating a 
linewidth of 47±5 Hz.   
    
Parameter In-vivo  
Single Echo 
In-vivo  
Multi Echo 
Ex-vivo  
Multi Echo 
TR (ms) 250 250 200 
minTE/dTE/maxTE (ms) 15 2.31/2.46/29.32 3.05/3.92/46.21 
FA (0) 32 32 36 
NE 1 12 12 
Averages 1 1 5 
Scan time 1hr,2s 1hr,2s 10hr,45min,2s 
Spectral width (Hz) 50000 100000 73529 
FOV (mm) 18x18x18 18x18x18 18x17.2x14.4 
Matrix 120x120x120 120x120x120 225x215x180 
Iso. Resolution (µm) 150 150 80 
Table 2. Spoiled GRE sequence parameters 
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Registration and mask generation 
With the exception of the preliminary brain separation step, a group wise registration of 
the magnitude images was conducted by collaborators using an automated pipeline 
described in section 5.3.2.2.  Masks of the brain were generated automatically for 
generation of susceptibility maps which were then transformed back into the atlas space 
using deformation fields from the non-rigid registration.  Mean susceptibility images were 
generated in this space for WT and rTg4510 groups. 
QSM pipeline optimisation 
Reconstruction of the phase of the in-vivo data involves a preliminary processing step 
where phase data from the two receive array coils is combined to remove phase shifts 
between channels.  This was achieved using a global offset correction technique(283). The 
offset was calculated as the mean difference in phase between the two coils calculated in a 
ROI measuring 10x10x10 voxels in the centre of the brain.  The receiver offset was then 
removed by global subtraction of the mean difference calculated from each voxel of one 
coil.  The coil phases with the offset removed were then combined by weighted average.  
The magnitude at each voxel provided the weighting to suppress noise(283). 
There are a number of methods by which to generate magnetic susceptibility maps from 
reconstructed phase data.  All involve three basic stages: phase unwrapping; background 
field removal; and magnetic susceptibility calculated through dipole inversion.  More 
information on these standard methods can be found in section 2.8.  Comparisons were 
made between algorithms that are freely available to download and commonly used in the 
literature.  Evaluation was done both qualitatively though visual observation of artifacts in 
processed data and quantitatively by calculating the standard deviation and CNR of the 
processed phase in ROIs.  A rostral slice was chosen for the quantitative analysis and ROIs 
were drawn manually in the corpus callosum and cortex across five slices in five wild-type 
mice selected at random from the cohort imaged ( the analysis was repeated in rTg4510 
mice to ensure no bias in the processing methodology had been introduced).  The CNR in 
the phase was calculated as 
     
            
              
 
Equation 65  
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where       and       are the mean of the white matter and grey matter regional 
measurements and     and     are the standard devations of the voxels within an ROI. 
Two commonly used phase unwrapping algorithms are path based and laplacian based 
techniques.  Phase data was unwrapped in 3D using algorithms downloaded online from 
the MEDI toolbox (Cornell MRI Research Lab).  For path based unwrapping, the 
unwrapPhase.m algorithm was used and unwrapLaplacian.m was implemented for 
laplacian unwrapping.  Background field removal comparisons were made for the 
projection onto dipole fields (PDF) (PDF.m, MEDI toolbox, Cornell MRI Research Lab) 
(107,262) and Variable Sophisticated Harmonic Artifact Reduction for Phase data 
(VSHARP)(284,285) methods.  The kernel width used in the VSHARP method equates to the 
diameter of a spherical mean value filter used.  The diameter chosen is a trade-off between 
the amplification of phase error using small widths and the increased erosion of data 
around the periphery of the brain using wider kernals(285).  To prevent erosion of white 
matter structures, the kernel width was limited to k=3 voxels for the in-vivo data and k=9 
for the ex-vivo data.  Once the field maps were optimised, the dipole inversion step was 
performed using thresholded k-space division.  The k-space filter threshold was varied 
between values of 2 and 10. 
The multi echo sequence used to collect the ex-vivo data required a further step of 
optimisation where field maps and susceptibility maps were compared to select the echo 
to use for QSM group comparisons.   A frequency field map may be generated by fitting 
phase values from a multi echo sequence across time.  To investigate the possibility of 
generating field maps by combining phase data from difference echoes in the ex-vivo data, 
phase was unwrapped across echo times voxel by voxel using the unwrap function in 
matlab before linear fitting using a least squares algorithm.  The gradient of the linear fit at 
each voxel was used to generate a field map of frequencies prior to susceptibility mapping 
by TKD. 
QSM and T2* group comparisons 
The outcome of the post processing optimisation experiments were used to develop a QSM 
pipeline for the in-vivo and ex-vivo data sets.  After coil combination, in-vivo phase data 
were unwrapped using the laplacian method before background field removal using 
VSHARP (k=3 voxels).  TKD was performed on the field map using a threshold t=5.  Ex-vivo 
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QSMs were generated by path based unwrapping of the fourth echo followed by VSHARP 
background field removal (k=7 voxels) and TKD using a threshold t=5. Susceptibility values 
at each voxel were then calculated for all QSMs relative to the mean susceptibility of the 
whole brain, calculated using the masks from the registration.  T2* estimates were 
calculated at each voxel across all echoes using a non linear least square fitting algorithm in 
matlab using a two parameter fit function. 
Mean QSM and T2* estimates were calculated for within the ROIs shown in Figure 52.  
Regions in the corpus callosum and striatum in a rostral part of the brain were chosen 
based on the increases in susceptibility in the rTg4510 in these regions in the pilot 
study(Figure 43, section 5.3.3).  In the previous chapter, NFT pathology was quantified 
histologically in a caudal region of the brain(Figure 35, section 4.4.3.1), and corresponding 
ROIs in these slices were taken in the QSM and T2* data.  ROIs were drawn manually on the 
magnitude atlas image using Amira software and then back propagated by a collaborator 
on to the susceptibility maps in their original space using deformation fields from the non 
rigid registration.  Errors in segmentation propagation were corrected manually using 
Amira software.  The reported p-values are from standard t-tests for differences in 
parameters between the rTg4510 and WT groups, unless stated otherwise. 
 
Figure 52.  ROIs for group comparisons 
ROIs were drawn in rostral and caudal sections of the brain(a).  In the rostral section(b), the 
corpus callosum CCr, Striatum, Str, and Anterior Commissure, AC, were segmented.  In the 
Caudal section (C) regions were drawn in the Cortex, Ctx, the Hippocampus, Hp, the 
Thalamus, Th, and the Corpus Callosum, CCc. 
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5.5.3 Results  
5.5.3.1 QSM optimisation 
5.5.3.1.1 Optimisation of ex-vivo QSM post processing 
To compare phase unwrapping methods in randomly selected wild-type mice (n=5), 
laplacian and path based region growing algorithms were combined with PDF and 
VSHARP(k=3) to generate field maps.  Reduced variations and artifacts were observed for 
both background field removal unwrapping using the region growing algorithm (Figure 53 
a,b).  In the field maps where laplacian unwrapping was used (Figure 53 c,d) the PDF 
method fails to remove variations across the brain and there are ripples and more local 
dipolar artifacts observed in the VSHARP image.  
 
Figure 53. Phase unwrapping comparison 
Axial images showing a path based region growing unwrapping algorithm combined with 
PDF background field removal(a) and the VSHARP method(b). Images are also shown for 
Laplacian unwrapping combined with PDF background field removal(c) and the VSHARP 
method(d). 
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To compare PDF and VSHARP background removal techniques, ROIs were taken in the 
cortex and corpus callosum to measure mean standard deviation of the phase of the voxels 
in the ROI and mean CNR for the mice in these regions in the field map of the fifth echo.  
The phase was unwrapped using the region growing algorithm and the background field 
contributions were removed using VSHARP with kernel widths of 3, 5, 7, and 9 as well as 
PDF.  In the corpus callosum, the phase standard deviation increased as the kernel was 
widened, and was even larger using the PDF method (Figure 54a). The contrast between 
grey matter and white matter was also greater at larger kernel widths and the CNR is 
greatest at k=9 voxels using VSHARP (Figure 54b).  The larger the kernel width, the more of 
the periphery of the brain is eroded using the VSHARP method, and at a width of 9 voxels, 
the white matter of the external capsule was eroded in some mice particularly in the 
rTg4510 mice where there is significant atrophy in the cortex at the age studied.  A kernel 
size of 7 voxels was selected as optimal since the CNR is similar to that achieved with a 
width of 9 (Figure 54b) and is greater than with the PDF method.  The improved contrast 
and uniformity within the cortex was observed in the field maps at this kernel size (Figure 
54d) compared to smaller kernals where ripples remain in the cortex (Figure 54c) and PDF 
where dipolar artifacts are observed near the olfactory bulbs(Figure 54e). 
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Figure 54. Ex vivo BFR comparison 
Comparison of mean phase standard deviation in the corpus callosum(a) for VSHARP field 
removal with kernel sizes 3 to 7 and PDF method.  CNR between WM and GM is at a 
maximal with the VSHARP method and a kernel size of 9(b).   Example phase field maps are 
shown for VSHARP k=3(c),7(d) and PDF(e). 
 
The SNR of the phase signal in white matter is maximum at TE=T2*, however, the SNR of 
the signal sampled is reduced due to T2* decay at longer echo times which may increase 
variability and error in phase estimates.  Field maps and susceptibility maps were 
generated for each mouse and values of phase variability and CNR was measured in the 
grey matter and white matter ROIs for both sets of data.  The field maps were generated by 
unwrapping using the region growing algorithm before field removal using VSHARP (k=7).  
QSMs were calculated by TKD using a threshold tF=5.  Mean variability in the corpus 
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callosum ROI increased with echo time and CNR in both the field maps and susceptibility 
maps peaked at the fourth echo (Figure 55a-c).  At this echo, susceptibility maps appeared 
to have greater contrast and less noise than those generated for earlier and later 
echoes(Figure 55d-f).  
 
 
Figure 55. Ex vivo echo comparison 
a)Phase s.d. vs echo, b) CNR in field map vs echo, c) CNR in susceptibility map vs echo, and field 
maps of echo=1, 4,and 10 respectively (path based unwrapping with vSHARP BFR(k=7)  TKD 
threshold =5)( d,e,f). CNR calculated between grey matter and white matter ROIs. 
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The final optimisation step involved selection of a TKD threshold value, tF.  At larger values 
of tF, less data is removed through truncation of the k-space filter and a better estimate of 
the susceptibility is expected, however more noise will be included in the inversion 
generating artifacts in the susceptibility maps.  Mean values of susceptibility in the white 
matter regions are shown in Figure 56a.  The values appear to decrease, converging 
towards a minimum value as the tF value increases.  Conversely, the variability in the 
susceptibility values increase with tF value (Figure 56b).  The CNR of the grey matter and 
white matter regions reaches a maximum value at tF=6, although there is a minimal 
increase from tF=5(Figure 56c).  The increased CNR is evident in susceptibility maps 
generated from larger tF values (Figure 56d,e).  At Echo 4, t=5, susceptibility in the corpus 
callosum was -28±2ppb, and in the cortex was -3.6±1.3ppb, and the mean difference of 
white matter relative to grey matter was -31±3ppb.  This is in reasonable agreement with a  
previous study at 9.4T which reported a mean difference value of -29.8ppb between white 
matter and grey matter in control mice(286).  To ensure that the optimisation did not bias 
the post processing towards the wild-type animals, measurements were taken in a 
randomly selected group of rTg4510 mice (n=5).  ROIs were taken in the corpus callosum 
and cortex and CNR in susceptibility maps was measured for each echo and for multiple tF 
values, repeating the wild-type experiments described above.  The results were in good 
agreement with those from the WT group with CNR peaking in susceptibility maps at the 
fourth echo collected and at a TKD threshold equal to 5(data not shown).   
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Figure 56. Ex vivo tF value comparison 
Mean susceptibility in corpus callosum vs t value(a),  s.d. of susceptibility in corpus 
callosum(b),  susceptibility CNR of white matter grey matter vs t value(c).  Examples of 
susceptibility maps at t=2(d) and t=10(e) respectively showing increased contrast but 
increased noise from streaking artifacts. 
 
5.5.3.1.2 Optimisation of in-vivo QSM pipeline 
The phase data was reconstructed from the in-vivo imaging data and after coil 
combination, post processing algorithms were compared through mean measurements in 
ROIs in n=5 WT animals as in the ex-vivo optimisation.  Firstly, phase unwrapping was done 
using both laplacian and path based methods and the background field was removed using 
PDF and VSHARP techniques.  For the VSHARP method, the kernel size was restricted to 
three voxels due to the significant erosion of the cortex at larger widths.  The variability in 
the field map phase was much reduced using the VSHARP field removal method (Figure 
57a).  The use of laplacian phase unwrapping with VSHARP produced the lowest standard 
deviation in the phase.  Additionally, the CNR in the field maps between the white matter 
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and grey matter ROIs was greatest using this combination of techniques (Figure 57b).  
Example field maps for a single mouse are shown in Figure 57c. 
 
Figure 57. In-vivo field mapping comparison 
Comparison of phase variation for various phase unwrapping and field removal 
combinations in the cc and ctx (a).  CNR in the field map for the same combinations(b). Field 
maps in coronal and axial plane with laplacian unwrapping and VSHARP field removal(c). 
 
The field maps generated from laplacian phase unwrapping with VSHARP background 
field removal were used to calculate susceptibility maps using TKD with different filter 
threshold values.  In both ROIs, mean susceptibility estimates peaked in magnitude at 
tF=5 whereas the standard deviation of the susceptibility values increased with tF 
value(Figure 58a-d).  Calculating the mean CNR in the susceptibility maps using the 
ROIs indicated a maximum value was reached at tF=5 before decreasing at larger 
threshold values(Figure 58e).  Mean susceptibility in the white matter ROI at tF=5 was -
29±1ppb and in the cortex the susceptibility was 3±1ppb.  Literature values are given to 
a reference which is rarely reported but the mean susceptibility difference of white 
matter relative to grey matter is  -32±1 ppb which is similar to the difference in a 
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previously published in-vivo paper at 9.4T(256) (cc= -59.9±7.3ppb, cortex = -
33.9±7.3ppb, mean diff = -25.1ppb – values relative to CSF).  To ensure optimisation did 
not bias the WT group, transgenic mice were selected randomly from the cohort (n=5) 
and CNR between grey matter and white matter ROIs in the susceptibility maps was 
measured over the same range of threshold values.  Susceptibility CNR peaked at 0.79 
in the transgenic mice at threshold values of tF=4 and tF = 5. 
 
 
Figure 58. In-vivo tF value comparison 
Mean and s.d. susceptibility in the cc (a,b), and mean and s.d. susceptibility in the 
cortex(c,d), and susceptibility CNR between grey matter and white matter (e) and a 
representative susceptibility map(f) 
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5.5.3.1.3 QSM using multiple echo data 
To combine multiple echo data with the aim of improving SNR in the field maps and 
subsequent susceptibility maps, the reconstructed ex vivo phase datasets were unwrapped 
temporally, voxel by voxel across the twelve TEs collected.  After this unwrapping step, 
spatial phase wraps were observed in the phase data at each echo (Figure 59a).  By 
performing a least squares linear fit at each voxel, the gradient of the fit was used to 
produce a frequency field map and the background field contributions were removed using 
the VSHARP method (k=7) (Figure 59b).  Maps of R2 of the fit were calculated (Figure 59c) 
and low values appeared to form coherent patterns that appeared to coincide with areas of 
large phase gradients in the phase images after temporal unwrapping(Figure 59a).  Plotting 
the phase values vs echo number for a voxel in one of these regions of poor fit, showed 
that the unwrapping had failed (Figure 59d).  As a result of the unwrapping and fitting 
errors in these regions, increased noise and artifacts can be observed in the susceptibility 
maps generated using multiple echoes compared to single echo data (Figure 59e,f).  In an 
attempt to improve the phase fitting, spatial unwrapping of the individual echoes was done 
both prior and post temporal unwrapping with no observed improvement in the 
susceptibility maps.  For this reason, QSM mapping using a multi-echo, temporal 
unwrapping approach was not pursued further and QSM maps were generated from data 
acquired at a single echo (informed by optimisation steps described above). Multi-echo 
magnitude data were used to estimate T2* (the more established biomarker of tissue iron 
concentration) for comparison to QSM metrics generated from simultaneously-acquired 
data.  
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Figure 59. Ex vivo multi-echo QSM 
a)Residual wraps remain after temporal unwrapping of echoes(image shows 12
th
 echo) 
b)field map generated by linear fit of unwrapped phase and background field removal c) 
map of R squared values for linear fits d) errors in temporal unwrapping from a single voxel 
within regions marked in c e) and f) are the multi echo susceptibility map and single echo 
susceptibility map respectively. 
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5.5.3.2 QSM group comparisons 
Deformation fields from the non rigid registration of the magnitude data were applied to 
the QSMs and T2* maps of the individual mice to transform them into the same space.  
Mean maps of the registered data were then calculated separately for the WT(in-vivo : 
n=10, ex-vivo: n=8) and rTg4510(in-vivo : n=10, ex-vivo: n=8) groups.  An axial slice of each 
of the mean QSM and T2* maps for both the ex-vivo and in-vivo datasets is shown in Figure 
60.  The anatomical structures are better delineated in the ex-vivo data owing in part to its 
finer resolution compared to the in-vivo maps.  In a rostral section of the external capsule, 
a marked reduction in contrast with the surrounding cortical grey matter is observed in the 
rTg4510 QSMs (Figure 60b,d).  This does not occur in the corresponding T2* maps (Figure 
60f,h).  A global reduction in intensity in the grey matter of the in-vivo T2* maps indicate a 
shortening of relaxation time compared to the ex-vivo data (Figure 60e-h). 
 
Figure 60. Mean QSM and T2* images 
Mean QSM (a-d) and T2*(e-h) images for registered ex-vivo (a,b,e,f) and in-vivo (c,d,g,h) 
datasets.  A reduction in the white matter / grey matter contrast(yellow arrows) can be 
seen in a rostral section of the external capsule in the rTg4510 QSMs that is not apparent in 
the T2* maps. 
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Regional mean estimates of quantitative measures were generated by delineation of ROIs 
in atlas magnitude images before transformation back into the original image space of each 
animal where maps were segmented.  Regional values of magnetic susceptibility and T2* 
for the WT group are provided in Figure 61.  There was good agreement between the ex-
vivo and in-vivo susceptibility in the deeper grey matter structures whereas an increase was 
observed in the hippocampus and the cortex in the ex-vivo data (p≤0.01, individual t-tests, 
FDR corrected q(<0.05)).  The T2* was elevated in all grey matter regions in the ex-vivo 
data(p≤ 0.0001).   
 
Figure 61. Magnetic Susceptibility and T2* regional estimates 
In-vivo and Ex-vivo mean magnetic susceptibility and T2* values for grey matter(a,b) and 
white matter(c,d). ROIs calculated for wild-type mice. 
 
In comparisons between grey matter regions in WT mice, the in-vivo susceptibility was 
increased in the Hippocampus compared to the Thalamus (p≤0.01, one way ANOVA) and 
Striatum (p≤0.001), and in the ex-vivo data, susceptibility was significantly greater in the 
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Hippocampus and the Cortex compared to the thalamus(p≤0.0001 for both) and 
striatum(p≤0.001 and p≤ 0.0001 respectively).  There were differences between all regions 
in the T2* ex-vivo data, the pattern of greater values in the hippocampus and cortex 
regions was similar to that observed in the QSM data.  These regions also exhibited 
differences, of lower significance, in the in-vivo data with the exception of the thalamus 
and cortex, and the hippocampus and striatum.  Interestingly the striatum T2* was greater 
than that for the thalamus (p≤0.05), with no difference in the magnetic susceptibility 
between these regions. 
In white matter ROIs, the ex-vivo data was found to have a larger negative susceptibility 
(p≤0.0001, t-tests, FDR corrected (q≤0.05)), the rostral corpus callosum (p≤0.0001) was the 
only region with different T2* to the in-vivo data(T2* significantly increased in ex-vivo) .  
The in-vivo magnetic susceptibility in this region was diamagnetic compared to the anterior 
commissure (p≤0.05, ANOVA) and in the ex-vivo data, susceptibility in the caudal corpus 
callosum more diamagnetic compared to both the more rostral measurement(p≤0.0001), 
and the anterior commissure(p≤0.001).  The rostral corpus callosum T2* measurements 
were significantly different to the anterior commissure and the caudal corpus callosum 
regions for both in-vivo(T2* increased, p≤0.01 for both) and ex-vivo (T2* decreased, 
p≤0.05,p≤0.001 respectively) data. 
Differences in magnetic susceptibility and T2* in rTg4510s relative to WT controls were 
most significant in the striatum.  In both the in-vivo, and ex-vivo datasets, an increased 
paramagnetic susceptibility and reduced T2* was calculated for the rTg4510 (Figure 62a,d).  
This region appears hyperintense in the mean ex-vivo QSMs (Figure 62b,c).  In the 
Hippocampus, an increased magnetic susceptibility was also observed in both in-vivo and 
ex-vivo data, with no differences in T2*.  A shortening of T2* in the cortex was observed in 
the in-vivo data only.  The ex-vivo measurements of susceptibility were elevated in the 
rTg4510 thalamus with a reduced T2*, findings that were not replicated in-vivo where 
magnetic susceptibility was found to be decreased with no change in T2*.  
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Figure 62. Magnetic susceptibility and T2* in the striatum 
In-vivo and ex-vivo magnetic susceptibility(a) and T2*(d) values in the striatum for WT and 
rTg4510 cohorts.  Coronal slices of mean ex-vivo QSMs(b,c) show hyperintensity in the 
striatum (black circle) with corresponding slices of ex-vivo T2* maps(e,f).    
 
An increased magnetic susceptibility was detected in the diamagnetic rostral region of the 
corpus callosum of the rTg4510s relative to WT controls.  This was consistent across both 
in-vivo and ex-vivo datasets and was evident as a loss in grey matter / white matter 
contrast in both the mean average images(Figure 60b,d) and coronal slices in unregistered 
representative QSMs(Figure 63b,c).  No significant changes were observed in T2* values 
and differences in representative T2* maps were less apparent (Figure 63e,f).  Other white 
matter measurements did not exhibit differences in rTg4510 values, although T2* was 
reduced in the anterior commissure in the ex-vivo data.  T2* and QSM values for all regions 
are listed in Table 3. 
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Figure 63. Magnetic susceptibility and T2* in the corpus callosum 
Measurements of magnetic susceptibility (a) and T2*(d) in the rostral ROI of the corpus 
callosum for WT and rTg4510 mice(in-vivo and ex-vivo).  Reductions in grey matter / white 
matter contrast were apparent in QSMs(b,c) but not in T2* maps(e,f) when comparing a 
coronal slice for a single representative(unregistered) WT and rTg4510 ex-vivo. 
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χ (ppb) Ex vivo In-vivo 
ROI WT rTg4510 WT rTg4510 
Striatum 0.61 ± 0.81 8.71 ± 3.21 0.54 ± 1.31 4.85 ± 3.09 
Hippocampus 9.45 ± 2.55 13.60 ± 2.91 5.82 ± 1.86 11.11 ± 4.84 
Cortex 7.01 ± 0.92 2.72 ± 5.37 3.46 ± 3.06 1.40 ± 1.79 
Thalamus 1.30 ± 0.97 3.03 ± 1.31 1.33 ± 1.09 -0.45 ± 1.2 
CCr -34.92 ± 4.29 -18.73 ± 7.6 -20.55 ± 6.15 -11.22 ± 5.21 
AC -32.32 ± 1.88 -31.58 ± 3.33 -13.33 ± 3.45 -9.42 ± 5.34 
CCc -46.01 ± 3.97 -48.70 ± 8.88 -18.31 ± 10.14 -17.10 ± 4.43 
     
T2* (ms)     
Striatum 39.79 ± 1.14 35.08 ± 1.61 34.99 ± 1.82 31.58 ± 1.42 
Hippocampus 50.16 ± 1.51 50.39 ± 2.39 36.89 ± 2.48 36.62 ± 2.55 
Cortex 46.14 ± 1.44 45.13 ± 1.81 33.67 ± 1.4 32.01 ± 1.8 
Thalamus 37.41 ± 1.1 35.57 ± 1 31.25 ± 2.44 31.72 ± 0.59 
CCr 25.23 ± 0.86 26.67 ± 2.1 22.58 ± 0.82 24.20 ± 3.2 
AC 24.60 ± 0.73 22.89 ± 0.81 26.46 ± 2.35 25.27 ± 2.08 
CCc 24.08 ± 1.07 23.54 ± 1.25 25.02 ± 1.54 24.73 ± 1.72 
Table 3. ROI magnetic susceptibility and T2* estimates 
List of mean and standard deviation of regional measures of magnetic susceptibility and 
T2*. Abbreviations for white matter regions : CCr – rostral corpus callosum, AC  - anterior 
commissure, CCc caudal corpus callosum. 
 
 
5.5.4 Discussion 
The rTg4510 mouse model develops NFT pathology associated with AD without beta-
amyloid plaques.  The increased presence of reactive microglia and astrocytes has been 
observed in this model previously using histological stains(70,87).  Their presence in brain 
tissue is associated with neuroinflammation in AD(287) and may be related to increased 
iron levels that give rise to ROS causing oxidative stress.  The aggregation of insoluble Tau 
protein found in tangled form in AD has been shown to be mediated by iron (227).  QSM 
and the more established T2* MRI techniques have been shown to be sensitive to iron 
content in the brain(233).  In this work, QSM and T2* were used to non invasively probe 
the magnetic susceptibility in the rTg4510 brain both in-vivo and ex-vivo.  Magnetic 
susceptibility increases relative to WT controls were identified in both grey matter and 
white matter regions and may indicate sensitivity to iron content in-vivo.   QSM in the 
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rTg4510 may therefore present a non invasive method by which to dissect the relationship 
between iron and tau pathology in AD. 
At high field, contributions from background susceptibility sources are increased(188) 
which may affect phase estimates throughout the mouse brain due to its large surface area 
to volume ratio.  Neurodegenerative mouse models such as the rTg4510 may be affected 
disproportionately since marked atrophy may make delineation of structures difficult and 
may decrease the size of the shim voxel relative to controls.  Compared to ex-vivo 
acquisition, additional error may be introduced into in-vivo datasets from increased noise 
and motion artifacts, primarily of physiological origin that fluctuate with the 
cardiorespiratory cycle(128,288) as well as from partial volume effects due to the lower 
resolution attainable.  Furthermore, the use of oxygen to deliver anaesthetic may alter in 
vivo blood oxygen saturation levels, shown to cause changes in the magnetic susceptibility 
in and around blood vessels(289).  This might suggest a fairer group comparison can be 
achieved using ex-vivo data.  However, tissue fixation processes and the difference in 
imaging temperature will alter relaxation properties(269,277) and measurements may not 
reflect in-vivo values. Ex-vivo T2* measurements were increased (relative to in-vivo) in all 
grey matter regions in the WT animals in this study.  This may have been caused by fixation 
and rehydration processes, known to alter the T2 properties of the ex-vivo tissue(269).  
Relative to in-vivo tissue, rehydration of ex-vivo tissue may have increased tissue water 
content, lengthening T2 relaxation.  There may also be reduced dephasing effects from the 
use of smaller voxel sizes.  Interestingly, this increase was not observed in the white matter 
regions which may be due to a decrease in water uptake during ex-vivo rehydration or 
partial volume errors in the in-vivo analysis.  The in-vivo voxel size used is large relative to 
the white matter structures in the mouse brain and incorporation of grey matter into ROIs 
is inevitable.  This may be reflected by the greater standard deviation of the in-vivo data 
compared to the ex-vivo data and may have produced inflated T2* estimates.  In group 
comparisons, regional T2* differences in the rTg4510 relative to controls were in good 
agreement between in-vivo and ex-vivo datasets.  This suggests that any T2* effects of ex-
vivo tissue processing were consistent between transgenic and wild-type mice. 
T2* star has been used previously to estimate iron concentrations in the brain and is 
regarded as an established technique for this purpose(233).  Both in-vivo and ex-vivo 
rTg4510 datasets showed a reduced T2* in the striatum, a region that is known to develop 
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tangle pathology at the age imaged(204).  The hippocampus and cortex also have a high 
density of NFTs present in the tissue whereas the thalamus is less affected(87,125,204).  
Although the rTg4510 exhibited differences in T2* in the cortex and relatively low 
pathology region of the thalamus, no differences were detected in the hippocampus.  This 
suggests that relationships between iron deposition( as inferred by T2* measurement) and 
tau pathology(estimated by histological assessment of NFT density) may not be straight 
forward in the rTg4510 model or that other factors are complicating the interpretation of 
T2* changes in the tissue.   
The QSM results support the notion of iron deposition in the striatum which was 
paramagnetic in the rTg4510s relative to controls.  This increase in magnetic susceptibility 
would cause more rapid spin dephasing in the transverse plane, expediting decay of the 
signal as reflected by the T2* shortening observed.  As with the T2* comparisons, 
differences in the striatum were the most marked of the measured grey matter regions.  In 
a recent QSM study in humans, AD patients were found to have particularly elevated 
magnetic susceptibility in the putamen, a sub region of the striatum(250).  Iron 
concentration in the healthy brain is particularly high in the basal ganglia structures, 
including the striatum, and abnormally high accumulation occurs in AD(214).  These 
findings in the rTg4510 specifically implicate tau as playing a key role in the dysfunction of 
iron storage in this brain region.  Iron-containing microglia have been identified in the 
hippocampus of AD patients(222) which may be responsible for the elevated magnetic 
susceptibility in the rTg4510.  A lack of T2* differences in this region may highlight the 
enhanced sensitivity of the QSM technique to iron.  The NFT histology in the rTg4510 in 
chapter 4 (Figure 35, section 4.4.3.1) showed greatest burden in the cortex, a region in 
where no QSM differences were detected in comparison to wild-type controls.  Similar to 
the T2* measurements, regional magnetic susceptibility estimates do not appear to have 
an obvious relationship with NFT density in the rTg4510 at the time point measured. 
The decreased diamagnetism of the rostral region of the corpus callosum of the rTg4510 
may be due to abnormal myelination.  The contrast with grey matter in this region is driven 
by myelination of white matter, and similar losses in contrast have been observed in mouse 
models of dysmyelination.  However, a reduction in diamagnetic material may cause the 
same effect as an increase in paramagnetic material in elevating the negative magnetic 
susceptibility of white matter.  Oligodendrocytes maintain myelination of axons and have 
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been shown to contain iron, which may increase in disease.  GFAP and IBA-1 staining in this 
region previously has also shown increased reactive microglia and astrocytes, also 
implicated in the elevation of iron and neuroinflammation. 
In chapter 4, reduced FA and increased radial diffusivity, findings suggestive of abnormal 
myelination in white matter, were observed in the rTg4510 mice at 8.5 months of age.  The 
significance was greater for these group differences in the rostral corpus callosum in 
comparison to a caudal region.  The reduced diamagnetism detected in the rostral white 
matter ROI of the rTg4510 in this study was not observed in the caudal section.  Although 
findings of reactive microglia in section 5.3.3 mean that an increase in paramagnetic iron 
cannot be ruled out, these results may reflect a disruption to myelination that is amplified 
in the rostral white matter in the rTg4510.  The magnetic susceptibility of the white matter 
in the WT mice measured in these regions was found to be more diamagnetic in the caudal 
section.  This may suggest that there is greater myelination in the caudal part of the corpus 
callosum.  Relative to the rostral section, the caudal corpus callosum is known to myelinate 
earlier in development(179) which may be the source of the observed resilience to 
pathology in accordance with retrogenesis theory. 
The advantage of QSM over T2* in its ability to provide contrast between tissue types of 
paramagnetic and diamagnetic magnetic susceptibility can be seen in the myelin 
driven(213) negative susceptibility of the white matter versus the positive values in the 
grey matter regions(Table 3).  There were few regions where group differences were 
identified in both the QSM and T2* data.  An increased magnetic susceptibility and 
decreased T2* was observed in the rTg4510 relative to wild-type controls in the in-vivo and 
ex-vivo data in the striatum and in the ex-vivo data only in the thalamus.  This is to be 
expected since the susceptibility effects of a paramagnetic increase in tissue may cause 
more rapid dephasing of the MR signal in the transverse plane, reducing relaxation time.  
The agreement of QSM group differences with the more established T2* measurement 
method lends credence to this novel technique.  In contrast, in-vivo and ex-vivo increases in 
magnetic susceptibility were observed in the rTg4510 in the rostral corpus callosum and 
hippocampus in the absence of T2* changes.  QSM is thought to be more directly related to 
iron content and tissue composition than T2* (which includes T2 effects)(101) which may 
explain the apparent improved sensitivity to changes in the rTg4510.  These measurements 
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can be acquired using a single pulse sequence and the differing mechanisms that drive their 
contrast highlight the complementary nature of the two techniques (101,290).  
The data acquired for in-vivo T2* mapping and QSM were collected using two separate 3D 
gradient echo sequences run sequentially.  T2* mapping was conducted using multi-echo 
data and a single echo sequence was used to acquire data for QSM, with the addition of 
flow compensating gradients to improve phase estimates.  Modification of the multi echo 
sequences to include first order gradient moment nulling(104) would enable simultaneous 
in-vivo acquisition of data for both measures and scan time could be reduced using EPI for 
inclusion in a multi-parametric protocol.  Additionally, further optimisation of the 
acquisition parameters and inclusion of recently developed phase unwrapping techniques 
such as CAMPUS(268) or non-linear field map estimation(291) may remove errors and 
reduce noise in field maps generated from multi echo data and improve the quality of 
magnetic susceptibility maps produced.  
5.6  Conclusions 
In this chapter, T2* mapping and QSM was conducted in a mouse model of AD exhibiting 
tau pathology for the first time.  The results indicate that both techniques are sensitive to 
alterations in the bulk magnetic susceptibility of tissue in-vivo in the rTg4510.   Further 
work to estimate iron and myelin content in post mortem tissue will be conducted using 
histopathological staining techniques and may help to determine the pathological basis for 
these differences.  Preliminary data, enhanced by contrast agent, showed increased 
magnetic susceptibility in white and grey matter regions of the rTg4510 illustrating the 
sensitivity of QSM to altered states in both tissue types.  These findings were replicated 
both ex-vivo, without contrast agent, and in-vivo using optimised acquisitions and post 
processing QSM protocols.  Histological markers of neuroinflammation suggested oxidative 
stress possibly caused by a disruption to iron homeostasis in grey matter regions of the 
rTg4510 where differences in T2* and QSM were detected.  Both T2* and QSM findings 
support the possibility of excess iron accumulation in the striatum of the rTg4510, and may 
provide a disease biomarker that may or may not be directly related to NFT burden.  The 
additional benefit of simultaneous acquisition means that these complementary 
measurements can be acquired in a relatively short scan time.   
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6 Thesis summary, discussion, and 
conclusions 
 
The long road to the development of a cure for Alzheimer’s Disease has now been tread for 
over a century with the urgency of this endeavour building as more and more people are 
left to face the tragic decline into dementia.  In Chapter 1, major scientific breakthroughs 
that have improved our basic understanding of the disease were described along with the 
promising diagnostic tools in development to aid early diagnosis and disease staging.  An 
emphasis was placed on the crucial role of mouse models of AD in the development of new 
biomarkers, the dissection of different aspects of the pathogenesis, in addition to the 
testing of potential therapies.  There is a variety of emerging MRI techniques that can be 
used to probe different aspects of tissue vitality in-vivo.  The benefits of their combination 
into so called ‘multi-parametric’ protocols have already been realised in a small number of 
studies and may provide a more comprehensive characterisation of AD.  As such, the 
application of multi-parametric MRI protocols to mouse models of AD may spawn novel 
imaging-based correlates of the condition and help unlock new mechanisms of disease.  
The Centre of Advanced Biomedical Imaging(CABI) and pharmaceutical manufacturer Eli 
Lilly has forged a collaborative relationship with a mission to develop treatments targeting 
the tangle pathology in AD.  Integral to this effort is the development and evaluation of a 
pre-clinical multi-parametric MRI protocol sensitive to NFT accumulation in the rTg4510 
mouse model of AD.  The staging of the progression of tau pathology through these 
measurements will provide a test bed for the evaluation of drug efficacy in longitudinal 
studies.  Ensuring the accuracy and precision of MRI data is paramount to achieving this 
goal.  In chapter 3, a protocol was developed to both calibrate and monitor imaging 
gradients of the 9.4T MRI scanner in CABI.  In addition, a post-processing technique was 
implemented to correct for spatial gradient non-linearity away from the magnet iso-centre.  
The use of structural MRI to measure volumetric changes is an established biomarker in AD 
and has formed the cornerstone of early multi-parametric MRI studies that have also 
included DTI protocols(42,43,46,70).  Prior to correction, gradient scaling errors were 
calculated that could give rise to a 2.7% overestimation in volumes and 9.8% errors in 
diffusion measurements.  These errors were greatly reduced after adjustments were made 
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to gradient scaling values on the MRI scanner, based on calculations using the new 
calibration method.  Measurements were also used to rescale structural MRI data sets to 
remove effects of scaling discrepancies between different gradient sets used in the 
acquisitions.  This highlighted the importance of consideration of this source of systematic 
error in studies utilising multiple hardware setups.  The stability of scaling values across 
time points was measured and the temporal monitoring of gradients has since been 
employed alongside longitudinal studies in CABI to identify any fluctuations that may occur.   
The incorporation of the gradient calibration protocol developed here into quality 
assurance procedures implemented in pre-clinical laboratories should be trivial.  The 
phantom design can be 3D printed with standard materials and has been made open 
source(https://www.ucl.ac.uk/cabi/publications/open_source) and the software used for 
post processing is freely available to download(http://cmic.cs.ucl.ac.uk/home/software/).  
The versatility of the protocol was demonstrated through acquisition of data using different 
pulse sequences and at multiple resolutions.  Accurate calibration and system monitoring 
was shown to be possible using a relatively low resolution scan to reduce scan time to four 
hours.  Hopefully this work will raise awareness of the importance of accurate gradient 
calibration in pre-clinical systems and provide a useful resource for the pre-clinical imaging 
community. 
This gradient calibration technique has formed the bedrock of the CABI/Eli Lilly multi-
parametric MRI protocol, essential to the acquisition of quantitative data.  In Chapter 4, a 
DTI protocol was developed for longitudinal study of the rTg4510 mouse.  Sitting alongside 
other quantitative MR methodologies, a portion of time for the DTI acquisition was 
allocated from the three hour anaesthesia duration limit stipulated for in-vivo imaging of 
mice.  A SNR and time efficient SE-EPI DTI pulse sequence was optimised to acquire data of 
suitable resolution to generate accurate estimates of diffusion measures in white matter 
regions in the mouse brain.  Steps were taken to reduce motion artifacts, known to plague 
multi-shot EPI acquisitions, and DTI parameter estimates were evaluated against published 
phantom and in-vivo values.  The optimised pulse sequence, which was forty three minutes 
in duration, was then used to acquire DTI data alongside other MRI measures in a single 
timepoint multi-parametric study in rTg4510 mice and wild-type controls.   
DTI parameters measured in the rTg4510 group were significantly different to controls in a 
number of regions.  Measurements in the thalamus, a region of low NFT density, indicated 
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an increased MD in the rTG4510 mice, indicating the sensitivity of this technique to tissue 
changes inflicted by mild pathology.  In the more severely affected regions of the 
hippocampus and cortex, FA and MD were also elevated relative to controls indicating a 
microstructural rearrangement in this tissue that causes a greater diffusion of spins with 
increased directional specificity.  Furthermore, a positive correlation was found between 
regional MD and FA estimates and ranking of hyperphosphorylated tau density.  The 
rTg4510 displays neurodegeneration at the time point imaged and tau pathology has been 
shown previously to correlate with tissue atrophy(13-16).  Therefore caution must be taken 
when interpreting these results, since it may be the case that these DTI measurements are 
also sensitive to other biological changes associated with tissue atrophy in this model. 
The DTI measurements in white matter regions mirror the reduced anisotropic diffusion 
observed AD patients.  In combination with the increased radial diffusivity and unchanged 
axial diffusivity in the rTg4510 relative to controls, this may indicate reduced myelination of 
axons in the white matter tracts of the corpus callosum(98,173,174).  Electron microscopy 
observations in a previous study indicated myelin abnormalities as early as 4 months in the 
rTg4510(205) and further DTI investigations in younger mice would inform on the ability of 
this technique to detect effects of tau pathology at earlier stages of pathogenesis.  The 
retrogenesis hypothesis states that later myelinating regions of white matter in 
neurodevelopment are more vulnerable to damage in AD.  The DTI changes in the rTg4510 
suggest that this may indeed be the case since they were of greater statistical significance 
in the later myelinating rostral section compared to the caudal section of the corpus 
callosum.  However, the promoter driven expression of mutated tau in this model is 
directed to the forebrain and more rostral sections of white matter may be exposed to 
higher levels of tangle pathology.  It is important to recognise that, as with all animal 
models, the rTg4510 does not capture all aspects of the human condition.  There is no 
amyloid pathology and the regional and temporal pattern of NFT progression deviates from 
Braak staging. Nonetheless it does enable the study of unique tau pathology to better 
understand it’s role in AD pathogenesis. 
The changes in microstructure inferred by DTI that were observed in the corpus callosum of 
the rTg4510 were further investigated in Chapter 5 using a recently described MRI 
technique, Quantitative Susceptibility Mapping.  QSM provides an estimate of the bulk 
magnetic susceptibility of tissue and is thought to be a more direct measure of the myelin 
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content in white matter tissue relative to DTI(213).  In this final results chapter, QSM 
protocols were developed and optimised for in-vivo and ex-vivo acquisition and post 
processing.  Regional estimates of magnetic susceptibility were conducted in the rTg4510 
and wild-type controls in the first application of QSM in a mouse model of tauopathy.   The 
QSM measurements in a rostral region of the corpus callosum were increased in the 
rTg4510 mice which may reflect a relative decrease in myelin content in agreement with 
DTI findings in chapter 4.  There were no differences detected in this region in T2* 
measurements and unlike QSM no reduction in contrast was visually apparent between 
rostral white matter and surrounding grey matter.  Like DTI, T2* measurements are 
modulated by a number of mechanisms besides myelin content in tissue.  Quantification of 
myelin using histological measures alongside QSM measures in white matter would allow 
better definition of the relationship observed.  It is also possible that the increases in 
magnetic susceptibility observed in the corpus callosum could be due to the increased 
presence of paramagnetic materials such as iron in the tissue. 
The basal ganglia is known to contain structures that are iron rich relative to the rest of the 
brain and are particularly vulnerable to pathological iron accumulation in AD(214).  The 
striatum, a constituent part of this system, was found to have increased magnetic 
susceptibility in the rTg4510.  Reductions in T2*, the more established method of in-vivo 
iron estimation, supported this finding.  These T2* and QSM findings are in good 
agreement with clinical studies of AD(250) and may indicate that iron deposition in the 
striatum may be related to tangle pathology.  QSM values in the hippocampus, a region 
previously shown exhibit iron accumulation in AD(222), were also paramagnetic in the 
rTG4510 relative to controls.  The lack of findings in the cortex, a region of high NFT 
pathology in the rTg4510, indicates that possible iron driven changes may not be caused by 
iron co localised with NFTs.  Increased histological staining for reactive astrocytes and 
microglia were visually apparent in the corpus callosum and striatum.   The increased 
magnetic susceptibility in the rTg4510 in this region may indicate that rather than tau 
pathology, neuroinflammation and associated iron accumulation may be responsible for 
these changes.  
The work in this thesis has laid the foundations for three MRI techniques important to the 
development of multi-parametric protocols for the in-vivo imaging of AD mouse models.  A 
complete protocol for the system calibration of MRI gradients in pre-clinical scanners has 
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been made open source and available to the imaging community.  The sensitivity of DTI, 
QSM and T2* measurements to effects of NFT accumulation in the brain has been 
demonstrated.  This work could be further extended through longitudinal studies using 
these proven biomarkers alongside detailed histological analysis in the rTg4510 as well as in 
other mouse models to elucidate the relationships iron and myelin have with tangle 
pathology and their roles in neurodegenerative diseases. 
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